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The incidence of non-melanoma and melanoma is increasing and becoming a greater 
public health concern.  Despite extensive research into the action spectra for the 
induction of skin cancers, the relative contributions of the different wavebands of 
ultraviolet radiation (UVR): UVB (290–320 nm), UVA2 (320–340 nm) and UVA1 
(340–400 nm) are largely unknown.  Until recently, UVA1 was thought to be 
relatively insignificant despite making up 75% of environmental UVR, as well as 
being the major spectral region in tanning lamps.  High dose UVA1 is also used in 
phototherapy. Recent work demonstrating UVA1-induced cyclobutane pyrimidine 
dimers (CPD) in vitro and human skin ex vivo provides a clear indication to examine 
its effects in vivo in humans.  The aims of this thesis was to assess DNA damage and 
other biological markers, in skin type I/II individuals after environmentally relevant 
doses of UVA1, and study its genetic effects using whole genome analysis.  UVA1 
formed CPD in human skin, predominantly in the basal epidermis, in contrast to 
erythemally equivalent doses of UVB of which these lesions were 3-4 times more 
frequent and were preferentially located in the upper layers of the epidermis.  
Previous studies suggest that repair of UVA1 CPD is slower than that induced by 
UVB.  Our studies show that CPD repair kinetics were the same for both UVB and 
UVA1 when the whole epidermis was examined, however UVA1 CPD were poorly 
repaired over a 48 hour (h) period when assessment was restricted to the basal layer.  
We show that this is probably due to an overexpression of basal epidermal p63 by 
UVA1, and a concomitant lack of apoptosis of damaged cells. Overall, this is likely 
to make UVA1 CPD more mutagenic, as they persist for longer and are more likely 
to be incorporated as mutations during replication.  Whole genome microarray 
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studies showed distinct time dependent changes in many cellular pathways, with 
inflammation through TH17 signalling being the top upregulated pathway at 6h, and 
extracellular matrix remodelling being the top upregulated pathway at 24h.  We 
found a dramatic upregulation in MMP12 gene expression by UVA1 at 24h.  
MMP12 protein is predominantly formed by UVA1 and also exhibits elastolytic 
activity.  Our studies may explain how UVA1 contributes to late solar elastosis 
characterized by elastin degradation, and clinically by ‘sagging’ of the skin.  
MMP12 is a good marker of UVA1 exposure and MMP12 inhibition may be a new 
therapeutic approach for delaying photoageing and also photocarcinogenesis.  To 
conclude, these results necessitate the long term follow up of patients receiving 
UVA1 phototherapy and clearer information for public health measures on 
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1.1 Ultraviolet radiation and the electromagnetic spectrum 
Ultraviolet radiation (UVR) forms part of the electromagnetic spectrum: a series of 
oscillating waves in which the frequency of each wavelength defines the energy it 
carries.  These include radiowaves, microwaves, infrared radiation (IR), visible light, 
x-rays and gamma radiation (Diffey and Kochevar, 2007) and the shorter the 
frequency, the greater the energy it carries (see Figure 1.1).  UVR (100-400nm) lies 
between the visible spectrum and the x-ray waveband.  Within this, the biological 
effects of UVR vary considerably with wavelength and for this reason the 
Commission Internationale de 1'Eclairage (CIE) (Diffey, 2002) has further 
subdivided UVR into 3 regions: UVC 100-280nm, UVB 280-315nm and UVA 315-
400nm.  Stratospheric ozone (03) effectively absorbs wavelengths shorter than 
290nm, and all of UVC and so for the purpose of this thesis its properties shall not 
be discussed further.  As there is significant photobiological activity at wavelengths 
<320nm, environmental and dermatological photobiologists usually define UVB as 
290-320nm and UVA as 320-400nm.  The UVA waveband has been subdivided into 









Figure 1.1  UVR and the electromagnetic spectrum 
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1.1.1 Solar UVR 
The spectral distribution of solar energy at sea level comprises roughly 3–7% UVR 
(290–400 nm), 44% visible light (400–700 nm), and 53% IR (700–1440 nm) 
(Frederick et al., 1989).  Of the ~5% of terrestrial UVR reaching the earth’s surface 
95-98% is UVA and 2-5% is UVB.  UVA1 makes up ~75% of terrestrial UVR.  The 
intensity and spectral composition of solar UVR fluctuates due to a number of 
environmental factors including the solar zenith angle (which depends on latitude, 
season and time of day), the stratospheric O3, atmospheric pollution, and attenuation 
by cloud cover.  For example daily UVR intensity varies throughout the day because 
as the solar zenith angle increases, the spread of UVR rays emitted by the sun is 
distributed over a larger area on the earth’s surface.  Also UVB rays are attenuated 
more than UVA rays due to absorbance by 03 thus whilst UVA remains relatively 
constant throughout the day (Diffey, 2002; Jansen et al., 2013b) the proportion of 
UVB changes.  Highest UVR intensity occurs between 11am and 3pm (81% of daily 
UVR (Diffey, 2002)).  Cloud cover also reduces UVB values by 25-30% which 
means that at higher altitudes the intensity of UVR is greater and the spectral 
distribution may vary (Diffey, 2002). 
 
1.2 Structure of human skin 
Human skin is composed of an outer cellular epidermis (~100-150μm) and an inner 
dermis (~ 2-4mm) below the basement membrane (Figure 1.2).  The epidermis 
contains 3 major resident cell populations: keratinocytes, Langerhans cells (LC) and 
melanocytes.  Keratinocytes are the predominant population and they originate from 
the actively dividing basal epidermal layer.  The process of terminal differentiation, 
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whereby keratinocytes differentiate and migrate towards the stratum corneum is 
under tight homeostatic control and takes approximately 4 weeks, (Iizuka, 1994; 
Weinstein et al., 1984) although rates of proliferation and maturation are faster in 
response to injury, inflammation and disease.  LCs function as antigen presenting 
cells (APCs) and melanins are synthesised by melanocytes, which are also thought to 
possess immunomodulatory capabilities (Lu et al., 2002).  The second layer of the 
skin, the dermis, is a connective tissue layer composed largely of collagen I and III 
(Gordon and Hahn, 2010) known as the extracellular matrix (ECM), and resident 
cells include fibroblasts, dermal dendritic cells and macrophages.  The epithelial 
layer is nourished by the blood vessels in the dermis, which also contains a network 
of sensory nerve endings responding to touch, temperature and pain including 
substance P and Calcitonin Gene-related peptide (CGRP). 
 
Figure 1.2  Structure of human skin at rest 
Ex vivo transmission (Bruls et al., 1984) with UVB at 297nm and UVA1 at 
365nm 
 
1.3 UVR transmission through the skin 
As UVR reaches the skin, a certain amount is reflected (approximately 4-7% 
throughout the UVR spectrum) (Anderson and Parrish, 1981).  The 93-96% of 






































of the skin, which determines the penetration of radiation.  Generally there is more 
transmission, scatter (by molecules smaller than the wavelength) or reflection (by 
molecules larger than the target wavelength) and dermal remittance (a type of back 
scatter/reflectance) at longer wavelengths (Anderson and Parrish, 1981; van Gemert 
et al., 1989) which explains how longer wavelengths penetrate deeper into the skin 
(Bruls et al., 1984).  On reaching the skin, UVR photons are absorbed by target 
chromophores to initiate a series of biological responses.   
1.3.1 Chromophores  
Each type of molecule in the skin: nucleic acids, aromatic amino acids (tryptophan, 
phenylalanine, tyrosine, histidine), melanins (phaeomelanin and eumelanin) absorb a 
unique combination of wavelengths and are termed chromophores (Diffey and 
Kochevar, 2007; Young, 1997).  The absorption spectrum of a given chromophore is 
the probability of absorption of photons as a function of wavelength.  Pure DNA has 
an absorption maximum (λmax) at 260nm (UVC), readily absorbs in UVB but 
weakly absorbs in the UVA waveband (Setlow, 1974; Sutherland and Griffin, 1981).  
At less than 300nm, aromatic amino acids, nucleic acids, urocanic acid and melanin 
are the major epidermal absorbers (Figure 1.4) (Anderson and Parrish, 1981).  Most 
chromophores absorb in more than one spectral region for example, NAD+ has an 
λmax at 260nm and in the reduced form (NADH) absorbs maximally at 339nm 
(UVA1).  Other than melanin, UVA chromophores in the skin include βcarotene, 
protoporphyrin IX (pIX) and riboflavin.  Exogenous UVA chromophores include 
antibiotics such as tetracyclines and quinolones (Makinen et al., 1997) which can 
cause drug-induced photosensitivity reactions, and topical/oral psoralens 
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(furocoumarins) which in combination with UVA form the basis of PUVA 
phototherapy (Morison and Honigsmann, 2007). 
 
Figure 1.3  Absorption spectra of skin chromophores 
Adapted from Diffey and Kochevar (2007)  
 
Energy states and electron transfer 
When a molecule or sensitiser (Sen) absorbs a UVR (or visible light) photon it enters 
an “excited state” (Sen*).  This is either an excited singlet state (existing for only a 
few nanoseconds) and returning to ground state by emitting excess energy as 
fluorescence or heat (internal conversion), or an excited triplet state which is at a 
slightly lower energy state and persists for longer.  A triplet excited state returns to 
ground state and gives off energy as phosphorescence.  Singlet or triplet states are 
determined by the electron spins which affects the amount of energy they hold.  In a 
singlet state, the electrons spin in opposite directions and exist at a higher energy 
level compared with an excited triplet state where the spin of both electrons in the 
energy shell are in the same direction (Figure 1.4). 
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Figure 1.4  Jablonski Diagram  
(Energy transitions following absorption of UVR by a photosensitiser) 
 
 
In both energy states the Sen can undergo chemical reactions (known as either type I 
or type II photosensitisation).  In type I, the excited Sen (which is generally in a 
triplet state) reacts directly with the substrate.  The substrate donates an electron (e-) 
to create a Sen radical anion (Sen -) and a substrate radical cation (Subst +).  
- can then transfer the e- to oxygen producing the superoxide (02 -) or 
-) radical ions, which also in the process regenerates the sensitiser.  
In type II photosensitisation the transfer of energy from the photosensitizer to 
oxygen produces an excited singlet oxygen (1O2) which can either undergo 
photochemical reactions (Figure 1.5), or undergo intersystem crossing, where the spin 
of the electron flips and transition to the lower energy triplet state (3O2), which 













































Figure 1.5   Type I and type II photosensitisation reactions 
In type I photosensitisation, the energy is transferred to produce an excited 
sensitiser and in type II the energy is transferred to oxygen leading to free radical 
production and tissue damage. 
 
Erythropoietic proporphyria (EPP) is an example of a skin disease where clinical 
symptoms manifest through type II photosensitisation.  Due to a metabolic defect, 
there is an accumulation of the photosensitiser protoporphyrin IX(pIX) in endothelial 
cells and on absorption of blue light (400-410nm), 1O2 is generated leading to 
cellular damage and causing the photosensitive symptoms of pain, oedema, necrosis 
and occasionally erythema.  Cytotoxicity through 1O2 also forms the basis of 
photodynamic therapy (PDT) (Ibbotson and Szeimies, 2007) and UVA1 























































There are also other electron transfer systems in the skin and one of the most 
effective oxidisation processes in cellular biology is the Fenton reaction.  In the 
presence of H2O2 and 02 - as often found in type I photosensitisation these oxidise 
Fe2+ to Fe3+ (ferric iron) forming - radicals and hydroxide (OH-) ions.  This is a 
powerful self-perpetuating cycle as Fe3+ can be reduced back to Fe2+ by another 
molecule of H2O2 and the damage cycle continues (Bickers and Athar, 2006).   
 
1.3.2 Action spectroscopy  
An action spectrum is a measure of the wavelength dependency of a given 
photobiological effect and is plotted as the reciprocal of the dose required to produce 
a given end-point (y axis) against the wavelength (x axis).  This plot is typically 
constructed by performing dose-response studies with monochromatic radiation.  In 
some cases, the slope of the dose-response curves is used as the index of efficacy. 
The CIE erythema action spectrum in humans (Figure 1.6) (CIE, 1998), shows that 
UVB is 3-4 orders of magnitude more erythemally effective than UVA however 
these data are variable at wavelengths greater than 340nm.  More recently, work 
examining erythema with lasers (Anders et al., 1995) has identified a further 
erythemal peak at ~360nm, suggesting two independent mechanisms of erythema 
induction.  Erythema is a marker of DNA damage up to 340nm (Young et al., 1998a) 
and as DNA is a chromophore for UVB, erythema is likely mediated through direct 
absorption by DNA whilst UVA is probably absorbed by another unknown 
chromophores in the skin in the presence of oxygen (Auletta et al., 1986) indirectly 
resulting in erythema. 
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Figure 1.6  Action spectra for erythema 
The CIE reference action spectrum for erythema in human skin (blue) and the 
Anders action spectrum using narrow waveband lasers (red) (Anders et al., 1995; 
CIE, 1998) 
 
Action spectroscopy has two main functions (i) chromophore identification: for 
example DNA is a chromophore for erythema and also TNFα (Walker and Young, 
2007) and (ii) the determination of biological weighting functions for a given 
emission spectrum: e.g. solar UVR where 3% UVB in a given solar simulated 
spectrum accounts for 65% of erythemally effective energy (EEE) (Young et al., 
2010).  
 
1.3.3 Sensitivity of skin to UVR 
A system based on self reported susceptibility to sunburn forms the basis of our 
current skin type I-VI classification (Fitzpatrick, 1988) (Table 1.1).  Studies on skin 
types I-III show an increase in the ratio of epidermal eumelanin (black/brown 
melanin) to phaeomelanin (reddish brown) through skin type groups I to III (Thody 
et al., 1991) which suggests eumelanin has photoprotective properties likely acting 
as a photoprotective cap to keratinocyte DNA (Kobayashi et al., 1998). Individual 
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skin sensitivity to UVR is assessed by determining the minimal erythema dose 
(MED); the dose of a given UVR source needed to produce visible erythema.  The 
MED is widely used as an exposure dose unit in phototherapy and experimental 
photobiology to assess a biological response (Diffey, 2002).  As UVB is 
approximately 1000 fold more effective than UVA per unit physical dose at inducing 
erythema i.e. at 300nm the dose needed to give a MED is 0.030 J/cm2 whereas at 
360nm this dose is 32J/cm2 (Young et al., 1998a), sunburn is often considered to be 
a UVB dependent response.  This is not entirely the case as a broad-spectrum 
sunscreen provides better protection to cumulative erythema than a UVB sunscreen 
(Young et al., 2010).  
The MED of individuals with skin type IV is about twice that of individuals with 
skin type I (Harrison and Young, 2002), however there is considerable overlap, thus 
skin type is not necessarily a reliable indicator of sensitivity to sunburn (Young, 
2006).  Given that the MED is variable even within a given skin type, the standard 
erythemal dose (SED) is increasingly used to measure erythemally effective 
exposure doses (Diffey et al., 1997).  It has the advantage of being independent of 
personal UVR sensitivity and emission spectrum of source.  1SED is equivalent to 
an erythemally effective exposure dose of 100J/m2 (or 10mJ/cm2).  Table 1.1 
classifies human skin according to its constitutive melanin pigmentation, ability to 













No of SED 
to give an 
MED 
I High White Very poor High 1-3 
II High White Poor High  
III Moderate White Good Low 3-7 
IV Low Olive Very good Low  
V Very low Brown Very good Very low 7->12 
VI Very low Black Very good Very low  
Table 1.1  Classification of skin type I-VI 
According to tanning ability and indicative MEDs expressed in SEDs that might be 
expected following exposure on UVR naïve skin (Diffey and Kochevar, 2007, 
Harrison and Young, 2002).  
 
1.4 Effects of UVR in the skin 
The acute and chronic effects of UVR on the skin are summarised in Table 1.2.   
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Table 1.2  Effects of UVR in human skin in vivo 
Adapted from (Lautenschlager et al., 2007) 
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1.4.1 Acute effects of UVR on the skin 
1.4.1.1 Molecular 
DNA damage: CPD, 64PP and Dewar isomer 
Peak DNA damage in human skin occurs at 300nm (Young et al., 1998a) due to 
absorption and diffusion of the shorter wavelengths of UVB in the skin.  UVB 
causes the formation of cyclobutane pyrimidine dimers (CPD) and pyrimidine (64) 
pyrimidone photoproducts (64PPs), which in the presence of UVA radiation (at 
320nm) (Cadet et al., 2005), is converted to its Dewar photoisomer.  Action 
spectroscopy for CPD and 64PP in vitro in human skin fibroblasts are similar from 
254-302nm although CPDs are induced 5-10 fold more frequently (Rosenstein and 
Mitchell, 1987).   
Dimers form after the absorption of a photon of energy which splits the C5=C6 
double bond of two adjacent pyrimidine (thymine (T) or cytosine (C)) bases, and 
forms new covalent bonds linking pyrimidines at the C5 and C6 positions.  A 4-
carbon cyclobutane ring is produced, giving the dimer its characteristic name.  With 
64PP, the C5=C6 double bond breaks and the surplus energy results in the rotation 
of one of the pyrimidine rings which offers its C4 (of the 3’-end) to form a new bond 
with the C6 (of the 5’-end) of the adjacent pyrimidine (Ichihashi et al., 2003) (Figure 
1.7).  In this case only one new covalent bond is formed.  This structure causes a 
more significant distortion in the double helix than the cyclobutane ring, which is 
thought to cause its more rapid recognition and repair (Mitchell and Nairn, 1989; 
Young et al., 1996).  
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Figure 1.7  DNA damage photoproducts (CPD, 64PP, Dewar isomer) 
 
8oxodG/8oxoGua 
Oxidative stress is a state in which the cellular antioxidant system is overwhelmed 
by reactive oxygen species (ROS) and results in modifications of cellular 
biomolecules including lipids, proteins and nucleobases.  Guanine has a low 
threshold for oxidation, and as guanosine (where it is attached to a deoxyribose 
sugar) it forms 8-oxo-7,8-dihydro2deoxguanosine (8oxodG) also known as 
8oxodGuo.  Its nucleobase equivalent is 8-oxo-7,8-dihydroguanine (8 oxo-guanine) 
(8-oxoGua) (Figure 1.8).  
  

































































































CPDs are responsible for >80% of UVB induced mutations in DNA repair proficient 
mammalian cells (You et al., 2001).  The TT is more persistent than C containing 
CPD in human skin in vivo because of its slower repair (Bykov et al., 1999; Xu et 
al., 2000).  If unrepaired, these interfere with base pairing during DNA replication.  
Briefly, C containing dimers are not appropriately recognised and instead of G, an A 
is placed opposite. This means that in subsequent replication cycles T is placed 
opposite A leading to a C→T transition (known as the C:G→A:T transition) or a 
tandem CC→TT transition.  These were typically known as “UVB signature 
mutations” as they were almost exclusively thought to be due to UVB (Brash et al., 
1987; Drobetsky et al., 1987).  Cytosine containing dimers are thought to be most 
mutagenic (Douki, 2013; Mouret et al., 2008)) as the mutation frequency recovered 
at dipyrimidine sites in UVR irradiated cells generally contain cytosine (Pfeifer et 
al., 2005).  Bulky TT dimers are repaired by the “A rule” which is where A is placed 
opposite appropriately due to bypass at the replication fork by DNA polymerase η 
otherwise known as bypass tolerance (Ikehata et al., 2008; Pfeifer et al., 2005).  
Hence, when the types of mutations in response to UVR are seen in cells or explant 
skin (Cadet et al., 2005; Courdavault et al., 2004; Douki et al., 1999; Douki et al., 
2003; Ravanat et al., 2001) the prevalence of TT dimers is thought to be a 
consequence of the rapid repair of cytosine containing lesions.  C to T transition 
mutations can be induced by both CPDs and 64PPs, and form the mutagenic basis of 
photocarcinogenesis (see section 1.4.1.3).  It has been noted that rapid repair of 64PP 
in human skin in vivo correlates with the onset of erythema suggesting that its repair 
or the lesion itself may initiate the human erythema response (Young et al., 1996).  
In mammalian cell mutagenesis studies however, 64PP are repaired quickly 
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(Mitchell and Nairn, 1989).  Repair of Dewar isomers is as rapid as 64PP, but they 
do not induce C→T transitions in mammalian genetic studies in vivo (Lee et al., 
2000).  
ROS induction occurs primarily in the UVA waveband with a peak at 390nm (Kvam 
and Tyrrell, 1997) thus the mutagenic potential of UVA was thought to be based on 
its induction of oxidative stress via 102 (Zhang et al., 1997b).  80% of 8oxodG 
formed can be attributed to 102 (Cadet et al., 2009), more commonly after UVA 
(Mouret et al., 2006), and probably due to the transfer of UVA photons to 
endogenous photosensitisers (such as cytochromes, flavin, haem, NAD(P)H and 
porphyrins) (Cadet et al., 2009). 
 
Figure 1.9  UVA and UVB mediated reactions to cellular DNA 



































Early work showed that the most common base change after UVA exposure was the 
A:T→C:G (T→G) transversion (Drobetsky et al., 1995).  This was initially 
considered a UVA fingerprint mutation, due to 8oxodG which is found 
predominantly at the basal epidermis of precancerous solar keratoses and squamous 
cell carcinoma (SCC) (Agar et al., 2004), also supported by other studies on human 
engineered skin (Huang et al., 2009).  ROS type mutations include T→G, G→T and 
T→A transversions (Halliday, 2005) due to a misincorporation of 8oxodG opposite 
adenine, vice versa, or oxidized thymine.   
In vitro studies show that UVA readily induces C→T transitions that were 
previously widely associated with UVB induced CPDs (Kappes et al., 2006; Runger 
and Kappes, 2008).  The first evidence for CPD damage by UVA came from studies 
in E.coli using monochromatic 365nm (UVA1) (Tyrrell, 1973) although this was 
initially attributed to contamination by UVB (Hacham et al., 1990).  UVA CPDs are 
formed at TT dipyrimidine sites in UVA-irradiated human cells (Drobetsky et al., 
1995; Rochette et al., 2003) and genotoxicity is probably the result of UVA1-
induced cytosine-containing CPDs (Mouret et al., 2006) that occur much less 
frequently.  Transversion mutations are likely the minor contributor to UVA and 
UVB mutagenesis.  This is because the UVA mutation spectrum in mammalian cells 
exhibits a predominance of the C:G→T:A mutation and in fact is the most common 
mutation produced by UVA and UVB (41% and 52% respectively) (Kappes et al., 
2006; Kappes and Runger, 2005).  The G:C→T:A and A:T→C:G transversions 
occur at similar frequencies after UVA and UVB at 13% and 15% respectively) 
(Kappes et al., 2006) suggesting minor roles in mutagenesis.  In a more recent study, 
the C→T transition was found at a frequency of 65% and 85% for UVA and UVB 
 35 
respectively (Ikehata et al., 2008) with 8% mutations attributable to 8oxodG.  UVA 
induced T→G mutations were also recovered at TT sites (Rochette et al., 2003) 
or the same site as G:C→A:T transitions (Benjamin et al., 2008) which might 
indicate that even this type of mutation was not always formed by an oxidized 
guanine, but by a CPD on the other strand.  The exact role of 8oxodG in mutagenesis 
is unclear but mice that cannot repair 8oxodG (OGG1 8-oxoguanine DNA 
glycosylase-1) knockout show an increase in skin tumour development compared 
with wild type mice (Kunisada et al., 2005) and G→T transversions, (G:C→T:A 
mutations) have been detected in the Brm gene in human basal cell carcinoma (BCC) 
and SCC (Moloney et al., 2009) cell lines.  Oxidative DNA damage has also been 
implicated in a wide variety of other pathological conditions, including 
cardiovascular disease, ageing, and neurodegenerative diseases (Cooke and Evans, 
2007). 
 
Mutation pattern  Causative damage Mechanism 
G:C→A:T transitions C→T transition CPD  
G:C→T:A mutations G→T transversion 8oxodG  
A:T→C:G transversions T→G transversion 8oxodG, oxidized thymine 
Table 1.3  DNA damage mutations induced by UVA and UVB 
 
It is now well established that the yield of TT CPD by UVA is larger than that of 
8oxodG in both mammalian cells (Courdavault et al., 2004; Douki et al., 2003; 
Kielbassa et al., 1997; Zhang et al., 1997a) and human skin (Burren et al., 1998; 
Freeman et al., 1989; Mouret et al., 2006; Young et al., 1998b) and the term solar 
UVR mutations more accurately implies the C→T transition mutation produced by 
UVB and UVA which if unrepaired over time leads to skin cancer.  Chapter 3 
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discusses CPD formation at biologically relevant doses of UVA1 in comparison to 
UVB and mechanism of formation in vivo.   
DNA repair 
In humans, the excision of damaged or inappropriate bases from the genome by 
multistep biochemical reactions are referred to nucleotide excision repair (NER), 
base excision repair (BER), and mismatch repair (MMR).  The principle of NER 
involves sensing UVR induced photoproducts, splicing out the damaged region, 
inserting new bases to fill the gap, followed by ligation of the two ends of DNA.  
Our understanding of its importance primarily comes from studies in xeroderma 
pigmentosum (XP) (Cleaver, 1968) in which there are mutational defects in different 
NER proteins. Clinically, these are described as complementation groups XPA-G 
and the XP variant of NER depending on the defective complementation repair 
group.  Failure to repair dipyrimidine lesions results in multiple skin cancers at an 
early age and an increased (1000-10000 fold) susceptibility to UVR induced skin 
cancer (Fassihi, 2013; Grampurohit et al., 2011).  NER consists of two sub-
pathways: global genome repair (GGR) which repairs damage in both transcribed 
and untranscribed DNA strands in active and inactive genes throughout the genome 
and transcription coupled repair (TCR) where repair is selectively directed at the 
actively transcribing strand as a further preventative measure to reduce the chance of 
DNA damage being passed onto daughter strands during replication.  
In GGR, damage is sensed by XPE and/or XPC whilst in TCR, RNA polymerase II 
stalls at a DNA lesion and cockayne syndrome complementation groups A and B 
(CSA and CSB) are recruited.  Repair in both processes then continues through a 
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common transcription factor replicosome complex consisting of 30 distinct proteins 
(Friedberg, 2003; Sugasawa, 2010) (Figure 1.10) enabling DNA to unwind, DNA 
damage removal and then repair by DNA polymerase. 
 
Figure 1.10  Repair of UVR induced DNA damage by NER  
Adapted from (Sugasawa, 2010) 
This shows that 6-4PP are recognized by both XPC and XPE whilst XPE must be in 
place first to recognize CPD before a complex can form with XPC.  This could 
explain how 6-4PP might also be repaired more rapidly than CPD as they can 
independently be sensed by two complementation proteins (Mitchell and Nairn, 
1989).   
 
DNA repair is error prone and a separate ‘overseer’ of NER is a DNA damage 
tolerance process known as translesional synthesis (TLS).  This is mediated by DNA 
polymerase η (Pol η) and effectively bypasses TT dimers, accurately placing A 
opposite (known as the A rule).  This ensures an error free bypass of UVR induced 
lesions and those patients who are unable to participate in this, have a mutation in 
the Pol η gene (XP variant) and are extremely susceptible to skin cancers. 
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BER recognises damage to non-distorting single base modifications caused by 
oxidation: 8oxoGua, 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG, 
FapyA), alkylation (methylation of bases producing 7-methlyguanine, 5-
methylcytosine), hydrolysis or deamination (hypoxanthine from deaminated adenine 
or xanthine from deaminated guanine).  BER is initiated by DNA glycosylases that 
cleaves the glycosylic bond between the target base and deoxyribose sugar.  This 
leaves an apurinic /apyrimidic site or naked sugar phosphate backbone attached to 
the deoxyribose sugar, commonly referred to as an AP site (Krokan et al., 1997)) 
which is also cytotoxic and needs to be removed by an AP endonuclease.  The 
resulting single-strand break can then be processed by either short-patch (where a 
single nucleotide is replaced) or long-patch BER (where 2-10 new nucleotides are 
synthesized).  
MMR corrects erroneous insertion, deletion and mis-incorporation of bases during 
DNA replication and is also strand specific.   
Photoisomerisation of trans-UCA 
trans-UCA (2E)-3-(1H-imidazol-4-yl)prop-2-enoic acid), a deamination product of 
histidine is present in high concentrations in epidermal stratum corneum and upon 
exposure to UVR (280-310 nm) (McLoone et al., 2005), undergoes 
photoisomerisation to its cis-isomer. Photoisomerisation by the UVA2 (330nm) 
(Gibbs et al., 1993) and UVA1 regions (Kammeyer et al., 1995) has also been 
reported.  
De Fabo and Noonan (De Fabo and Noonan, 1983) first reported that trans-UCA 
was important in systemic immunosuppression as removal of the stratum corneum in 
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mice by tape stripping, also prevented UVR-induced systemic suppression of the 
contact hypersensitivity (CHS) response.  In fact a topical application of cis-UCA 
suppresses both induction and elicitation of CHS responses to contact allergens, 
including oxazolone, 2,4,6- trinitrochlorobenzene and dinitrofluorobenzene in mice 
(Hart et al., 1997; Kurimoto and Streilein, 1992).  An example of a delayed type 
hypersensitivity (DTH) model involves infection with herpes simplex virus: mice 
were infected subcutaneously with the virus, and 8-10 days later challenged 
intradermally in the ear with inactivated virus to produce an immune response.  The 
epicutaneous or intradermal administration of cis-UCA before infection significantly 
suppressed the DTH response in a dose-dependent manner as measured by ear 
swelling (Ross et al., 1986).  These observations formed the basis for proposing than 
trans-UCA is a chromophore for UVR-induced immune suppression.  Subsequent 
studies using hairless mice showed that topical application of trans-UCA increases 
both the number and malignancy of skin tumours induced by chronic exposure to 
UVR, suggesting that immunosuppression by cis-UCA can also promote 
photocarcinogenesis (Reeve et al., 1989) by enabling CPD persistence and thus 
incorporation into the next cycle of DNA replication. 
In humans, it has been reported that the relative production of cis-UCA following a 
single exposure to UVR was significantly higher in individuals with a past history of 
BCC or malignant melanoma (MM) compared with healthy individuals (De Fine 
Olivarius et al., 1998) and recently, it has been shown that higher levels of cis-UCA 
were detected in SCC but not BCC biopsies compared with those from healthy skin 
(Decara et al., 2008).  Following UVR exposure, cis-UCA alters antigen presenting 
function of LCs and enhances prostaglandin E2 (PGE2) formation which 
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subsequently can inhibit tumour necrosis factor α (TNFα) production in human 
peripheral blood mononuclear cells (PBMCs) (Hart et al., 1993) and increase 
expression of IL10 mRNA (el-Ghorr and Norval, 1995; Holan et al., 1998), resulting 
in immunosuppression and a lack of immunoregulated clearance of DNA 
photoproduct.   
1.4.1.2 Cellular 
Immunomodulation 
See section 1.9 The immune response to UVR 
1.4.1.3 Clinical 
Inflammatory reactions including erythema 
Erythema (or sunburn) is an acute inflammatory response of the skin to UVR and is 
associated with increased blood flow and sensitivity to thermal and mechanical 
stimuli, and a series of molecular/cellular changes (Harrison et al., 2004; Rhodes and 
Lim, 2007).  UVR damages many tissue compartments including membrane 
phospholipids, proteins and nucleic acids, which trigger a variety of 
proinflammatory responses.  There is an influx of PGE2 and nitric oxide (NO) 
(Rhodes et al., 2001) after UVR exposure. At lower doses (1 MED), erythema is 
primarily mediated by NO whilst at higher doses both NO and PGE2 have 
cumulative vasodilatory effects.  UVR also directly causes a release of the 
proinflammatory cytokines TNFα, interleukin (IL)1, IL6, IL8 and IL12, and 
upregulates nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) 
and transcription factor (TF) activator protein 1 (AP1) via cytokine signal 
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transduction pathways (mitogen activated protein kinase (MAPK): p38, JNK and 
ERK) that control expression of a wide range of genes (see Figure 1.14).  
 
Vitamin D synthesis  
Vitamin D is a group of fat soluble hormones comprising vitamin D3 
(cholecalciferol) and D2 (ergocalciferol), responsible for enhanced intestinal 
absorption of important metal ions in the body including calcium, phosphate, 
magnesium, and zinc.  Dietary sources equate to ~10% of vitamin D3 and include 
oily fish (herring, salmon, sardines), liver and egg yolk.  Vitamin D2 is found as 
ergosterol in alfalfa, rye and mushrooms), as well as fortified foods in the US (milk, 
margarine and cereals).   Both D2 and D3 are also available in vitamin supplements, 
however the major source of vitamin D is D3, is formed following UVR absorption 
in the skin (λmax at~297-300nm (Adams et al., 1982) with no production above 
315nm (Norval et al., 2010)).  The first step in cutaneous D3 synthesis is absorption 
of UVB by 7dehydrocholesterol (7DHC) (provitamin D3) (Webb et al., 1988), in all 
layers but predominately the spinous and basal layers of the epidermis (Webb and 
Holick, 1988), and its resultant photoconversion to previtamin D (cholecalciferol).  
Concentrations of pre-vitamin D reach a maximum after a relatively low UVR 
exposure (<1MED) (Gilchrest, 2008), and further UVR exposure results in 
conversion of pre-vitamin to the inactive photoproducts lumisterol and tachysterol.  
Thus, this rate limiting step ensures that previtamin D levels remain at 10-20% of 
epidermal 7DHC concentrations (Adams et al., 1982; Holick et al., 1980), and 
vitamin D intoxication following UVR can not occur (Gilchrest, 2008).  Previtamin 
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D3 is then thermally converted to Vitamin D3 which is released from the cell 
membrane into the extracellular space where it combines with a carrier protein 
(vitamin D binding protein) and is further metabolised to 25hydroxyvitamin D and 
finally 1,25dihydroxyvitamin D (1,25(OH)2D3) (calcitriol).  These last two steps 
occur commonly in the liver and kidney respectively, although the whole pathway 
can take place in the skin (Lehmann, 2005) and other organs such as bone (Anderson 
and Atkins, 2008).  1,25(OH)2D acts on vitamin D receptors (VDR) in tissue 
including colon, skin, breast and prostate to initiate a series of effects.  The most 
established action of 1,25(OH)2D3 is on the intestines and bone for calcium 
homeostasis.  Recent work shows a lack of increased expression of VDR after 
multiple UVR exposures, which might also explain the absence of vitamin D and 
calcium toxicity in the body after UVR (Lesiak et al., 2011).  The binding of 
1,25(OH)2D3 to VDR results in proapoptotic and anticancer effects, modulating over 
60 genes with prodifferentiating, antiproliferative, and antimetastatic effects on cells  
(Raimondi et al., 2009).  VDR is also expressed by BCC and SCC.  Circulating 
1,25(OH)2D3 levels are maintained by a negative feedback mechanism that regulates 
renal 1α-hydroxylase and conversion of 25(OH)D to 1,25(OH)2D3, thus plasma 
concentration of 25(OH)D is a good reflection of cumulative exposure to sunlight 
and dietary intake of vitamin D3, and is widely regarded as a robust “gold standard” 
indicator of vitamin D status (Dawson-Hughes et al., 2005).  
It is hard to define optimal vitamin D status because different disease outcomes may 
depend on different levels.  Table 1.4 reflects a general consensus view, but some 
authors advocate optimal levels of 75–100 nmol/L 25(OH)D (Bischoff-Ferrari et al., 
2006) or 80nmol/L (Heaney, 2000), but generally this is felt to be unachievable in 
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UK summer sunshine in white skin types (Rhodes et al., 2010), as simulating 
summer UVR exposure produced sufficient vitamin D levels (50nmol/L) but not the 
proposed optimal status (80nmol/L).  Levels below 50mmol/L are associated with a 
30-50% increased risk of colon, prostate and breast cancer (Garland et al., 2006).  
25(OH)D <12.5nmol/L is generally accepted as severe vitamin D insufﬁciency and 
is associated not only with an increased risk of bone disease (Holick, 2007, 2008) 
but also of type I diabetes, hypertension and multiple sclerosis (Webb et al., 2010). 
At Guy’s and St Thomas’ NHS Foundation Trust the optimum level has been set at 
≥50nmol/L, as not only will this prevent bone disease but also this threshold level 
prevents compromise of macrophage/monocyte activation as part of the innate 
immune response (Holick, 2007).  Active 1,25(OH)2D3 can also reverse UVR-
induced DNA damage and photoimmunosuppression in some models (Kuritzky et 
al., 2008). 
Vitamin D status Serum 25(OH)D level 
(nmol/L) 
ng/mL 
Sufficiency >50 >20 
Insufficiency 25–50 10-20 
Deficiency 12.5–25 5-10 
Severe deficiency <12.5 <5 
Table 1.4  25(OH)D values in nmol/L and ng/mL  
Targets used by the biochemistry laboratory at Guy’s and St Thomas’ NHS trust, 
and adapted from Pedersen et al (2008), where 1ng/mL = 2.5nmol/L.  These units 
are used interchangeably in the literature.    
 
Adequate bone health is thought to be achieved with supplementations of 800-
1000IU of daily vitamin D3 or 5000IU a month (Heaney, 2000; Lehmann, 2005) as a 
standard dose of 400IU (and 1000mg calcium) (1μg= 40IU) does not appear to 
significantly reduce hip fractures in a prospective study of 36,000 women (Jackson 
et al., 2006).  Fortified foods contain about 400IU per 8oz milk/juice/butter, salmon: 
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fresh (600-1000IU), farmed (100-250IU) per 3.5oz, sardines 300IU, mackerel 
250IU, canned tuna 230IU, egg yolk 20IU, and one teaspoon of cod liver oil 400-
1000IU.  200IU (5mcg) daily for 2-3months will increase vitamin D by 5nmol/L in 
comparison, 0.5MED UVB whilst wearing a swimsuit produces 10,000IU vitamin D 
(Holick, 2007)  
UVR induced Vitamin D 
People living near the equator who are exposed to sunlight without sun protection, 
have robust levels of 25(OH)D above 80nmol/L (Lee et al., 2007).  There has been 
work suggesting that people living at high latitudes are at increased risk of various 
cancers such as Hodgkin’s lymphoma, colon, pancreatic, ovarian, breast compared to 
lower latitudes likely related to lower vitamin D levels (Garland et al., 2006).  
Extrapolation of the CIE action spectrum for conversion of 7DHC to previtamin D 
(produced ex vivo on type III skin types) (Holick et al., 1980; MacLaughlin et al., 
1982) shows that at mid-latitudes (around 40°) a fair skinned person should achieve 
maximal vitamin D3 synthesis (after suberythemal exposures) within 5–10 minutes 
during midday on a summer day if this is done 2–3 times weekly.  The time should 
be increased to 30 minutes for dark skin or if the sky is cloudy and exposure should 
to be on the face and forearms (Holick, 2007; MacLaughlin et al., 1982).  Few 
studies have actually measured sunlight induced conversion of 7DHC to previtamin 
D3 at different latitudes at different times of the year.  One group analysed this 
reaction using a solution of 7DHC exposed to sunlight for one hour on a cloudless 
day over the noon period (Webb et al., 1988) and found no production of vitamin D3 
during the winter months at 42°N (Boston) or at 52°N (Edmonton), even if the 
exposure time was extended to 3h (Webb et al., 1988).  In the mid-summer months 
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of June and July, vitamin D3 levels are produced at 52°N.  We know that in the 
summer months in the UK, 80nmol/L levels are unachievable (Rhodes et al., 2010),  
however if these levels can be produced by late summer (Webb et al., 2010) this is 
associated with winter sufﬁciency (50 nmol/L) probably as excessive vitamin D 
formed in the summer is stored in fat for winter use.  This group suggested that 
rather than a year round phenomenon, optimum vitamin D level should be 
considered as an end of summer status.   Darker skin type individuals were unable to 
synthesise optimal vitamin D levels and a group of 15 Asian individuals exposed to 
solar simulated radiation (SSR) for 6 weeks to 35% body surface area would 
probably need oral supplementation (Farrar et al., 2011) as they were unable to 
synthesize sufficient vitamin D over the summer months.  This is likely to be related 
to melanin absorption attenuating UVB induced vitamin D synthesis.  Recent work 
from our group (unpublished) show that in 50 individuals with skin types I/II and 
V/VI, the rate of Vitamin D synthesis surprisingly did not vary but baseline vitamin 
D level was race dependent with skin types V/VI having the lowest levels.  This is 
supported by a recent audit on vitamin D levels in our photodermatology clinic 
where we also found lowest vitamin D levels in patients with skin types V/VI 
(21nmol/L) compared with skin types I/II (41nmol/L, p<0.001).  A recent study 
suggests that sun seeking behaviour (sun and ski holidays) results is an increase in 
vitamin D although as there is concomitant DNA damage, thus vitamin D status is 
more safely mediated through oral vitamin D supplementation (Petersen et al., 
2014).  Previous work suggesting that vitamin D can be influenced through sunbed 
use (Tangpricha et al., 2004; Thieden et al., 2008) or that sunscreen use should be 
minimized to get more vitamin D production (Youl et al., 2009) is no longer 
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considered safe due to long term risks of photocarcinogenesis, although tanners have 
been shown to have robust levels of 25(OH)D (112nmol/L) and a higher bone 
density compared to non-tanners at the end of winter (Tangpricha et al., 2004). 
Sunscreens were initially felt to inhibit vitamin D photosynthesis (Matsuoka et al., 
1987) and by definition allow transmission of 1/SPF of incident erythemally 
weighted UVR (Gilchrest, 2008), i.e. 1/15th or 7% for an SPF 15 product.  Since 
users customarily apply half or less of the FDA/EC stipulated amount required to 
generate the stated level of protection (2mg/cm2) (Bech-Thomsen and Wulf, 1992), 
they achieve far less protection, and calculations show that with an SPF 15 
sunscreen, cutaneous vitamin D synthesis can occur after 10-20minutes of solar 
UVB exposure (Gilchrest, 2008).  Supporting this, a recent in vivo study in Tenerife, 
Spain (data unpublished) showed that in skin type I/II individuals, judicious 
application of a broadband sunscreen will reduce UVR induced erythema however 
will not effect vitamin D synthesis.  It is also important to note that exposure to 1 
MED whilst wearing a bathing suit is equivalent to ingestion of approximately 
20000IU of vitamin D2.  The greatest change is also seen in those individuals with 
the lowest baseline suggesting that the dose response relationships for vitamin D 
synthesis from UVB might be more complex. 
Tanning 
Three “tanning” processes occur in response to UVR: immediate pigment darkening 
(IPD), persistent pigment darkening (PPD) and melanogenesis or delayed tanning 
(DT) (Young, 2006). 
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IPD refers to the transient grey discoloration (Moan et al., 2012b) of the skin due to 
immediate photooxidation of existing colourless melanin precursors following 
exposure to predominantly UVA wavelengths (established peak at 340nm) (Irwin et 
al., 1993) and visible (400-500 nm) light (Pathak et al., 1962), and fades within 15 
minutes (Rhodes and Lim, 2007).  This occurs at low doses (1-4J/cm2 UVA) 
(Routaboul et al., 1999) and the colour varies with individual complexion.  It may be 
almost undetectable in fair-skinned individuals, but is easily observed in skin of 
types IV (or darker) (Young, 2006) due to the larger amounts of melanin 
(particularly eumelanin) in such skin  (Brenner and Hearing, 2008) and is a 
reversible process. 
IPD does not offer protection against erythema (Honigsmann, 2002) and its 
biological importance is unclear, although it has been recently suggested that its 
oxidized products absorb in the visible wavebands and thus prevents photodamage 
by visible  light to other important molecules such as 5-Methyltetrahydrofolate 
(5MTHF) in the blood (Moan et al., 2012b).  5MTHF deficiency may increase the 
risk of cardiovascular diseases, colorectal carcinoma and megaloblastic anaemia 
(Strickland et al., 2013). 
Development of a persistent brown colour (Miyamura et al., 2007) in response to 
larger UVA doses (>10J/cm2) in Caucasian skin peaking 2h post irradiation and 
lasting for up to 24h and sometimes 3-5 days later (Hwang et al., 2011) is known as 
PPD and was first described in the 1970s (Kaidbey and Kligman, 1979).  It is often 
perceived as a UVA tanning response (Rhodes and Lim, 2007) due to a permanent 
oxidation of melanin precursors  (Wolber et al., 2008).  The action spectrum of PPD 
declines very slowly in the UVA region (Moyal et al., 2000) and thus PPD been used 
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as the endpoint to assess UVA photoprotection by sunscreen (see 1.7.1 Sunscreens) 
to give a UVA protection factor (PF); the ratio of MPD (minimal pigmenting dose or 
PPD) with sunscreen compared to without sunscreen (Moyal et al., 2000).  
Interestingly the IPD was recently suggested to be a more useful marker for UVA 
protection as it is less time consuming to produce, and needs lower UVA exposures 
(Hwang et al., 2011), although it is a less stable response to UVA than PPD. 
IPD and PPD proceeds differently in fair-skinned individuals than in darker persons 
(Monash, 1963).  In fair skinned individuals, the MED is achieved before IPD 
(Lavker et al., 1995), as there are very small amounts of melanin and its precursors, 
thus UVB is attenuated relatively less and so smaller doses produce erythema.  
Repeated exposures will result in cumulative erythema, and importantly a formation 
of a small amount of pigment, which means that although it is completely negative 
initially in some individuals, it may become slightly positive and a marker of 
previous UVR exposure.  The process of tanning in dark skin pursues a different 
course.  Here, the MED dose needed is higher than the dose to produce IPD and 
exposure to the sun produces considerable pigment darkening due to larger amounts 
of melanin precursors, with prolonged or repeated exposure increasing the duration 
of pigmentation to many months.  Tanning is mostly due to IPD and PPD and 
sunburn is rare (Monash, 1963). 
Delayed melanogenesis (DT), facultative pigmentation or neomelanogenesis is due 
to stimulation of new melanin synthesis by basal epidermal melanocytes which is 
then transported via dendrites to adjacent keratinocytes and redistributed towards the 
surface of the skin (Tadokoro et al., 2005).  The density of melanin varies with body 
site and declines with age (Whiteman et al., 1999).  Melanin is synthesised either as 
 49 
dark-coloured brown–black insoluble eumelanin or light-coloured red–yellow, alkali 
soluble, sulphur-containing phaeomelanin.  More eumelanin is produced in skin type 
III compared to skin type I, however no correlation has been observed for 
phaeomelanin (Thody et al., 1991).  Eumelanin is thought to be the major factor in 
the photoprotective properties of melanin, which when induced in white skin types, 
results in a protection factor of about 2–3 against DNA photodamage and erythema 
as well as a visible tan (Agar and Young, 2005). New melanin is eventually 
redistributed to the stratum corneum and is evident ~3 days post irradiation.  The tan 
fades when the surface layer is shed over several weeks, although this can persist 
depending on complexion and UVR dose protocol (Sheehan et al., 2002; Sheehan et 
al., 1998; Young, 2006).  There is in vitro evidence that products relating to 
phaoemelanin may have photosensitising properties contributing to the skin cancer 
susceptibility of people with red hair (Vincensi et al., 1998) and recent mice studies 
show that the free radicals produced by UVA photosensitized phaeomelanin may 
increase the risk of melanoma (Noonan et al., 2012). 
The action spectrum for DT in human skin in vivo shows a peak at 290nm (Parrish et 
al., 1982), similar to the peak for erythema (Parrish et al., 1982) and CPD induction 
(Young et al., 1998a) and is thought to occur predominantly following UVB (Moan 
et al., 2012b; Wolber et al., 2008).  Larger doses of UVA will also evoke DT and 
studies show that the amount of UVA required to cause melanocyte activation and 
melanogenesis stimulation is more than 100 J/cm2 in skin type III and IV (Beitner, 
1986).  This amount of UVA is over 5 times more than the dose at which UVA PPD 
occurs and is reported to correspond to more than 8h of sunlight in midsummer 
(Maeda and Hatao, 2004).  Thus, the predominant response by UVA is not 
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melanogenesis.  Recently, it was reported that although UVB, UVA and SSR 
showed comparable tanning responses, eumelanin and phaeomelanin levels were 
much higher only after UVB or SSR exposure (Wolber et al., 2008) and not UVA.  
A recent gene study shows that the pigment changes after repetitive doses of UVA 
and UVB are entirely different (Choi et al., 2010) supporting the concept that they 
occur via different mechanistic processes (see below on gene differences). 
Pigmentation and melanocyte precursors 
UVR induced DT is due to an increase in tyrosinase activity (seen 72h following 
UVB (Lavker and Kaidbey, 1982)) stimulating the rate limiting step: the conversion 
of tyrosine to L-DOPA.  Other precursors include dopaquinone, 5,6-dihydroxyindole 
(DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA).  DHICA can be 
methylated to produce 6-hydroxy-5-methoxyindole-2-carboxylic acid (6H5MICA) 
and 5-hydroxy-6-methoxyindole-2-carboxylic acid (5H6MICA) in the cytoplasm of 
melanocytes (Maeda and Hatao, 2004) to eventually yield melanin. 
 


















PPD and IPD are due to photooxidation of preexisting DHI, DHICA and 6H5MICA, 
which gives the characteristic brownish black persistent pigmentation, without 
concurrent reddening.  These are oxygen driven processes as DHICA and 6H5MICA 
in vitro will only produce a colour change following the application of hydrogen 
peroxide (a prooxidant) (Maeda and Hatao, 2004).  In fact repeated UVA exposure 
produces similar changes to IPD and PPD, which reflects oxidative changes in pre-
existing melanin and its precursors (Miyamura et al., 2007; Wolber et al., 2008).  
Mechanisms of neomelanogenesis 
Tyrosinase activity and downstream melanin synthesis can be stimulated by UVR 
induced release of membrane-associated diacylglycerol (DAG) from keratinocyte 
plasma membranes, which activates PKC-β and in turn activates tyrosinase in 
melanocytes (Friedmann and Gilchrest, 1987).  A small degree of tyrosinase 
stimulation also occurs through ﬁbroblasts, neurons and mast cells, (Eller and 
Gilchrest, 2000).  A recent study looking at gene expression after multiple UVR 
doses in vivo humans showed that UVB is a strong stimulator of various pigment 
related genes, such as tyrosinase (TYR) gene, tyrosinase-related protein 1 (TRP1) 
and dopachrome tautomerase (DCT), as well as the transcription factor 
microphthalmia-associated transcription factor (MITF) (Tadokoro et al., 2005) and 
SSR is more effective in eliciting these effects than UVB alone suggesting a 
synergistic effect of UVA and UVB on melanogenesis (Choi et al., 2010).  UVA 
alone did not induce such upregulation of pigment cell-specific genes.  
Melanogenesis is also mediated via DNA photodamage (Gilchrest and Eller, 1999).  
In vitro experiments show that topical DNA repair enzyme (T4N5) treatment of 
murine S91 melanoma cells and human melanocytes exposed to SSR demonstrated 
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greater melanogenesis than when treated with heat-inactivated enzyme (Gilchrest et 
al., 1993).  The release of single stranded DNA fragments during CPD repair is 
thought to stimulate melanogenesis by increasing tyrosinase activity leading to an 
increase in tyrosinase protein and down stream new melanin formation (Gilchrest 
and Eller, 1999).  This might explain how skin types V/VI who may have a faster 
DNA repair capacity release more DNA fragments stimulating increased tyrosinase 
activity and contributing to the deeper darkening of the skin (Barker et al., 1995). 
UVR induced DNA damage induces p53 (Chen et al., 2014; Eller et al., 1996) which 
is also a mediator of melanogenesis.  p53 causes an upregulation of 
proopiomelanocortin (POMC), which is then processed to adrenocorticotrophic 
hormone (ACTH) and α-melanocyte stimulating hormone (α-MSH).  Secreted 
αMSH binds to the melanocortin 1 receptor (MC1R) on melanocytes and via an 
increase in cAMP, increases tyrosinase activity.  
1.4.2 Chronic effects of UVR on the skin  
The hallmarks of chronic exposure to UVR are photocarcinogenesis and 
photoageing.  
Photocarcinogenesis  
It is common practice to use the term skin cancer for 3 main types of tumours 
derived from epidermal cells (Young and Wikonkal, 2007): MM from melanocytes, 
SCC and BCC from keratinocytes.  MM is the 5th most common cancer in the UK, 
accounting for 4% of all new cases.  Over the last 30 years, the incidence of MM has 
increased more than for any other common cancer in the UK (Parkin et al., 2011) 
and in 2011, there were  13,348 new cases in the UK.  SCC and BCC are collectively 
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known as non-melanoma skin cancer (NMSC) although a minority remainder 
comprises a mixed group of rare skin cancers including Merkel cell carcinoma, 
which has an extremely poor prognosis.  NMSC are extremely common and in 2011, 
there were 102,628 cases registered in the UK: BCC (74%) and SCC (23%) although 
this might be an under representation as many cancer registries record only the first 
skin cancer of each histological type per person and often information on small 
NMSCs treated in primary care or the private sector never reach the registries 
(Brewster et al., 2007; de Vries et al., 2012).  
The concept that chronic sun exposure might cause NMSC was first introduced in 
1894 (Unna, 1894) with the observation that sailors, who were chronically exposed 
to large amounts of sunlight, were predisposed to skin cancers on sun exposed sites. 
Overall cumulative UVR dose is a good predictor of SCC risk, particularly in lighter 
skin types where skin cancer incidence is higher compared to darkly pigmented 
individuals (Leiter and Garbe, 2008).  Interestingly, this may not be the case with 
vitiligo, a disease in which there are isolated depigmented patches of skin.  Recent 
work found a significant decrease in the incidence of MM, BCC and SCC 
particularly in affected areas compared to normal skin, and after multiple courses of 
UVB phototherapy (Teulings et al., 2013).  The link between BCC and sun exposure 
was unclear until a cardinal study demonstrated that mice with mutant PTCH and 
chronically exposed to UVR produced BCC (Aszterbaum et al., 1999).  In contrast 
to SCC, the incidence of BCC (Kricker et al., 1995) and MM (Newton-Bishop et al., 
2011) are related to intermittent large dose solar UVR exposure in childhood and 
adolescence.  MM are found typically on the legs of women and backs of men, areas 
that are typically covered up but receive intermittent UVR exposures (Godar et al., 
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2009).  Studies show that regular recreational sun exposure is associated with 
photoadaptation and vitamin D synthesis, which are thought to be protective whilst 
intermittent acute sunburn exposure causes more damaging effects, furthermore, 
outdoor workers, chronically exposed to sunshine, do not get MM (Davis et al., 
2002; Godar et al., 2009; Newton-Bishop et al., 2011).  The proportion of UVA in 
sunlight (UVA/UVB) increases with increasing latitude, as does the ratio of 
MM/SCC.  This suggests that the greater proportions of UVA in sunlight as found in 
temperate latitudes, may play a role in MM induction (Moan et al., 2012a) although 
a lack of vitamin D production at temperate lattitudes must also contribute (Godar et 
al., 2009).  MM likely occurs through two process: an initiation stage or acute 
sunburn by UVB, and a propagation stage, possibly by UVA which can be 
transmitted through clothing (Mitchell and Fernandez, 2012) with two different 
wavelength specific pathways of melanoma induction (Noonan et al., 2012) 
In terms of the relative contributions of UVR on carcinogenesis, studies with 
polychromatic sources in hairless albino mice have been used to generate an action 
spectrum for non-melanoma skin cancer (known as SCUP- Skin Cancer Utrecht-
Philadelphia) (de Gruijl et al., 1993) which has been mathematically corrected for 
differences in UVR transmission between murine and human epidermis to produce 
an action spectrum for SCC induction in humans (de Gruijl and Van der Leun, 
1994).  This spectrum when considered with the action spectrum of CPD (Freeman 
et al., 1989) clearly indicates the importance of UVB induced CPD in the formation 
of SCC as the action spectra are similar to ~330nm (see Figure 1.12).  From early on 
CPD was known to exhibit biological activity (Setlow and Setlow, 1962), and 
recently it has been shown that DNA is a chromophore for erythema up to 340nm 
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(Young et al., 1998a). There is a second SCC induction peak around 380nm (within 
the UVA1 spectrum), of which the second erythemal peak (~360nm) may play a 
contributory role in its formation (Anders et al., 1995).  The action spectrum for 
melanoma induction in Xiphophorus fish is different from the SCC action spectrum 
as there is a greater contribution from UVA (Setlow et al., 1993).  If the Setlow 
study is weighted for the relative presence of UVA in sunlight, 90-95% of human 
MM induction can be primarily attributed to UVA wavelengths. although this has 
been recently refuted (Mitchell et al., 2010). The increased sensitivity to UVA can 
be seen when comparing melanoma induction to UVB (300nm) where UVA1 
(360nm) is only one order of magnitude less potent.  This is not the case with SCC 
induction where UVA1 is 3 orders less potent at induction then UVB.  
 
 
Figure 1.12  Action spectra for selected UVR endpoints 
Adapted from (CIE, 1998) for erythema, (de Gruijl et al., 1994) for SCC, (Setlow et 
al., 1993) for melanoma, (Young et al., 1998) for DNA damage. 
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Constitutive skin pigmentation protects against UVR-induced damage from a single 
MED exposure (Del Bino et al., 2006; Tadokoro et al., 2003) and there is more CPD 
damage in skin types I/II compared to II/IV after approximately 2-3SED (Mouret et 
al., 2011b).  Melanin has a major role in individual skin UVR sensitivity, and there 
is an inverse relationship for the risk of skin cancer (Miyamura et al., 2007) with a 
70-fold higher risk factor for BCC and SCC in Caucasian Americans compared with 
black or African-American skin (Lea et al., 2007) and an 18-fold (women) and 26-
fold (men) lower incidence of melanoma in black compared to white individuals 
(Horner et al., 2009). 
The stages of photocarcinogenesis are initiation and promotion.  DNA damage 
causes inactivating mutations in selected tumor suppressor genes (TSG), or 
activating mutations in oncogenes.  During the promotion stage, mutant 
keratinocytes undergo additional biochemical changes, and clonal expansion, that 
may result in visible pre-malignant papillomas.  Some of these will acquire a further 
mutational alteration that allows them to become invasive carcinomas.  Probably the 
most extensively studied TSG is TP53 whose crucial role is the orchestration of a 
cell's response to UVR-induced DNA via its activation through signal cascade 
induced phosphorylation and subsequent triggering of DNA repair enzymes, cell 
cycle arrest, DNA synthesis and programmed cell death: apoptosis (sunburn cells 
(SBC)) (Harris and Levine, 2005), all of which suppress photocarcinogenesis (see 
Chapter 4).  The C→T transitions and CC→TT resulting from replacement of 
cytosine have been known for many years to be UVR specific.  In one study, over 
90% of SCC were shown to have a mutation in the TP53 gene and approximately 
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60% were found to be C→T or tandem CC→TT transitions (Brash et al., 1991).  
These signature mutations were also found to occur in 90% of precancerous actinic 
keratosis (Ziegler et al., 1994).  In BCC, mutational analyses of TP53 show that 60% 
of tumours harbour the UVR signature transition (Ziegler et al., 1993), which is also 
found in the PTCH gene (Zhang et al., 2001).  
 
UVR exposure is a known environmental risk factor in the development of MM 
(Leiter and Garbe, 2008; Pfeifer et al., 2005) however, only recently a link to the 
characteristic UVR mutation has been established.  Advances in sequencing 
technology make it possible to comprehensively catalogue a melanoma cell line 
where the most common somatic mutation karyotyped was the C→T transition in 
90% of base substitutions throughout the genome and the CC→TT in 70% of 
dinucleotide substitutions.  Although a link with p53 and UVR has not been 
established in MM (Ragnarsson-Olding et al., 2002; Zerp et al., 1999), its 
transcriptional activity is thought to be inactivated (Houben et al., 2011) in MM. 
An additional biochemical change that occurs during the promotion and progression 
stages of UVR carcinogenesis is increased expression of cyclooxygenase-2 (COX2) 
which converts arachidonic acid to PGE2, and whose upregulation can be easily 
detected in actinic keratosis (AK), SCC and BCC.  Prostaglandins have been 
associated with a broad range of functions including inflammation, angiogenesis and 
immunosuppression.  COX2 inhibitors such as diclofenac are successfully used to 
treat AKs (An et al., 2002) and prevent UVR induced skin cancers in animal models 
(Fischer et al., 1999).  Interestingly, individual who regularly take NSAID have a 
lower incidence of cutaneous SCC than those who do not, although a causal 
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relationship has not established (Butler et al., 2005).   
 
Photoageing  
Skin ageing occurs as two distinct phenomena: intrinsic chronological ageing which 
are the changes attributable to the passage of time and can be accelerated by external 
agents such as cigarette smoke (Lahmann et al., 2001; Morita et al., 2009) and 
lifestyle factors such as stress, illness and pollution (Flament et al., 2013), and 
photoageing: the superposition of changes caused by chronic UVR exposure (Yaar, 
2007b). Intrinsic ageing is regarded by many authorities as a cancer prevention 
mechanism (Campisi, 1996) as the eventual arrest of cell cycle division known as 
‘replicative senescence’ is thought to prevent proliferation of abnormal DNA and 
possible tumour induction.  Intrinsic ageing of the skin presents as finely wrinkled, 
lax, dry, rough skin and a variety of benign neoplasms, whilst photoaged skin by 
definition affects predominantly the face (responsible for 80% of facial skin ageing 
(Flament et al., 2013),) dorsal hands, forearms and upper chest.  Two types are 
described in the literature (Wlaschek et al., 2001): a severe atrophic subtype, with 
multiple telangiectasia, minimal wrinkle formation and a variety of premalignant 
lesions such as AK, and the Milian’s citrine skin which presents with deep wrinkles, 
a leathery appearance, laxity, increased fragility, blister formation and impaired 
wound healing.  White patients presenting with BCC are less wrinkled than peers of 
similar complexion and degree of photodamage (Brooke et al., 2001) suggesting a 
possible protective role of wrinkling in the second subtype of photoageing.  
Photoageing in darker skin types appears as dry, sallow (Yaar, 2007a) and wrinkling 
at later stages but also increasingly pigmented skin due to an increase in melanocyte 
 59 
number and a consequent increase in melanin (Gilchrest et al., 1979).  In terms of 
wrinkling, generally fairer skin types are more severely affected than darker skin 
types, although african skin has been shown to have a higher baseline level of 
collagen I, III and fibrillin rich microfibrils (Chung, 2003) and these differences 
could related to UVR penetration properties in different skin types as demonstrated 
in skin cultures (Kaidbey et al., 1979) in which black skin allows approximately 6% 
of UVB to be transmitted into the dermis compared with almost 30% into the dermis 
of white skin.  Furthermore, only 18% of UVA is transmitted into black dermis 
compared with more than 55% penetration in white skin.  The incidence of skin 
cancer is much lower in this phototype (Yaar and Gilchrest, 2007) see section 1.4.2 
Photocarcinogenesis. 
Histology of ageing 
The dermis consist of collagens, (fibrillar: I, II, III, V, XI, anchoring: VI and VII) 
and elastic fibres encased in the dermal matrix (Langton et al., 2010, 2012; Thurstan 
et al., 2012) consisting of a gelatinous amorphous mix of glycoproteins such as 
fibronectin which stabilise fibres and give flexibility to the skin and proteoglycans 
(which have a lower protein content than glycoproteins) such as glycosamine which 
are mostly produced by fibroblasts and are rich in hyaluronic acids.  These are 
associated with moisture retention.  The different collagens in the skin exert different 
functions in different parts of the dermis: for example the anchoring collagens IV 
and VII are localised at the dermal epidermal junction (DEJ) (in the papillary 
dermis) where they play key roles in binding and stabilisation of tissue layers whilst 
the widely distributed fibrillar collagens I and III, found predominantly in the 
reticular dermis, form covalently bonded fibrils which resist tensile forces.  Except 
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for collagen IV (Watson et al., 2001a) these are all reduced in photoageing 
(Wlaschek et al., 2001).  The elastic fibres, which drive passive recoil and give the 
skin elasticity (Uitto, 1979), are composed of an elastin core and a microfibril 
scaffold (with a 10-20nm diameter), which in an adult is composed largely of 
fibrillin I (Watson et al., 1999).  The elastic fibres are sometimes referred to as 
tropoelastin (rich in valine and alanine as well as hydroxyproline).  The key 
characteristic histological change in photoaged skin is a significant accumulation of 
dystrophic cross-linked elastic fibres sheathed in fibrillin rich microfibrils in the 
reticular dermis which gives it the amorphous appearance on histology and is 
classically termed solar elastosis (Bernstein et al., 1994; Calderone and Fenske, 
1995; Mitchell, 1967).  Recent work has shown a significant decrease in fibrillin 1 
protein in early photoaged skin (Watson et al., 1999).  Furthermore, an increase in 
mast cells, mononuclear cells and neutrophils have been reported in murine 
photoaged skin (Kligman and Murphy, 1996) likely mediated through an 
upregulation of IL1B (Qin et al., 2014).  The impact of UVA1 and UVB on solar 
elastosis is examined in Chapter 5.  
With intrinsic ageing, the skin exhibits epidermal and dermal atrophy and a reduced 
number of mast cells and dysfunctional fibroblasts (which produce less collagen and 
more matrix metalloproteinases (MMP) see below).  This can be explained by the 
age associated increase in senescent fibroblasts that become increasingly 
collagenolytic (West et al., 1989) 




Figure 1.13  Histological changes in ageing and photoageing 
 
MMP and photoageing 
Extracellular matrix proteins known as MMP are a large family of proteases that 
share common structural and functional elements, and all contain a conserved zinc 
containing binding site that is found in their catalytic domain (Klein and Bischoff, 
2011).  MMP are released as proenzymes where a blocking cysteine residue must be 
removed in order to activate enzyme activity.  This is largely in order to ensure 
MMP activity is focussed at target sites.  Their main physiological function is 
ascribed to the modulation and regulation of extracellular matrix (ECM) turnover by 
direct proteolytic degradation of dermal ECM proteins and non-matrix proteins 
(Woessner, 1991) as well as liberation of biologically active cytokine growth factors 
and chemokine from their membrane anchored preforms.  MMP upregulation forms 
part of normal physiological processes such as wound healing and angiogenesis 
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There are many different MMP classification systems.  The most biologically 
relevant system involves classification according to function, and subdivides MMP 
into collagenases (capable of degrading the triple helical collagens e.g. MMP1, 
MMP8, MMP10, MMP13), gelatinases which primarily act on type IV collagen and 
gelatin and include MMP2, MMP9, the stromelysins which cleave extracellular 
matrix proteins but not the triple helix of collagen and include MMP3, MMP10, 
MMP11 and the membrane type (MT) MMP (MMP14, MMP15, MMP16, MMP17, 
MMP24, MMP25), although it is quite clear that there are a series of MMP that do 
not fit into these groups, namely MMP7 and MMP12.  There is also considerable 
overlap in function as MMP2 also has collagenolytic activity, as does MMP14. 
Enzyme MMP ECM substrate 
Collagenases 






Collagens (I, II, VII, VIII, X) gelatin, aggrecan, 
veriscan, tenacin, entactin 
 













Collagens (I, II, III, IV, IX, X, XIV) gelatin, aggrecan, 
fibronectin, osteonectin 
Collagenase 4 MMP18 - 
Gelatinases 




Collagens (I, IV, V, VII, X, XI and XIV), gelatin, 
elastin, fibronectin, lamnin-1, laminin 5, aggrecan 




Collagens (IV, V, VII, X and XIV) gelatin, elastin 
aggrecans, fibronectin, entactin, osteonectin 
Stromelysins 






Collagens (III, IV, V, IX) gelatin, aggrecan, versican, 
perlecan, decorin, fibronectin, laminin, entactin, 
osteonectin 
Stromelysin 2 MMP10 Collagens (III, IV, V), gelatin, casein, aggrecan,  
Stromelysin 3 MMP11 Casein, laminin, fibronectin, gelatin, collagen IV 





Collagen (IV, X), gelatin, aggrecan, decorin, fibronectin, 
laminin, elastin, casein, transferrin 
Matrilysin 2 MMP26 - 






Collagen IV, gelatin, elastin, casein, laminin, 
fibronectin, enactin 





Collagens (I, II, III), casein, elastin, fibronectin, gelatin, 
laminin, vitronectin, entactin, proteoglycans 
MT2-MMP MMP15 Fibronectin, laminin, entactin, aggrecan, perlecan 
MT3-MMP MMP16 Collagen III, gelatin, casein, fibronectin 
MT4-MMP MMP17 - 
MT5-MMP MMP24 - 
MT6-MMP MMP25 - 
Other 
  - MMP19 Gelatin 
- MMP23 - 
- MMP21 - 
- MMP22 - 
Table 1.5  Classification of MMPs  
This table shows the substrates acted on by all MMP.  These have formed the basis 
of enzyme activity staining protocols (in situ zymography) in an attempt to more 
accurately localise MMP in the skin (Mook et al., 2003; Yan and Blomme, 2003) 
 
MMP activity also occurs in pathological tissue destruction processes as found in 
chronic wounds, dermal photoageing, bullous skin disease, cancer invasion (MMP1 
and MMP10 in SCC (Ramos et al., 2004)) and MMP12 induction in epithelial SCC 
and BCC and head and neck SCC (Kerkela et al., 2000), and metastasis (MMP12) 
and vulval cancer invasion (Kerkela et al., 2002) and this has been extensively 
reviewed elsewhere (Deryugina and Quigley, 2006).   
Pathological increases in MMP: MMP1, MMP3 and MMP9 form the basis of the 
photoageing process in human skin (Fisher et al., 1996; Fisher et al., 1997; Quan et 
al., 2013) predominantly through AP1 induction.  UVR induction of MAPK (JNK, 
ERK, p38) signalling activation causes an upregulation of AP1 (cFos-cJun) complex 
through cJun upregulation (Fisher and Voorhees, 1998) which occurs at 2h post 
irradiation and 8h maximally, without a concomitant increase in tissue inhibitors of 
matrix metalloproteinases (TIMP 1-4) (Quan et al., 2009).  Interestingly MMP2 
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upregulation is not mediated by AP1 (Fisher et al., 1996).  Upregulated MMP1 
protein degrades collagen I and III and these accumulated collagen fragments also 
have an effect of further inhibiting fibroblast ability to produce new collagen.  The 
net result is a degradation of collagen in the dermis, which reduces the structural 
integrity of the skin.  UVR also causes transforming growth factor β1 (TGFβ1) 
suppression which decreases collagen I and III levels, whilst UVR activation of 
NFkB (which controls expression of a large array of genes involved in immune 
function and cell survival) directly upregulates MMP8 that is released from activated 
neutrophils and contributes to the dermal matrix remodelling process.  Other UVR 
upregulated MMP include MMP10 in a SCC cell line (Ramos et al., 2004) and 
MMP2 (Brenneisen et al., 2002) and recently other work has shown that MMP11, 
MMP17, and MMP27 mRNA are upregulated in photoaged skin (Quan et al., 2013).  
Work has extensively studied the mechanisms by which UVR induces MMP, and the 
wavelengths responsible for MMP1 and MMP3 induction have been shown to be 
distinct from the absorption spectrum of DNA (Brenneisen et al., 1996) suggesting 
another mechanism of induction other than direct DNA damage.  MMP can be 
triggered by CPD formation (Dong et al., 2008) as well as indirectly via the 
generation of ROS and ROS induced lipid peroxidation (Brenneisen et al., 1997; 
Brenneisen et al., 1998; Scharffetter-Kochanek et al., 1993).  MMP may also be 
induced by mediators such as IL6/IL1 (Wlaschek et al., 1993; Wlaschek et al., 1994) 
and TNFα (Steenport et al., 2009), which is readily induced in the skin by UVR, 




Other mechanisms of photoageing 
There is an emerging view that photoageing is the result of a repeated microscopic 
abnormal wound healing responses which coalesces into ‘solar scars’ (Fisher et al., 
1996) over time, although the free radial theory of photoageing due to repetitive 
protein oxidation in the dermis has also been entertained (Sander et al., 2002; Yaar 
and Gilchrest, 2007), and supporting this is the lower constitutive levels of the 
antioxidant enzymes catalase and superoxide dismutase 1 and 2 (SOD1 and SOD2) 
in the dermis compared to the epidermis. 
Genetic damage and instability outside the nuclear genome has been suggested to 
contribute to ageing.  Cellular mitochondria generate energy (ATP) via a series of 
redox reactions mediated through the electron transport chain and antioxidants 
(NADH, FADH2, coenzyme Q).  Despite these constitutive enzymes and 
mitochondrial BER, mitochondria DNA (mtDNA) is particularly sensitive to ROS 
induced damage and the mutation incidence for mtDNA is about 20 fold increased 
compared to nuclear DNA (Wlaschek et al., 2001).  Photodamaged skin has a higher 
mtDNA mutation frequency when compared with sun protected skin (Berneburg et 
al., 2000) which also correlates with higher MMP1 levels. 
UVA and UVB contribution to photoageing 
Although the action spectrum for photoageing in humans has not been determined, 
the relative contributions of different wavebands in mice have been studied (Bissett 
et al., 1989; Kligman and Sayre, 1991; Wulf et al., 1989) and UVB is more potent 
than UVA.  Because of its >10 fold greater abundance in terrestrial sunlight, far 
greater year round and day long average irradiance and greater average depth of 
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penetration into the dermis compared with UVB, UVA is still thought to play a large 
role in photoageing.  There have also been reports of facial photoageing asymmetry 
in car drivers with more damage on the side of the face closest to the car window 
(Singer et al., 1994) which is possibly more likely caused by UVA, and not UVB, 
penetrating through glass.  Studies in reconstructed human fibroblasts in vitro 
showed that UVB primarily affected epidermal cells forming CPD and SBC whereas 
UVA induced apoptosis of fibroblasts located in the upper dermal compartment as 
well as secretion of MMP (Bernerd and Asselineau, 1998; Herrmann et al., 1993). 
Histological examination of the skin after multiple sub-erythemogenic doses of 
UVA1, UVA2 and SSR showed that inflammatory infiltrates (lymphocytes, 
histiocytes and mast cells) appeared to be a predominantly UVA mediated dermal 
response (Lavker et al., 1995).   
Measuring photoageing 
Several systematic approaches have been developed to measure photoaging.  A 
photonumeric scale in which clinical parameters (fine wrinkling, coarse wrinkling, 
mottled pigmentation and sallowness) are graded from 0-8 showed 80% agreement 
by 7 independent dermatologists (Griffiths et al., 1992) has also been adapted in 
white females (Larnier et al., 1994), and a similar approach has been set up for 
Korean skin (Chung, 2003). Other approaches include assessing skin topography 
with a modified dermatoscope  (Dermascore), using a corneometer to assess stratum 
corneum hydration and confocal microscopy visualisation of the various layers of the 
skin (Yaar, 2007b) and mechanical models have been developed to measure 
elasticity of the dermis (Pailler-Mattei et al., 2008).  These methods can be used as 
endpoint measurements and recently, the use of silicone moulds to obtain skin 
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surface markings has been used in over 900 adults on the backs of hands  
demonstrating the effectiveness of daily sunscreen use in retarding photoageing 
compared to ad hoc sunscreen users over a period of 4 years (Hughes et al., 2013). 
Treatment of photoaged skin 
The gold standard pharmaceutical therapy for photoageing is the use of all trans 
retinoic acid (tRA).  This is a derivative of vitamin A, and was first used to treat AK 
and acne in the 1970s (Pedace and Stoughton, 1971) and incidentally found to also 
improve periorbital wrinkles.  Subsequent studies have shown that topical tRA 
improves fine wrinkling of the skin after 3-4 months of therapy with an increase in 
mean epidermal thickness (Kligman et al., 1984) and similar efficacy can be 
achieved at 0.025% and 0.1% but with lower irritancy (tretinoin associated 
dermatitis) (Griffiths et al., 1995).  The mechanism of action has been extensively 
studied and shown to involve fibroblast stimulation and new collagen synthesis, via 
nuclear retinoid receptors (RAR and RXR) which prevents c-Jun activation, and 
hence AP1 expression and downstream reduction of MMP activation in the 
epidermis and dermis (Fisher et al., 1996; Fisher et al., 1998).  Pretreatment with all 
trans retinoic acid also results in significant inhibition of UVR induced MMP1, 
MMP3 and MMP9 mRNA and protein levels with no effect on TIMP1 expression 
(Fisher et al., 1997) although photosensitivity has been described (Birner and Meyer, 
2001). There is also a partial restoration of fibrillin 1 that occurs after daily 
application of tRA measured over a 4 years (Watson et al., 2001b).  
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1.5 Infrared and visible light  
In direct sunlight, the temperature of human skin can rise above 40°C after the 
conversion of absorbed IR into heat (Cho et al., 2009), and erythema ab igne 
characterised by reticular pigmentation, and histologically by the presence of solar 
elastosis in the dermis, is a well known heat induced skin condition (Kligman, 1982).  
Gene studies in human fibroblasts indicate that IR is a potent regulator of key 
signalling molecules such as ERK1/2, p38, JNK, PI3K/AKT, STAT3 (Calles et al., 
2010) and at physiological doses, corresponding to 2-3h of summer sunshine in 
central Europe (360-720J/cm2), there is approximately 8 fold upregulation of MMP1 
mRNA compared to control (Schroeder et al., 2007).  Mechanism of induction is 
thought to be absorption by copper in complex IV of the mitochondrial respiratory 
chain and generation of intramitochondrial ROS resulting in an activation of MAPK 
in cell cytoplasm and subsequent intranuclear transcription of MMP1 presumably via 
AP1 (Schroeder et al., 2008).  Multiple doses of IR on human skin in vivo over a 
period of 4 weeks increased MMP1 mRNA and protein levels and decreased 
procollagen 1 levels (Kim et al., 2006) although chronic heat exposure in hairless 
mice causes an increase in MMP1 MMP3 and MMP12 (Chen et al., 2005) but not 
MMP2, as well as clinically observed skin wrinkling (Kim et al., 2005).  
Comparing effects of the different components of sunlight in human volunteers after 
a 3h summer sunshine exposure in Korea, there appears to be a synergistic effect of 
IR and visible light in inducing slightly higher MMP1, MMP9 expression as well as 
a decrease in procollagen 1 levels (Cho et al., 2008).  The effects of IR on CPD 
induction has not been studied however visible light does not induce TT dimers.  
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Clearly IR contributes to photoageing however it will not be discussed further in this 
thesis. 
1.6 Genetic effects of UVR on the skin 
Following UVR absorption there is direct damage, as well as indirect damage to 
DNA, lipids, proteins in the skin via production of ROS.  These can oxidize free 
lipids in the stratum corneum or keratinocyte membranes causing release of 
ceramides which via protein kinase mediates signal transduction (MAPK activation), 
activates AP1 resulting in expression of many stress response genes, including 
intercellular adhesion molecule 1 (ICAM1) on keratinocytes and vascular endothelial 
growth factor (VEGF), ICAM1 and E-selectin on endothelial cells which enables 
chemotaxis of neutrophils and lymphocytes (Hawk et al., 1988) respectively to 
propagate the inflammatory response.  AP1 also interferes with TGFβ transcription 
that ultimately blocks dermal collagen I and III production and also activates MMP 
(see Photoageing).  Oxidized lipids are cleaved by phospholipase A2 (PLA2) to form 
arachidonic acid that is the substrate for COX1 and inducible form 2 (COX2). These 
enzymes convert arachidonic acid into prostaglandins and mediate many of the 
inflammatory reactions in the skin in response to UVR.  MAPK activation (via c-Jun 
N-terminal kinases (JNK) and p38 signalling) can also occur via growth factor and 
growth factor receptor (epidermal growth factor receptor (EGFR).  ROS induced 
protein oxidation leads to activation of damage response pathways leading to MMP 
production, inflammation and clinical signs of erythema. 
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Figure 1.14  UVR signalling and gene regulation 
 
1.7 Photoprotection  
1.7.1 Sunscreens 
Traditionally, sunscreen filters are categorized according to their optical properties; 
organic sunscreens absorb UVR, convert it to heat and prevent photons from 
interacting with skin molecules (Jansen et al., 2013a) and inorganic (or physical) 
sunscreens which contain particles that reflect and absorb photons.   Organic filters 
are aromatic compounds, and some of the earlier ones include Avobenzone and 
octinoxate (Jansen et al., 2013a). They are invisible; hence aesthetically pleasing 
although UVR absorption may activate molecules leading to unwanted clinical 
reactions such as photoallergic contact dermatitis.  According to an Australian study, 
adverse reactions from sunscreen ingredients can occur in up to 19% of sunscreen 


















































phototoxic and photoallergic reactions, contact urticaria and in rare circumstances, 
anaphylaxis.  More recent sunscreens however, such as Mexoryl SX (λmax 345nm), 
Tinosorb (305nm, 360nm) and UVAsorb (312nm) are less likely to cause adverse 
effects.   
Inorganic sunscreens are chemically inert and do not cause allergic sensitization, 
although they are often visible on the skin surface due to their scattering properties.  
They include zinc oxide and titanium dioxide.  Generally, commercial formulations 
contain a mixture of both types of sunscreen (Tuchinda et al., 2006; Yaar, 2007b) 
although none of these filters protect against visible and infrared radiation.  There is 
an overlap in the way filters work as zinc and titanium oxides have absorbing as well 
as scattering effects, hence a more recent and probably more appropriate 
categorisation of sunscreens are into soluble and insoluble forms (Jansen et al., 
2013a; Osterwalder et al., 2014).  
 
The sun protection factor (SPF) is the ratio of the MED of protected skin over the 
MED of unprotected skin.  The end point is cutaneous erythema assessed 24h after 
exposure to SSR, thus it is primarily used as a measure of UVB protection.  A higher 
SPF affords greater sun protection and work done in vitro with an SPF 15, 30 and 60 
demonstrates that after a given 10 minute exposure, 80% of a sunburn dose is 
reached using an SPF 15 sunscreen compared with 40% and 20% respectively for 
SPF 30 and SPF 60 (Osterwalder et al., 2014; Sambandan and Ratner, 2011). In 
terms of transmittance, an SPF 60 sunscreen transmits half as much erythemal UVR 
as an SPF 30 sunscreen i.e. 1.7% compared to 3.33% (Osterwalder et al., 2014).  
SPF is measured in vivo at 2mg/cm2 although it is well known that the public use 
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sunscreens at much lower concentrations at 0.5mg/cm2 (Lim and Honigsmann, 
2007), therefore in such cases, the SPF provided by a labelled sunscreen is likely to 
be 4 times lower in practice.  Analysis of the specified solar simulator spectrum used 
to determine SPF indicates that if 100% of the UVB is blocked, it is mathematically 
impossible to achieve an SPF in excess of approximately 11 without also blocking at 
least some UVA and that UVA protection needs to be provided in order 
for sunscreen products to achieve SPFs of 15 and higher (Sayre et al., 2008) 
suggesting significant erythemal contribution from UVA.  Practically complete 
blockage of UVB by means of the two most efficient UVB filters (5 % Octyltriazone 
(EHT) plus 10 % Iscotrizinol (DBT)) yields an SPF 14, whereas with the addition of 
only 4% bisoctrizole (MBBT) the SPF jumps to SPF 50.  
 
Methods for testing UVA protection vary by country.  In the EU, in order to give 
broad band cover; UVA-PF/SPF ≥ 1 /3 (Jansen et al., 2013a) UVA cover should be 
at least 1/3 of the SPF.  In the UK, the Boots 5 star rating, with 5 star providing a 
UVA/UVB ratio >0.9 provides closer to uniform UVB/UVA protection which may 
be regarded as ideal sunscreen performance (Hexsel et al., 2008).   
 
The US uses a different strategy to measure broadband sunscreen efficacy based on 
the critical wavelength (CW), defined as the wavelength at which 90% of the total 
area under the absorbance curve occurs.  Sunscreens that have a CW of >370 nm 
claim broad-spectrum status (Jansen et al., 2013a). 
 
It has previously been unclear whether sunscreens are of any benefit in the 
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prevention of skin cancer.  Some have argued that they may just serve to increase the 
amount of time users spend in the sun, subject them to larger doses of UVA and 
hence ultimately increasing skin cancer risk. This has been supported by a frequently 
cited study of university students who increased their time in the sun during a spring 
vacation while using a sunscreen with a high SPF (Autier et al., 1999).  However, a 
land mark randomized trial in Queensland Australia, showed that SPF15 broadband 
sunscreen users had 39% fewer SCC on head, neck, arms and hands compared to the 
control group (Green et al., 1999) over a 4.5 year period.  In a further 8-year follow-
up there was nearly a 40% reduction in SCC (van der Pols et al., 2006) and a 50% 
reduction in melanomas over a 15-year period (Green et al., 2011).  
 
1.7.2 Topical DNA repair enzymes 
The use of DNA repair enzymes is an emerging approach to enhance DNA repair 
after UVR exposure.  In the mid 1970s, the bacteriophage T4 DNA repair enzyme 
endonuclease V (T4N5) was found to augment NER in XP cells (Tanaka et al., 
1975).  T4N5 catalyzes two reactions. It acts as a glycosylase, cleaving the glycosyl 
bond linking the base to the deoxyribose phosphate chain to leave an 
apyrimidinic/apurinic (AP) site. It has endonuclease activity which cleaves the 
phosphodiester bond leaving the ‘free’ phosphate backbone. Enzymes of the host 
cell then continue the process by removing the hanging CPD lesion by exonuclease 
activity and repair the site via polymerases (see Figure 1.15). 
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Figure 1.15  Repair initiated by T4N5 which has binding, glycosylase and endonuclease activity 
Adapted from (Friedberg and Wood, 1995) 
   
The use of T4N5 to enhance DNA repair in the skin can be delivered via liposomes 
(lipid bilayer molecules) where T4N5 is encapsulated between membranes in order 
to facilitate delivery across the skin.  T4N5 can be delivered to epidermal cell (in 
keratinocytes and Langerhans cells) cytoplasm within 1h (Yarosh, 2002) and is 
available as Dimericine®,  Studies with these enzymes (Yarosh, 2002) show that 
CPD repair is associated with a reduction in MMP1 (Dong et al., 2008), erythema, a 
decrease of immunosuppressive cytokines such as TNFα and IL10 (Wolf et al., 
2000) and thus the CPD triggers a series of biological processes   It also reduces 
UVR immunosuppression. (Kripke et al., 1992; Kripke et al., 1996).  Treatment with 
UVR prior to the application of a contact sensitizer such as dinitrochlorobenzene 
(DNCB) prevents the normal CHS response.  However, topical application of T4N5 











































blocks UVR suppression of the DTH response and formation of Treg cells (Kripke et 
al., 1992; Wolf et al., 1993) (see 1.9 The immune response to UVR).  This has 
implications for skin cancer, numbers of which can be reduced in mice with the 
topical application of T4N5 (Yarosh et al., 1992).  In a landmark randomized study 
in XP patients, topical T4N5 was found to reduce the incidence of AKs and BCCs by 
>68% and 30% respectively (Yarosh et al., 2001).   
Photoreactivation is the term used to describe the repair of UVC and UVB induced 
DNA damage using long wave UVR, and in the presence of specific enzymes 
(Jagger, 1960) termed photolyases. These are found in non-placental mammals, as 
well fish, reptiles, prokaryotes and eukaryotes, although controversially the presence 
in human white blood cells (Sutherland and Bennett, 1995) has been suggested.  
DNA photolyases were first shown over 40 years ago to enhance DNA repair but it 
is only in the last few years have sufficient quantities been purified to permit detailed 
studies.  Photolyases are specific to the type of DNA photolesion and there are CPD 
(class I and II) and 6-4PP photolyases (class III): (Weber, 2005).  All photolyases 
have a flavin adenine dinucleotide (FADH) cofactor and a second chromophore.  In 
class 1, the second chromophore is either a folate (MTHF) or deazaflavin (8-HDF) 
which absorbs at either 384nm or 438nm respectively (Sancar, 1990).  The 
absorption maximum for flavin is at 313nm. 
The non-covalently bound flavin cofactor plays the essential role in catalysis and in 
the fully reduced form: FADH-, acts as a 2-electron donor.  The second 
chromophore absorbs near UV and visible wavelengths and transfers the excitation 
energy to FADH to yield the excited singlet state FADH-*.  Electron donation then 
breaks up the cyclobutane ring of the CPD (Sancar et al., 1987; Weber, 2005), 
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following which electron restabilisation returns it to the fully reduced FADH- 
cofactor.  Other work (Sancar, 2003) suggests both chromophores absorb 
photoreactivating UVR/light and that as it has a higher extinction coefficient (more 
likely than flavin to absorb light at a given wavelength)  the second chromophore 
acts to improve CPD repair by 10-1000 fold (Sancar, 2003).  
Repair of CPD in the opossum (Monodelphis domestica) by photoreactivation 
reduced UVR induced erythema (Ley, 1985).  This not only enabled an 
understanding of a biological role of CPD in the skin but also introduced the concept 
of manipulating biological processes through repair of DNA damage.  Liposome 
encapsulated photolyase also has immunomodulatory functions and restores APC 
activity in mice (Vink and Roza, 2001), reduces UVR induced apoptosis and reduces 
the inhibition of CHS in vitro (Stege et al., 2000).  Using mice expressing a 
marsupial CPD photolyase transgene, the vast majority of acute responses in the 
UVR exposed skin (sunburn apoptosis, hyperplasia and mutations induction) can be 
ascribed to the CPD (Schul et al., 2002) with a minimal contribution by 6-4PP (Jans 
et al., 2005).  CPD photolyase mice remained tumour free for longer than 6-4PP 
photolyase mice after multiple UVB doses.  This work supports the CPD as the 
principal cause of NMSC.  In humans, two main studies have looked at the impact of 
photolyase on CPD repair.  Stege and coworkers (Stege et al., 2000) showed that 
DNA photolyase repair reduced CPD by 40-45% after a 30-minute exposure to 
UVASUN (365nm, maximum peak).  Photolyase also prevented UVR induced  
ICAM1 expression (important to recruit inflammatory cells to the skin) as well as 
prevented the suppression of the elicitation of hypersensitivity to nickel, sunburn cell 
formation and erythema.   
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Recently the addition of photolyase to topical sunscreens (SPF 50) has been shown 
to significantly reduce CPD 72h after 4 daily 3MED SSR exposures (Berardesca et 
al., 2012).  In terms of clinical endpoints recent work showed that over a 3 month 
period 6 patients had improvement in the number of AK with a topical application of 
a lotion containing photolyase (Puviani et al., 2013), although this study did not have 
a control study population. 
Plant derived, liposome encapsulated OGG1 enhances 8oxoG removal from human 
epidermal keratinocytes and recent work incorporating T4N5, photolyase and OGG1 
as well as topical antioxidants into sunscreens had the effect of decreasing CPD in 
the skin (Emanuele et al., 2014) but interestingly not 8oxodG.  Of note certain 
sunscreens (phenylbenzimidazole-5-sulfonic acid (PBSA) appear to oxidise guanine 
in vitro following UVB irradiation (Bastien et al., 2010).  
 
1.7.3 Antioxidants 
The skin contains many antioxidant enzymes (AOx): SOD, catalase and glutathione 
(GSH) peroxidase as well as non-enzymatic antioxidant molecules: α-tocopherol 
(vitamin E), L-ascorbic acid (vitamin C) and GSH.  Topical AOx convert free 
radicals to less reactive molecules through pairing a single electron or by removing 
the unstable electron.  For example SOD catalyses the conversion of O2 - radicals 
into H2O2 and O2, which is further reduced to H2O2 and O2 with the aid of catalase 
and GSH peroxidase.  However sub-erythemogenic UVR doses deplete tocopherol in 
human stratum corneum (Thiele et al., 1998) resulting in increased oxidative stress 
leading to lipid peroxidation, protein oxidation (Sander et al., 2002) and DNA 
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damage, which over time leads to photocarcinogenesis, photoageing and 
immunosuppression (Chen et al., 2012).  Work has examined the usefulness of 
exogenous antioxidants in mice.  Oral AOx such as green tea (Elmets et al., 2001) or 
grape seed extract (Jansen et al., 2013b) is thought to play in role in reducing UVR-
induced skin cancer formation.  Topical green tea extracts (polyphenols) have also 
been shown to reduce DNA damage and p53 formation after PUVA therapy in 
reconstructed skin (Zhao et al., 1999), probably mediated through IL12 dependent 
DNA repair and a subsequent reduction in skin inflammation (Meeran et al., 2009; 
Schwarz, 2008). 
Vitamin C (1% vitamin C, L-
ascorbic acid) 
Also found as ascorbyl phosphate and ascorbyl 6-
palmitate yet these do not achieve same activity 
levels as ascorbic acid or vitamin C in vivo.  
Vitamin C increases collagen synthesis and reduces 
MMP1 expression. 
Vitamin E (α tocopherol acetate, α 
tocopherol succinate) 
Multitude of animal and human studies show a 
reduction in lipid peroxidation, photoageing, 
immunosuppression and photocarcinogenesis 
Vitamin A (retinoids (isotretinoin, 
tretinoin, tazarotene, carotenoids 
(βcarotene and lycopene) 
Early animal studies suggested that retinyl palmitate 
(vitamin A- retinol derivative) had 
photocarcinogenic effects (Wang et al., 2010b) 
although results were inconclusive and this 
derivative is used infrequently 
Carotenoids on the skin scavenge 102 and quench 
lipid peroxidation 
Tea polyphenols  
(epicatechin, epicatehin-3-gallate, 
epigallocatechin) 
Tea polyphenols are unstable and activity 
diminishes quickly. Formations are stablished to 
reduce susceptibility to oxidation.  Have anti-
inflammatory and anticarcinogenic effects and can 
inhibit collagenase activity.   
Plant antioxidant – caffeic acid 
(ferulic acid, phenethyl ester) 
Soy isoflavones 
Found in topical preparations particularly in 
combination with L-ascorbic acid and α tocopherol.  
Contains genistein and daidzein.  Diets high in 
soybeans are anticarcinogenic.  Topical genistein 
decreases UVR induced oxidative damage, 
immunosuppression and inflammation. 
Table 1.6  Common topical antioxidant preparations  
Adapted from Chen et al (Chen et al., 2012) 
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Thus there is a growing trend to incorporate non-enzymatic AOx into skin care 
products and sunscreens, specifically to combat photoageing.  Two have been tested 
to penetrate the skin.  Topical vitamin E has been shown to be particularly useful in 
reducing UVB induced sunburn cell formation in animal models whilst vitamin C 
(stable form; L-ascorbic acid) is particularly effective against PUVA induced 
phototoxic insults (Darr et al., 1996).  The protective benefit of combining these 
AOxs with sunscreens has been demonstrated in human studies.  Participants 
received either a sunscreen with SPF 25 or the same sunscreen with a combination of 
caffeine, vitamin E, vitamin C, and after UVR, the sunscreen and antioxidant group 
had a 17% greater reduction in MMP1 levels compared with sunscreen alone 
(Matsui et al., 2009).  In another group using vitamin C and vitamin E, there was 
significant protection against MMP9 induction and pigment formation (Wu et al., 
2011).  
Other effects include a reduction of erythema, sunburn cell formation (SBC) and a 
reduction in UVR immunosuppression likely due to a reduction in lipid peroxidation 
and migration of LC from the epidermis (Yuen and Halliday, 1997).  Some animal 
studies also suggest vitamin E reduces the chronic effects of UVR on the skin 
particular skin cancer formation (Burke et al., 2000).  For a comprehensive review 
see Chen 2012 (Chen et al., 2012). 
 
1.8 The immune response 
The skin is a mechanical defence barrier, but also has the capacity to induce an 
immune response via the skin associated lymphoid tissue (SALT) (Streilein, 1989).  
The immune response has innate and adaptive arms.  The innate response is rapid 
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and its essential components include cytokines, complement, mast cells, microbial 
peptides and lymphoid derived natural killer cells as well as leukocytes: granular 
(neutrophils, eosinophils and basophils) and agranular (monocytes and 
macrophages).  Leukocyte derived cytokines that exert effects on other white blood 
cells are called interleukins (IL), and those that have chemoattractant activity are 
termed chemokines and sub grouped as CXC or CC according to the position of the 
cysteine (C) or amino acid (X) residue.  Induction of the adaptive immune system is 
critically dependent on cytokines, and is specific and enhanced with each successive 
antigen encounter due to T cell memory.  It consists of humoral (B cell) and cellular 
(T cell) immunity.   
Many cell types including B cells and macrophages are involved in antigen 
presentation or can reactivate memory lymphocytes.  Dendritic cells (DC) are the 
only type of APC capable of initiating activation of naïve lymphocytes (CD45RA) 
upon their first encounter with antigen and are termed professional APC. These 
include epidermal LC (CD45+, CD1a+) and dermal dendritic cells (dDC).  
Exogenous antigen is internalized and processed by DC which migrate to draining 
lymph nodes. DCs (most literature indicate these as LC) to present antigenic peptide, 
in association with MHC class I or class II molecules, to T cells (Duthie et al., 
1999).  According to the cytokine milieu and co-stimulatory molecules, T cells 
express either CD4+ or CD8+ with different functions.  Memory T cells (CD45R0+) 
are also produced which remain in an inactive state until antigen is reencountered 




The major TH1 derived cytokine is IFNγ that activates macrophages to kill 
intracellular pathogens (mycobacteria, fungi, protozoa) and stimulates natural killer 
(NK) cell cytotoxicity.  Stimulated macrophages also release IL12 that continues to 
drive THO cells towards a TH1 phenotype.  The TH1 arm facilitates cell mediated 
immunity and also contributes to the pathogenesis of autoimmune disease such as 
rheumatoid arthritis, multiple sclerosis, allergic contact dermatitis and psoriasis (see 
Figure 1.11). 
 
Figure 1.16  Cellular immunity 
Stimulation of CD4+ T cells to differentiate to TH1, TH2 or TH17 cells depending on 
cytokine milieu and via presentation of antigen with MHC class II and stimulation 
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TH2 cells produce primarily IL4, IL5, IL6, and IL10, and are generally associated 
with allergic diseases.  IL10 inhibits development of TH1 responses.    
TH17 cells  
CD4+ T cells that produce IL17, but not IFNγ or IL4, are referred to as TH17 cells.  
They secrete IL17A, IL17F, IL21 and IL22, all of which are driven by IL23.  TH17 
cells are rapidly induced in response to bacteria and fungi, and also have important 
roles in chronic inflammation and in mediating autoimmune reactions.  They are 
upregulated in rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease 
and psoriasis where genetic studies have linked variants of the IL23 and IL23 
receptor genes to susceptibility to psoriasis and psoriatic arthritis (Cargill et al., 
2007).  In fact biological therapy with ustekinumab (a monoclonal antibody to p40 
and a subunit of both IL12 and IL23) represents one of the most effective 
interventions for psoriasis (Leonardi et al., 2008). 
1.9 The immune response to UVR 
Host immune defences have evolved to eliminate “non-self” which includes 
neoplastic cells.  The first evidence demonstrating UVR immunosuppression 
emerged from the mid 1970s where highly antigenic skin tumours were rejected on 
transplantation to normal recipient mice of the same genetic background, however 
were not rejected and progressively grew when transplanted onto UVR irradiated 
recipients (Fisher and Kripke, 1977; Kripke and Fisher, 1976).  
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Depending on dose and wavelength, UVR markedly depletes epidermal LC, mostly 
inducing their migration to draining lymph nodes. High UVR doses may also trigger 
LC apoptosis (Schwarz et al., 2000; Schwarz et al., 2004), and some LC reaching the 
draining lymph nodes are CPD-positive (Sontag et al., 1995).  UVR suppresses the 
surface expression of adhesion and co-stimulatory molecules on migrating LC such 
as ICAM-1, CD80 and CD86, which impairs their antigen presentation capability to 
stimulate CD4+ TH1 cells, although the capacity to activate TH2 cells remains intact 
(Simon et al., 1990).  Thus, there is a reduction of TH1 cytokines (IL12 and IFNγ) 
and a switch to IL4 and IL10 cytokines.  Various soluble immunomodulatory 
mediators are produced both locally and systemically (Clydesdale et al., 2001; 
Duthie et al., 1999) including pro-inflammatory (TNFα, IL1, IL6, IL8 and IL12) and 
anti-inflammatory (IL4 and IL10) cytokines.  T and B cells, monocytes, 
macrophages and keratinocytes (de Vries, 1995) are activated to produce IL10, as 
well as PGE2. Downstream production of PGE2 as well as through UVR induced 
lipid peroxidation leads to a cytokine cascade also producing IL4 and IL10 
(Shreedhar et al., 1998).  Histamine, platelet-activating factor (PAF) and 
neuropeptides (substance P, CGRP) are released which alter skin sensitivity 
explaining how the skin often feels slightly tender post UVR exposure (Harrison et 
al., 2004).  UVR stimulates the production of regulatory T cells (Treg) either natural 
nTreg produced in the thymus or iTreg, induced in the periphery which exert 
inhibitory functions through the release of cytokines (IL10, IL35, TGFβ), apoptosis 
of target effector T cells via release of granzymes and perforins, and sequestration of 
IL2 resulting in TH1 anergy (Schwarz et al., 1996). 
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Figure 1.17  UVR induced immunosuppression 
Migration of Langherhans cells (LCs) to the lymph nodes (LNs), reduction of TH1 
cells and a switch to IL10 and IL4 cytokines and a production of regulatory T cells 
(Treg) cells. 
 
Measuring UVR immunosuppression 
UVR induced suppression of acquired immunity in human skin is a normal 
phenomenon and can be clinically assessed using the CHS response to epicutaneous 
haptens (Kelly et al., 1998; Moyal, 1998) or DTH responses to intradermally 
injected antigens (Moyal and Fourtanier, 2001, 2003).  In the sensitisation phase, 
novel antigens are presented by LCs and other DCs to produce antigen specific 
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recognise those specific antigens and provoke a cutaneous inflammatory reaction, 
which is termed elicitation.  Exposure of the skin to UVR prior to sensitisation 
induces impairment of antigen presentation and other immune changes that result in 
the suppression of elicitation.  For instance, it has been shown that low doses of 
SSR, typically experienced after one hour of exposure to midday summer sunlight at 
mid-latitudes, can suppress the CHS response to 2,4- dinitrochlorobenzene (DNCB) 
in healthy humans (Kelly et al., 2000).  Exposures to doses of UVR that are only 30-
50% of an MED suppress immunity in skin type I/II individuals (Kelly et al., 2000). 
Therefore normal daily outdoor activities during spring and summer months will 
cause some degree of immunosuppression in a large proportion of individuals. 
UVR can induce immune suppression both locally and systemically (Damian et al., 
1998; Kelly et al., 2000; Moyal, 1998).  Experimentally, local immunosuppression 
occurs when a sensitizing hapten/antigen is applied directly to the low UVR-
irradiated site and is due to a depletion in the number of LC at the site of exposure 
(Toews et al., 1980) although recently it has been suggested that LC exhibit 
regulatory activity (Beissert et al., 2006; Schwarz et al., 2000).  Systemic (distal) 
immunosuppression, generally after a higher initial UVR dose is defined as the 
reduced immune responses detected when the sensitising hapten/antigen is applied to 
a distant non-irradiated site (Ullrich, 2005) .  There is a reduced TH1 response 
(Noonan et al., 1981; Ullrich, 2005) and often a reduced immune response after 
application of the same hapten several weeks later (Toews et al., 1980).  This can be 
explained by stimulated keratinocytes releasing immunosuppressive soluble 
mediators, including IL10, TNFα (Ullrich et al., 2007) and IL4 (el-Ghorr and Norval, 
1997) (Hart et al., 2000) in the microenvironment, preventing LC presenting antigen 
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to TH1, as well as an induction of tolerance mediated via hapten specific Treg cells 
(Beissert et al., 2006).   
Immunosuppression can also be mediated by UCA (see section 1.4.1.2) as well as 
DNA damage.  In fact, repair of UVR induced DNA damage also inhibits UVR 
induced immunosuppression in humans (Kripke et al., 1992; Nishigori et al., 1996) 
and induction of Tregs.  Inhibition of UVR induced NO also appears to prevent UVR 
immunosuppression in human skin (Kuchel et al., 2003).  
It is well known that both UVA and UVB contribute to sunlight induced 
immunosuppression (Damian et al., 1999; Poon et al., 2005) with suggestion that 
sunlight is more immunosuppressive than either waveband alone (Poon et al., 2005) 
and that UVA may protect the immune system from the suppressive effects of UVB 
(Reeve et al., 1998; Reeve and Tyrrell, 1999).  With UVB, increased levels of 
immunosuppression occurs with increasing dose however UVA has a bell shaped 
dose response curve so that after the peak immunosuppressive dose has been reached 
higher doses actually cause lower levels of immunosuppression until a dose is 
reached that is no longer suppressive (Byrne et al., 2006).  This complicates our 
understanding of UVA immunosuppression.  Recent characterisation of the 
immunosuppression action spectrum using induction of nickel CHS model produced 
a peak at 370nm corresponding to UVA1 (Damian et al., 2011) although the overal 
major immunosuppressive peak is in the UVB waveband.  
 Several studies have reported that organ transplant patients undergoing 
immunosuppressive therapy have an elevated risk of both NMSC and MM especially 
if they have a history of high sun exposure (Euvrard et al., 1997).  Drugs such as 
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azathioprine also cause DNA photodamage on UVR exposure, which probably plays 
a significant role in skin cancer induction (Kelly et al., 1989; O'Donovan et al., 
2005; Yoshikawa et al., 1990).   
Pathological failure in UVR induced immunosuppression causes an abnormal 
inflammatory response to sunshine as seen in clinical conditions such as 
polymorphic light eruption (PLE) where following UVR exposure (primarily UVA 
(Ortel et al., 1986)) there is in a DTH type response to a UVR unknown neoantigen 
(see 1.10.2 Photodermatoses), and a lack of LC migration and TH2 mediated 
immunosuppressive cytokines (IL4, IL10) (Kolgen et al., 2004; Kolgen et al., 1999). 
 
1.10 UVR and Dermatology 
1.10.1 Phototherapy 
Over the centuries, dating back from as early as 1400BC, sunlight has been used to 
treat skin diseases.  Heliotherapy, named after the Greek god of the sun Helios, was 
used in ancient Egypt, Greece and Rome, but it wasn’t until the second half of the 
19th century that the use of UVR moved from being anecdotal to a more focussed 
form of therapy (Roelandts, 2007). During World War I, heliotherapy provided 
benefit to soldiers with traumatic leg ulcers and was also used in thermal stations to 
treat tuberculosis.  There are reports of Florence Nightingale protesting against the 
orientation of the Royal Victoria Hospital in Southampton, UK, after observing that 
no sunlight could enter its wards.  By the end of the 19th century, Niels Finsen used 
sun exposure in a more standardized way for treatment of Lupus Vulgaris.  He was 
the first to make a switch from heliotherapy with natural sunlight to phototherapy 
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with artificial lamps providing a specific UVR output and won the Nobel Prize in 
1903 for his work.  Photochemotherapy has had a long history with the use of 
psoralen containing plant extracts (Psoralea corylifolia and Ammi majus) and sun 
exposure, to treat vitiligo dating from as far as 2000BC (Pathak and Fitzpatrick, 
1992).  These extracts have now been isolated and used as oral/topical/bath 8 
methoxypsoralen (8MOP), oral 5-methoxypsoralen (5MOP) or bath trioxsalen with 
UVA (PUVA: peak emission 352nm) irradiation for treatment of vitiligo, psoriasis 
and other proliferative diseases.  Notable improvement has been seen in psoriasis 
and the action spectrum for the phototoxic reaction lies in the 330-360 nm range 
(Plewig et al., 1978) although earlier studies show peak photosensitization at 320-
340nm (Cripps et al., 1982).  PUVA is marred with a series of side effects related to 
the agent including nausea as well as increased photosensitivity to sunlight during 
therapy causing burning, itching and an increased risk of skin cancer (Stern, 2001; 
Stern et al., 1998).  Considerable research in the 1980s went into developing 
alternative sources of phototherapy.  Broad band UVB although considerably less 
efficient than PUVA for psoriasis was useful, but it wasn’t until the identification of 
a peak at 313nm in the action spectrum for psoriasis clearance (Parrish and Jaenicke, 
1981) that changed phototherapy practice.  Narrowband (NB) UVB TL01 
phototherapy (311–313 nm) has largely replaced broadband UVB although PUVA is 
probably more effective for treatment of psoriasis in the UK (Ling et al., 2016).  
Other types of phototherapy that have been developed include extracorporeal 
photophoresis (Zic et al., 1992) for cutaneous T cell lymphoma (CTCL) and chronic 
graft-versus-host disease (GVHD), topical photodynamic therapy with visible light 
for actinic keratoses and superficial BCC (Ericson et al., 2008) and UVA1 
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phototherapy.  The rationale for the development of the latter was the need for a 
unique high output mercury lamp (Mutzhas et al., 1981; Plewig et al., 1978) that 
emits biologically effective UVA1 doses and reduces the adverse effects of sunburn 
with the UVA2 part of the spectrum.  Initial work for its use in acne and vitiligo 
proved unsuccessful and it was primarily used as a diagnostic tool for 
photoprovocation of UVA sensitive photodermatoses such as PLE.  It was initially 
considered to have no adverse effect on tissue due to normal histology findings 72h 
after a single 60J/cm2 dose (Mutzhas et al., 1981), however it wasn’t until the early 
1990s, its therapeutic potential in disease was recognised.  Krutmann and colleagues 
reported that exposure to high doses of UVA1 was beneficial for patients with severe 
acute atopic dermatitis (AD) (Krutmann et al., 1992; Krutmann et al., 1998).  
Strongest evidence now exists for its use in localised scleroderma (Andres et al., 
2010), systemic lupus erythematosus (SLE) as well as acute AD.  However, 
treatment depends on the most convenient strategy to implement and in many centres 
the UK, UVA1 is first-line for localized scleroderma only.  There are no 
internationally agreed definitions but 10–29 J⁄cm2 is generally considered ‘low dose’, 
30–59 J⁄cm2 ‘medium dose’ and >70J⁄cm2 ‘high dose’ (Kerr et al., 2012a).  
Established practice at St John’s Institute of Dermatology is medium/low dose 
therapy, and as a general rule, one treatment course does not exceed 30 exposures 
once or twice a year (Krutmann and Akimichi, 2007).  It is advised that 
immunosuppressive drugs such as azathioprine are not combined with UVA1 (Brem 
and Karran, 2012)  and in children its use is limited for only severe cases of 
scleroderma where no other treatment options exists. The high output metal halide 
lamps (Sellamed 4000W, Sellas Medizinische Geräte GmbH, Ennepetal, Germany) 
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deliver biologically effective UVA1 at high doses (Gambichler et al., 2013), yet 
despite this, exposure times are long (often 45 minutes) (von Kobyletzki et al., 1999) 
which patients may find uncomfortable, in particular due to the heat generated from 
infrared emission.  The use of cold light lamps offering UVA1 without infrared have 
also been assessed (Polderman et al., 2005; von Kobyletzki et al., 1999) but outputs 
are lower and thus treatment times longer.  Other adverse events include 
hyperpigmentation: particularly unwanted in darker skinned individuals and limits its 
use in this subpopulation, erythema and pruritus; likely due to mild PLE 
photoprovocation (Beattie et al., 2005a).  Activation of herpes infections have also 
been noted following UVA1 therapy (Krutmann and Morita, 1999).  To reduce the 
risk of precipitating a UVA sensitive photodermatoses or photosensitive AD, UVA1 
photosensitivity testing is performed on all patients prior to starting therapy although 
this is not standard practice in Germany (Gambichler et al., 2013).   
 
The use of UVA1 phototherapy can be split into 4 main categories based on 
pathogenesis (Krutmann and Akimichi, 2007).  All effects are likely mediated by its 
generation of 1O2 (Morita et al., 1997) causing T cell apoptosis (Krutmann and 
Morita, 1999), MMP1 upregulation (which is also mediated through inflammatory 
markers IL6/IL1β) and decreased mast cell and LC numbers and function 






Method of Action Supporting Evidence 






ROS mediated apoptosis 
of skin infiltrating T cells 
(Morita et al., 1997), 
decreased IFNy, reduction 
in LC (Ig E binding) and 
mast cells in the dermis 
(Grabbe et al., 1996), and 
a decrease in CD4+ CD1a 
dendritic cells and 
activated EG2+ 
eosinophils (Breuckmann 
et al., 2002).   
For acute AD (Krutmann et al., 1992; 
Krutmann and Schopf, 1992)—UVA1 medium 
dose more effective than NBUVB and PUVA 
and high dose used in Germany (Krutmann et 
al., 1998) although for most centres, expense 
of high output UVA1 apparatus is not 
justifiable. Inferior to NBUVB and PUVA 
(Tzaneva et al., 2010) for chronic AD although 
no studies comparing acute and chronic AD 








Increased synthesis of 
MMP1 (Jinnin, 2010) to 
break down fibrotic 
lesions (caused by 
increased type 1 and III 
collagen) causing 
softening of plaques and a 
lack of new collagen 
synthesis through TGFB 
down regulation 
(Breuckmann et al., 2004; 
Gambichler et al., 2013).   
Medium (Sator et al., 2009; Su et al., 2011) 
and high doses (Stege et al., 1997; Su et al., 
1998) effective for localised scleroderma and 
medium doses has been shown to be more 
effective than NBUVB (Kreuter et al., 2006) 
and improves function especial joint 
movement.  Medium dose softens fibrosis in 
systemic sclerosis (SSc) (Morita et al., 2000), 
improves microstomia (Tewari et al., 2011a), 
Raynaud’s syndrome (Comte et al., 2009) and 
low dose is useful in acrosclerosis (Kreuter et 
al., 2004; Rose et al., 2009).  Improvement 
also noted with PUVA (Morita et al., 1995; 






Reduced density, number 
and function of dermal 
mast cells (Grabbe et al., 
1996), 
No relapse after 2y following high dose 
UVA1.  Relapse with PUVA after 5-8 months 





Likely decrease in T cell 
mediated disease.   
Compared to UVB, UVA1 does not affect HIV 
viral load.  Whole body UVA1 









MMP1 activity on 
collagen over-production 
 
Marked softening, flattening and reappearance 
of normal looking collagen and elastic fibres 
(particularly good for large scars and burn 
scars) (Asawanonda et al., 1999) 
Use in PRP (Herbst et al., 2000)  
Low dose UVA1 for lupus, decrease in clinical 
indices as well as titres of anti-SSA/ANA abs 
(McGrath, 1994; McGrath et al., 1996).  Risk 
of PLE provocation 
Table 1.7  Use of UVA1 phototherapy in skin disease  




Caution needs to be exercised due to the potential increased risk of skin cancer and 
photoageing however there is a lack of studies examining the long-term effects of 
multiple UVA phototherapy courses on the skin.  
 
1.10.2 Photodermatoses 
The photodermatoses are skin disorders in which an abnormal pathological response 
is precipitated by normal exposure to sunlight and/or artificial sources of UV and/or 
visible radiation.  An adapted classification system based on our experience at our 
tertiary photodermatology clinic at St John’s Institute of Dermatology, London of 
patients presenting to clinic over a 6-year period (2006-2012) is shown in Table 1.5.  
Category Photodermatoses Number % of total 
 
Immunologically  Polymorphic Light eruption (PLE) 337  27 
Mediated Chronic Actinic Dermatitis (CAD) 204  16 
 Solar Urticaria (SU) 66   5 
 Actinic Prurigo (AP) 48   4 
 Hydroa Vacciniforme  (HV) 6  0.5 








Photoallergic contact dermatitis 
16   





porphyrias)     
Erythropoietic protoporphyria  
(EPP) 
Porphyria cutanea tarda (PCT) 
Congenital erythrpoeitic porphyria  
(CEP) 
Variegate porphyria (VP) 
68   
29   
 
6    






Undiagnosed  24   2 
Other  72   6 
Defective DNA 
repair 









Table 1.8  Classification of photodermatoses 
 
Photosensitivity patterns of some of the most common photodermatoses (PLE, SU, 
EPP, drug induced, XP) at St John’s Institute of Dermatology photodermatology 
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department are shown in  Table 1.8. CAD tends to persist through out the spring/ 
summer period with intermittent flares and is not included in the figure below.  
 
Figure 1.18  Photosensitivity patterns in common conditions presenting to a photodermatology 
clinic 
Adapted from data kindly given by Dr D McGibbon.  
 
PLE is the most common photodermatosis, and is characterised by an itchy 
erythematous papulo-vesicular rash, which often develops the day after sun 
exposure, and resolves within a few days or weeks.  Its prevalence is 15% in the UK 
(London 51.5°N) (Pao et al., 1994) and 5% in Perth (32.0°S) which is explained by 
its primarily UVA provocation (Janssens et al., 2007) and is seen more commonly at 













































1.11 Aims of the thesis 
Most work in photobiology has focussed on non-terrestrial UVC, and UVB.  Recent 
data suggest that UVA may have more potential biological consequences in human 
skin than previously thought, although these concepts are based on in vitro work in 
mouse and explant human skin.   Understanding the carcinogenic and other adverse 
effects of UVA in human skin in vivo has important public health concerns, 
particularly as UVA1 is used for phototherapy in the UK and abroad for treatment of 
predominantly dermal skin diseases.  Furthermore, UVA1 is the main spectral source 
in tanning lamps and represents over 75% of the environmental exposure from 
terrestrial UVR.    
The main goals of this thesis were to assess the contribution of UVA1 to the 
molecular and cellular effects of sunlight in the skin in vivo.  Studies with UVA1 
were done along side those with UVB, because the latter has known effects and can 
act as a positive control. Action spectra (see section 1.3.2) typically show that UVB 
is several orders of magnitude more effective than UVA, so skin exposures were 
based on erythemally equivalent doses rather than physical measures of exposure 
(e.g. J/m2). 
The specific aims of the PhD studies were to:  
 Evaluate the production and repair of DNA photodamage in the 
epidermis and dermis. The endpoints for this study were the thymine 
(TT) dimer, which is a type of cyclobutane pyrimidine dimer (CPD) 
and the 6-4 photoproduct (see Chapter 3). 
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 Compare CPD repair in melanocytes and basal epidermal 
keratinocytes (see Chapter 4). 
 Assess UVR-induced changes in gene expression by micro array and 
validate selected gene changes using RNA and protein 
expression/function studies (see Chapter 5). 
 Assess downstream DNA damage and other cellular changes in the 
skin following application of topical repair enzymes (see Chapter 6). 
In each chapter the impact of research on human health is discussed.  These studies 
resulted in 4 publications, which are included at the end of the thesis. One of the 
publications was subject to a commentary in the Journal of Investigative 
Dermatology and this is also included.  3 other publications, unrelated to the thesis, 
are included to demonstrate the scope of my interest in photodermatology. 
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Chapter 2 Materials and methods 
2.1 Volunteer recruitment 
The study was approved by the St Thomas’ Hospital, London, UK, Ethics 
Committee (REC no: 09/H0802/98) and conducted in accordance with the 
Declaration of Helsinki Principles.  The details of all healthy skin type I/II 
(Fitzpatrick, 1988) volunteers studied in are shown in Table 2.1.  All volunteers gave 
written informed consent.  








DNA damage dose response study (Chapter 3) 
001 28 F I 48.8 30.0  IFb 
002 25 F I 48.8 30.0 IF 
003 20 M II 48.8 30.0 IF 
004 21 F II 53.0 30.0 IF 
005 22 F I 48.8 23.0 IF 
006 34 M I 61.1 19.0 IF 
DNA repair time course study (Chapter 3) 
001 28 F I 31.3 19 IF 
002 28 F I 31.3 30 IF 
003 22 M I 48.8 23 IF 
004 24 F II 31.3 30 IF 
005 23 M I 48.8 23 IF 
006 23 F II 48.8 23 IF 
Apoptosis and DNA repair study (Chapter 4) Volunteers taken from DNA repair time 
course study (Chapter 3) and protein validation study (Chapter 5) 
001 28 F I 31.3 19 IF 
002 28 F I 31.3 30 IF 
003 22 M I 48.8 23 IF 
004 24 F II 31.3 30 IF 
005 23 M I 48.8 23 IF 
006 23 F II 48.8 23 IF 
       
001 24 F II 61.1 37 IF 
002 27 F II 61.1 37 IF 
003 22 F I 48.8 30 IF 
Gene time course study (Chapter 5) 
001 21 M II 48.8 30.0 Microarray, 
RTqPCRc 
002 27 M I 48.8 30.0 Microarray, 
RTqPCR 
003 21 M I 48.8 3 0.0 Microarray, 
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RTqPCR 
004 21 F I 61.8 37.0 Microarray, 
RTqPCR 
005 21 F I 61.8 23.0 Microarray, 
RTqPCR 
Gene dose response and UVA1 and UVB comparison study (Chapter 5) 
001 20 M I 61.1 19 Microarray, 
RTqPCR 
002 21 M I 61.1 23 Microarray, 
RTqPCR 
003 23 F II 61.1 30 Microarray, 
RTqPCR 
004 22 F I 61.1 23 Microarray, 
RTqPCR 
005 28 F II 76.2 30 Microarray, 
RTqPCR 
Protein validation study (Chapter 5) 
001 24 F II 61.1 37 IF 
002 27 F II 61.1 37 IF 
003 22 F I 48.8 30 IF 
Table 2.1  Demographics for all volunteers used in the study 
a Fitzpatrick skin type (see Introduction Chapter 1) 
bImmunofluorescence 
cReverse transcription quantitative PCR  
 
2.2 UVR sources and dosimetry  
The UVA1 irradiation source was a Sellamed 24000 System Dr Sellmeier (Sellas 
Medizinische Geräte GmbH, Gevelsberg, Germany).  Irradiance was measured prior 
to each volunteer irradiation with a radiometer (Model IL1400A, International Light 
Technologies, Peabody, MA) and was typically ~74mW/cm2 at a 24.5cm distance.  
Narrowband UVB (300nm) was produced by a monochromator (Oriel, Irvine, CA).  
This was a 1-kW xenon arc; grating blazed at 250 nm: slits set for 3nm full width at 
half maximum bandwidth.  UVB was delivered with a liquid light guide (Oriel), with 
an exit diameter of 5mm in direct contact with the skin.  Irradiance (~0.5 mW/cm2) 
was measured with an SEL623 thermopile (International Light Technologies) 
attached to an IL1400A radiometer (detector and meter calibrated by the United 




SSR was generated by a 1-kW xenon arc solar simulator (Oriel Corp., Didcot, 
Oxfordshire) giving an even field of irradiance (290–400 nm) of ~15 mW/cm2 on the 
skin surface when 11 cm from the source. Irradiance was routinely determined with 
a wide band thermopile radiometer (Medical Physics, St Thomas’ Hospital, London). 
 
Emission spectra and irradiances of the UVA1, UVB and SSR sources were checked 
with a DM150BC double-monochromator spectroradiometer (Bentham Instruments, 
Reading, UK) using an integration sphere and gratings blazed at 250 nm. 
 
Figure 2.1  Emission spectra for UVA (300nm), UVA1 and SSR 
The UVA2 (320–340 nm) content of the UVA1 source was 0.2%, which is 
equivalent to 0.6% of the overall erythemally effective energy (EEE) when the 
emission spectrum is weighted with the action spectrum for erythema (CIE, 1998) 
(calculations not shown).  For the SSR source, 6.8% UVB corresponds to EEE of 
88%. 
 
2.3 Irradiation protocol and assessment of erythema 
To determine the MED, eight areas each measuring 1cm2 on the left buttock were 
exposed to doses ranging from 15 to 74J/cm2 for UVA1 and 12 to 58mJ/cm2 for 
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UVB in 25% increments.  These starting doses were based on advice from our 
clinical unit.  A template made of leatherette (John Lewis, UK) with 8 x 1cm2 areas 
was used to define the area of irradiation. The dose that caused just perceptible (jp) 
erythema at 24h (jpMED) was used, as it has been shown to provide a more reliable 
threshold end point than ‘erythema with a definite border’ (Ouinn et al., 1994).  An 
erythemal response to UVA is biphasic with an early phase due to heat emitted the 
UVA1 source, which fades rapidly (Diffey et al., 1987) and peak UVA1 erythema 
occurring 8h post irradiation but the time course of erythema is broad and the peak 
often extends to 24h post irradiation (Beattie et al., 2005a) with the reaction either 
fading or being replaced by pigmentation at subsequent time points (Ibbotson and 
Farr, 1999.  With UVB, time to maximal erythema occurs 8-12h post irradiation 
(Farr et al., 1988) with other studies showing that maximal erythema is reached 24h 
post UVB (Man et al., 2003).  Readings are generally carried out at 24h for practical 
reasons and in this thesis exposed sites were visually assessed by one clinician (AT) 
according to the following criteria: 0, no erythema; ±, observer not sure; 0.5, just 
perceptible erythema; 1, erythema with a definite border; 2, intense erythema  ± 
papular response at 24 hours.  Reflective spectroscopy was carried out 3 times per 
test site per volunteer, and the mean value was used to quantify erythema (Dia-Stron, 
Andover, UK).  The difference between the mean measurement from each test site 
and an adjacent non-irradiated control site is the  erythema index value (EI) and 
generally at 1MED this difference is approximately 60. 
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2.4 Volunteer irradiations 
Our studies were based on fixed doses determined from the MED in the first 3 
individuals: mean values for 1MED was 30.0±0 (SD) mJ/cm2 for UVB (300nm) and 
48.8±0 (SD) J/cm2 for UVA1 which we defined as the ‘notional MED’ see Table 2.1.  
Volunteers were given fixed increments of this as shown in Table 2.2.  For the gene 
studies, the UVA1 dose given was 50J/cm2 (1MED), UVB at 30 mJ/cm2.  The actual 
MED of all individuals was within 2 increment of the notional MED.  This approach 
was used rather than an individualised dosing regime because it was thought that 








































































































































































































































































































































































































































































The biopsy protocols are shown diagrammatically in Figure 2.2 (1MED UVB 
=30mJ/cm2 and 1MED UVA1 =~50J/cm2). 
A      B 
            
C      D 
            
E         
 
Figure 2.2  Irradiation and biopsy protocols for all studies (A-E) 


















0.5 MED UVB 
90mJ/cm2  
3 MED UVB 
146.4J/cm2  
3 MED UVA1 
73.2J/cm2  
1.5 MED UVA1 
24.4J/cm2  
0.5 MED UVA1 
45mJ/cm2  






















3 MED UVB 
90mJ/cm2  
3 MED UVB 
146.4J/cm2  
3 MED UVA1 
146.4J/cm2  
3 MED UVA1 
146.4J/cm2  






























































































For the DNA repair time course study, due to the limit on the number of biopsies that 
could be taken on the buttock (maximum 7 on one site) there was a spread of time 
points.  These are shown in Table 2.3.   
Volunteer 
Time post irradiation that 
biopsies were taken 
UVA52-A2-001 Controla, UVA1:0h, 24h, 48h 
               UVB  :0h, 24h, 48h 
UVA52-A2-002 
UVA52-A2-003 Controla, UVA1:0h, 3h, 24h 
               UVB :0h, 3h, 24h 
UVA52-A2-004 
UVA52-A2-005 Controla, UVA1:0h, 6h, 24h 
               UVB :0h, 6h, 48h 
UVA52-A2-006 
Table 2.3  DNA repair time course study: biopsy time points 
a control unirradiated biopsy taken at the immediate time point 
 
2.5 Skin biopsy processing  
2.5.1 DNA studies (paraffin embedded) 
4mm punch biopsies were performed in a clinical setting (St Thomas’ Hospital 
Outpatients Surgery room) under local anaesthetic (1% xylocaine with 1:200000 
adrenaline, AstraZenaca, UK).  Biopsies were fixed in 10% neutral buffered formalin 
(4% formaldehyde) for ~16 hours, followed by alcohol dehydration steps (50%, 
70%, 90%, 100% ethanol in distilled water) and were then embedded in paraffin.  
Sections were cut at 4μm and placed on VWR superfrost® slides to ensure firm 
electrostatic attraction of formaldehyde-fixed paraffin sections. 
2.5.2 Gene studies (RNA extraction) 
All biopsies were immediately placed in cryovials and snap frozen in liquid nitrogen 
(~80°C).  RNA was extracted using Trizol (Invitrogen, UK), quality checked via the 
Agilent 2100 Bioanalyzer platform (Agilent Technologies, Waldbronn, Germany) 
and a RNA integrity number (RIN) was generated. This value is calculated using a 
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specific algorithm, which takes into account the 28S/18S peaks and any unexpected 
peaks in the 5S region that affect purity.  A RIN of 10 indicates very high quality and 
according to published data (Fleige and Pfaffl, 2006) RIN >6 is of sufficient quality 
for gene expression profiling experiments.  All RIN numbers in the gene study were 
between 7.6 and 9.6. 
2.5.3 Protein validation (frozen)  
Biopsies were embedded in OCT (VWR chemicals, Leuven, Belgium), cooled in 
Isopentane (VWR chemicals, Fontenay-sous-Bois, France), placed in cryovials and 
then frozen in liquid nitrogen.  5-7m sections were mounted on Superfrost® plus 
slides and stored at -80ºC.   
 
2.6 Immunostaining 
Immunofluorescence (IF) was performed on paraffin and frozen sections. 
Immunohistochemistry (IHC) was performed on paraffin embedded samples.   
2.6.1 Slide preparation 
First, paraffin sections were placed in xylene (VWR Chemicals, Fontenay-sous-Bois, 
France) for 5 minutes followed by graded concentrations of ethanol for 2 minutes 
each (100%, 90%, 70% 50%) and washed in MilliQ distilled water (Millipore, MA, 
USA) for 5 minutes.  Frozen sections were left at room temperature for 10 minutes 
and then placed in cold (5C) 4% paraformaldehyde (PFA, Sigma Aldrich, St Louis, 
USA) for 10 minutes and then they were allowed to dry completely.  All slides were 
then circled with a PAP pen (Dako, Ely, UK) before being washed in phosphate-
buffered saline (PBS, Life technologies, Paisley, UK). 
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2.6.2 Immunofluorescence  
Sections were incubated with 0.1% trypsin (Gibco, Paisley, UK) at 37C for 30 
minutes; and washed twice in PBS for 5 minutes. 
Slides were incubated in 0.6% H202 and 0.1% triton X-100 in PBS for 10 minutes, 
washed twice in PBS (for 5 minutes) and incubated for 20 minutes in blocking buffer 
(10% goat serum, 0.1% bovine serum albumin, and 0.1% Tween-20 in PBS). After 
this the following primary antibodies were added and incubated for 90 minutes at 
room temperature see Table 2.4 for supplier and dilution.  For CPD, 6-4PP, 8oxodG, 
70 mM NaOH in 70% ethanol for 4 minutes was added first to denature the DNA).  
Sections were washed twice in PBS (5 minutes) and incubated with secondary 
antibodies: Alexa Fluor goat anti-mouse or goat anti-rabbit 488/555 (Invitrogen, 
Paisley, UK) at 1:200 for 30 minutes, counterstained with prolong gold antifade with 
DAPI (4',6-diamidino-2-phenylindole, Molecular Probes, Paisley, UK), cover-







Clone Supplier Dilution 












































































































































Fluorescein 494 521 Green ISZ 
BODIPY 505 515 Green ISZ 
AlexaFluor 
488 




555 565 Red 
IF 
DAPI 340-380 425 Blue ISZ, IF 




Sections were immersed in Harris’ Haematoxylin, (Sigma- Aldrich, UK) for 7 
minutes then washed in running tap water for 1 minute.  They were then dipped in 
1% acid alcohol (1ml HCL, 100ml ethanol), 1% eosin, (Sigma-Aldrich, Dorset, UK), 
then washed with running tap water for 2-3 minutes.  Slides were then rehydrated in 
graded ethanol. They were rehydrated in graded ETOH (50%, 70%, 90% and 100% 
for 2 minutes each) followed by xylene and then mounted using p-xylene-bis-
pyridinium bromide (DPX, Sigma Aldrich, Dorset, UK).   
2.7 In situ zymography (ISZ) 
MMPs are released from nucleated cells as inactive proenzymes (Woessner, 1991).  
Although current primary antibodies pick up active forms, ISZ is useful for 
measuring the extent of MMP activity. This is done by applying a dye-quenched 
(DQ) substrate (collagen I, collagen IV, gelatin or elastin) to the section that has 
been heavily labelled with fluorescein isothiocyanate (FITC) so that its fluorescence 
is quenched (Mook et al., 2003).  After cleavage by the appropriate MMP, the degree 
of fluorescence released corresponds to activity. The added benefit with this is 
localisation of the activity in the skin.  In this thesis, collagenolytic I and IV (DQI 
and DQ IV) activity and elastinolytic (DQ elastin) activity was assessed with the 
following protocol. 
ISZ method 
Frozen skin sections were prepared (see 2.6.1) and then incubated with 60l 
substrate.  This was made up of low gelling agarose (Sigma, Dorset, UK) (1g 
dissolved in 500ml PBS), with 4-6 drops of DAPI with antigold fade/1ml 
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(Invitrogen, Paisley, UK) and DQTM collagen type 1, DQTM collagen type 4 or DQTM 
elastin  (all from Molecular Probes, Paisley, UK)) at 1:10.   Sections were allowed to 
set at 4°C for 1h and then placed at room temperature for ~18h in the dark.  Substrate 
specificity is shown in Table 2.6. 
Substrate 
 MMP specificity 
Collagen I MMP1, MMP2, MMP3, MMP9, MMP13 
Collagen IV MMP2, MMP7, MMP9, MMP12, MMP25 
Elastin MMP12, MMP7, MMP9 
Gelatin MMP2, MMP9  
Table 2.6  In situ zymography MMP specificity  
taken from Yan and Blomme, 2003 
 
2.8 Imaging analysis 
Imaging was performed with a Zeiss Axiophot microscope (Harpenden, UK, Nikon 
DS-U2 camera (Kingston-upon-Thames, UK). Images were captured in 2560x1920 
format at x20 magnification (and x1.25 eyepiece magnification). Contrast settings 
were kept constant and the gain and exposure times used for IF and ISZ are shown in 
Table 2.7.  The SPS5 Leica confocal microscope (Leica Microsystems GmbH, 
Wetzlar, Germany) was also used to acquire images at x20 and x80 magnification at 
specific settings for p63, TRP1, Ki67, K1 and K14.  These were set according to the 





Nuclear CPD 20 x1.40 
 64-PP 20 x1.40 
 8oxodG 20-30s x1.40-4.0a 
 p53 4 x1.40 
 DAPI Variable (1-4) x1.40 
 Ki67 Confocal settingsb 
 TRP1 Confocal settings 
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 p63 Confocal settings 
Extracellular 
Matrix 
Keratin 1 Confocal settings 
Keratin 14 Confocal settings 
Keratin 10 2 x1.40 
 Involucrin 4 x4.00 
 MMP1 4 x2.40 
 MMP12 4 x2.40 
 MMP2 2 x1.40 
 MMP9 2 x1.40 
 DQ ™ Collagen I 4 x4.00 
 DQ ™ Collagen IV 4 x4.00 
  DQ ™ Elastin 4 x2.40 
Table 2.7  Fluorescence light microscopy capture settings for all antibodies used 
a staining was attempted but could not be optimised 
b confocal capture settings set for each unirradiated control 
 
Epidermal and dermal quantification 
This was performed with NIS elements BRv3 software package (Melville, NY, 
USA).   
Nuclear staining 
DAPI stained nuclei were gated and mean red intensity (AlexaFluor555) assessed 
within each nucleus, in at least 200 nuclei.  Mean background intensity was 
calculated and intensity from each non irradiated control was subtracted from 
treatment sections to adjust for nonspecific nuclear staining.  Settings for nuclei 
capture (circularity and diameter of nuclei) were constant, and nuclei ‘‘separated and 
smoothed’’ as necessary. 
To assess staining as a function of depth in the epidermis, the 3MED sections from 
the thickest part of the epidermis from each of the 12 individuals were selected. The 
mean red intensity in each of the nuclei down to the basal epidermis was calculated 
and adjusted for average background staining in unirradiated controls. This was 
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plotted against the distance from the stratum corneum.  For dermal staining, first the 
average basal epidermis thickness was calculated in µm (approximately 75µm).  A 
total of 50 individual nuclei in the dermis from the 3MED sections from each of the 
12 volunteers were gated and CPD/64PP staining assessed. Two calculations were 
done (once background unirradiated staining was removed) to show 1) staining in the 
dermis 2) combined staining in epidermis and dermis.  Here, as there was an average 
of 10 nuclei in the epidermis across 75µm, average staining could be plotted across 
the whole skin.   
 
Extracellular staining 
Quantification was performed by gating the epidermis or dermis and then assessing 
the intensity of colour intensity within each region to give a numerical value.   
 
2.9 Microarray  
This section was performed by Milteyni Biotech, Bergisch, Gladbach, Germany. 
Single colour hybridization on Agilent Whole Human Genome Oligo Microarrays 
(4x44K) and bioinformatics was performed (Milteyni Biotech, Bergisch Gladbach, 
Germany). 100ng of total RNA was used, converted to cDNA, and T7 RNA 
polymerase was used to simultaneously amplify and produce cyanine 3-labelled 
(Cy3) cRNA (Agilent Low Input Quick Amp Labeling Kit, Agilent technologies, 
Bershire, UK).  Concentrations were >200ng/μl and this was measured with the ND-
1000 Spectrophotometer (NanoDrop Technologies, Wilmington, USA).  1.65μg 
Cy3-labeled fragmented cRNA was hybridised (~17h, 65°C) to Agilent Whole 
Genome Oligo Microarray chips (4x44K) using the Agilent Gene Expression 
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Hybridization kit (Agilent technologies, Bershire, UK).  Fluorescent signals were 
detected using the Agilent Microarray Scanner system and Agilent Feature 
Extraction Software (FES) was used to process the intensities.  This software 
removes background, rejects outliers and calculates statistical confidences.  
Background corrected intensity values were normalized between arrays using 
quantile normalization (Bolstad et al., 2003) where sample values were divided by 
their median.  Log2 transformed intensity values were used for subsequent statistical 
analysis.  Rosetta resolver gene expression data analysis system, (Rosetta 
Biosoftware) was used to compare single intensity profile in a ratio experiment (i.e. 
control versus sample experiment).  The microarray data are deposited at NCBI GEO 
with accession number GSE45493.  The data were then processed using specific 
software programmes (Genego Metacore v7 and the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.7 see section 2.11. 
 
2.10 Polymerase Chain Reaction (PCR) 
2.10.1 Reverse transcription polymerase chain reaction (RTPCR) 
RTPCR was performed following the manufacturer’s protocol (high capacity cDNA 
reverse transcription kit, Applied Biosystems, Paisley, UK). Master mix was 
prepared (see Table 2.8) in a 1:1 ratio with total RNA (90-188ng/μl).  The mix was 
incubated at 25C for 10 minutes, 37C for 120 minutes and 85ºC for 5 minutes on 





Volume ( ) 
per well 
10xRT Buffer 2 
25xdNTP Mix 0.8 
10xRT Random Primers 2 
Multiscribe RT 1 
Nuclease-free H20 4.2 
Total 10 
Total RNA 10 
Table 2.8  The reverse transcription mix 
 
2.10.2 Real time quantitative PCR (RTqPCR) 
Real time quantitative PCR (RTqPCR) assesses mRNA fold change compared to 
control unirradiated skin using the 2-∆∆CT method (Yuan et al., 2006).  The TaqMan® 
Gene Expression assay (Applied Biosystems, Paisley, UK), uses FAM™ (6-
carboxyfluorescein) labelling and is quenched by dihydrocyclopyrroleindole (MGB) 
whilst the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(Applied Biosystems, Paisley UK), is VIC™ (undisclosed formulation from Applied 
Biosystems) labelled and quenched with MGB.  This enables duplex experiments 
(i.e. probe and housekeeping gene in each well) for analysis, which were made up as 
shown in table 2.9 using cDNA made in section 2.10.1.  The selection of these genes 
was based on the microarray data as described in Chapter 5. 
Agent Quantity per well (µl) 
Probe 1 
GAPDH 1 
Master mix 10 
Distilled 
water 
6-7.5 (depending on the 
amount of cDNA used) 
cDNA 
0.5-2 (depending on 
probe used) 
Table 2.9  RTPCR master mix 
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RTPCR was performed using the Applied Biosystems 7900HT fast real time PCR 
system (50ºC for 2 minutes, 95ºC for 10 minutes, 40 cycles of 95ºC for 15 seconds 
and 60ºC for 1 minute).  Reporter (FAM/VIC) fluorescence was captured using SDS 






























Table 2.10  Genes validated with RTPCR using TaqMan ® DNA probes 
 
2.11 Statistical Approaches 
For microarray data, bioinformatics analysis was based on normalized Log2 
intensities using R/Bioconductor and software packages (http://www.R-project.org; 
http://www.bioconductor.org).  ANOVA with repeated measurements followed by 
Tukey post-hoc tests was used to test for expression differences among the following 
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groups:  UVA1 time course, UVA1 6h vs UVA1 24h (50J/cm2 doses), UVA1 vs 
UVB at 6h, UVA1 vs UVB at 24h.  All p values were adjusted for multiple testing 
(Benjamini and Hochberg, 1995).  Differentially expressed genes were considered if 
both the ANOVA and Tukey post-hoc test p-values were ≤ 0.05 (adj. p-value or false 
discovery rate (FDR) ≤ 0.3) and the expression difference was at least two fold.  
Functional analysis of candidate genes was done using DAVID v 6.7 (Dennis et al., 
2003) to identify biological clusters and GeneGo Metacore v7 to identify key 
pathways.  Briefly, gene ratio lists for pooled individuals (fold change ≥2, p≤0.05) 
from the 6h and 24h biopsies were uploaded to the software program, and in DAVID 
these gene lists orientate into biological clusters or Gene Ontology (GO) groups.  
With GeneGo, upregulated gene lists are processed and this generates pathway maps, 
networks, processes and diseases and the p values given show the statistical 
likelihood of a sequence of genes occuring with a particular pathway due to chance. 
For mRNA and protein analysis, all graphs were generated using Graphpad Prism v6 
or Microsoft Excel for Mac 2011 for statistical tests including linear regression 
analysis and unpaired/paired t tests, or Mann Whitney/Wilcoxon signed-rank test 
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UVB readily induces cyclobutane pyrimidine dimers (CPD), mainly thymine dimers 
(TT), and pyrimidine (64) pyrimidone photoproducts (64PP) in DNA and has 
recently been shown to occur following UVA exposure without concomitant 
production of 6-4PP in explant skin.  In this chapter, the induction of TT and 64PP in 
human skin in vivo by broadband UVA1 has been investigated, and compared with 
erythemal doses of monochromatic UVB (300 nm).  Our data show that UVA1 
induces TT in the epidermis of healthy volunteers in vivo and did not form 64PP, 
whilst UVB induced both types of photoproduct, suggesting different mechanisms of 
action for induction.  UVB induces 3-4 times more epidermal TT than UVA1 for the 
same level of erythema.  UVA1 induced TT increased with epidermal depth with 
predominance at the rapidly dividing basal epidermis whilst the reverse pattern was 
seen with UVB and a predominance at the upper epidermis.  This pattern is also seen 
in the dermis with a continued decrease of UVB induced CPD with depth and an 
increase with UVA1 induced CPD with depth.   UVA1 and UVB induced TT are 
repaired at a similar rate across the whole epidermis, but repair is much slower for 
UVA1 induced CPD when kinetics at the basal epidermis are examined only.  Our 
conclusions focus on how UVA1 may be more carcinogenic than has previously 
been thought which has important implications for public health education and the 




It is well established that UVA forms CPD in cultured cells and human whole 
explant skin, and that these lesions are more frequent than oxidatively generated 
lesions such as 8oxodGua (Douki et al., 2003; Ravanat et al., 2001).  A series of 
studies have demonstrated that UVA causes damage to DNA (Basu-Modak and 
Tyrrell, 1993; Kielbassa et al., 1997; Tyrrell and Pidoux, 1989), protein and lipids 
via indirect mechanisms, primarily mediated by singlet oxygen (Morita et al., 1997).  
Direct absorption and damage to DNA has also been proposed (Jiang et al., 2009; 
Mouret et al., 2010) for the formation of CPD, where dAdT may absorb UVA1 
directly, particularly at 354nm (of note second erythema peak at 360nm (Anders et 
al., 1995) see Introduction 1.4.1.1).  
 
As both UVB and UVA predominantly form TT dimers (Mouret et al., 2006), we 
used a monoclonal antibody directed against the TT dimer to assess CPD in human 
skin in vivo after erythemally equivalent doses of UVB (300nm) and UVA1 (340-
400nm), as well as a monoclonal antibody against 64PP.  Erythema was used as the 
dose determinant because it is a key response to UVR damage and is widely used to 
define UVR exposure. Furthermore, human action spectroscopy has specifically 
implicated TT formation as a trigger for erythema (Young et al., 1998a) particularly 
at 300nm (Freeman et al., 1989), as well as other biological effects (Walker and 
Young, 2007) in the skin.  In addition to induction assessed by a dose response 
study, we assessed the repair of photoproducts (time course study) with UVA1 and 
UVB in vivo, because it has been reported that TT repair is slower ex vivo after 
UVA1 than UVB, which is relevant to the formation of mutations (Mouret et al., 
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2006).    
 
3.2 Materials and Methods 
Materials and methods are described in Chapter 2. 
Volunteer Demographics 
Table 2.1 gives the volunteer demographics for the time course study (6 volunteers) 
and dose response study (6 volunteers) and the mean MED for all 12 skin type I/II 
participants was 25.8 ± 4.6 mJ/cm2 (UVB) and 45.8 ± 9.4 J cm2 (UVA1). 
3.3 Results 
3.3.1 Staining of control tissue 
It was not possible to stain and assess all slides in a single batch. The reproducibility 
of staining and image analysis was measured for both the dose response and time 
course studies by staining the same positive control slides (3MED) for UVA1 and 
UVB with each experimental run with background unirradiated control sample 
intensity removed.  Figure 3.1A and B show the small standard deviation for 3MED 
UVA1 and UVB sections with each staining run, confirming that any variation in 
immunostaining was unlikely to be due to operator bias. 
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A       B 
     
Figure 3.1  Staining of control tissue when biopsies were taken immediately after exposure 
Error bars represent minimum and maximum values. Mean intensity refers to 
amount of fluorescence; the greater the amount of CPD the greater the intensity. 
 
3.3.2 Erythema 
The erythema index (EI) was calculated by converting the incremental exposures for 
MED assessment to factors of the notional MED.   
 
Figure 3.2  Erythema dose response based on notional MED 
The data show that the slopes for both UVA1 and UVB are highly significant (UVB 
p = 0.001, UVA1 p = 0.0006) and there was no difference between the slopes (p = 
0.21), i.e. there are comparable dose responses for UVB and UVA1.  
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Figure 3.3  UVA1 vs UVB erythema 
There was no correlation between a given individual’s UVB and UVA1 MED (n = 
12: note numbers on the figure correspond to the number of volunteers with the 
same MED). 
 
3.4  CPD and 64PP staining 
Representative examples of CPD and 64PP staining for the dose response study and 
the time course study are shown in Figure 3.4 and Figure 3.5 respectively.  
3.4.1 CPD and 64PP quantification 
Dose response and time course staining quantification is shown in Figure 3.6 and 
Figure 3.7.  The dose-response study showed that, for a given multiple of the notional 
MED, UVA1 produced fewer TT than UVB.  The slope for UVB is 3.4 fold steeper 
than for UVA1 (p = 0.001).  64PP are induced by UVB in a dose-dependent manner 
but no 64PP are induced with UVA1 at any dose in vivo.   
 




























































































































































































































































Figure 3.6  Dose response quantification for UVB and UVA1 induced CPD and 64PP at 0h. 
 
A      B 
       
Figure 3.7  Time course for repair kinetics of (A) CPD and (B) 64PP in whole epidermis 
 
Examining the time course repair kinetics for CPD (Figure 3.7A), the slopes for the 
loss of UVB and UVA1 induced CPD with time are not significantly different (p = 
0.71).  By 48h, the majority of UVA1 induced CPD has disappeared.  However, 
UVB induced CPD are still present.  The comparable repair rate for CPD induced by 
both spectra suggests that the same host repair machinery is used.  Our data are 
different from published ex vivo studies (Mouret et al., 2006) that suggest that UVB 
induced CPD is repaired faster than those induced by UVA1.  Repair of UVB 
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induced 64PP is fast and complete by 24h, as previously reported in vivo (Bykov et 
al., 1999; Young et al., 1996) for UVB using SSR.  
 
3.4.2 Distribution of CPD staining in epidermis 
A      B 




Figure 3.8  Distribution of CPD in epidermis at 3MED immediately post-UVR 
Example of UVA1 (A) and UVB (B) CPD staining across the epidermis in 3MED 
sections and (C) quantification per nuclei through the epidermis. Scale bar = 50μm. 
 
UVA1 causes more intense staining in the lower epidermis, whereas UVB leads to 


























and epidermal depth was quantified by linear regression analysis to a depth of 10 
nuclei (Figure 3.8C).  With UVB there was significant (p = 0.01) reduction in CPD 
staining with increased epidermal depth.  In contrast, for UVA1, there was a 
significant (p = 0.001) increase in staining with increased depth.  This pattern of 
staining is similar at lower doses.  With 1.5MED and 0.5MED the patterns are the 
same, but the statistical significance is variable which is probably related to the fact 
that actual intensity values are smaller, and at 1.5MED there is a statistically 
significant attenuation of UVB induced CPD (p = 0.006) across the epidermis but 
not for UVA1 CPD (p = 31).  Interestingly at 0.5MED there is a significant increase 
in CPD intensity across the epidermis with UVA1 (p = 0.001) but no effect with 
UVB (p = 0.25). 
A      B 
       
Figure 3.9  CPD staining across the epidermis at different doses (A) 1.5MED (B) 0.5MED 
 
3.4.3 Distribution of CPD staining in dermis 
Using the dose response and time course tissue, CPD staining was calculated in the 

















































expected, there is a dose dependent increase in CPD for UVA1 (slope p = 0.009) and 
UVB (slope p < 0.0001) according to notional MED but maximal damage with UVB 
is only 2.5 fold greater that with UVA1, compared to 3-4 fold difference in the 
epidermis.  Figure 3.11A shows the degree of CPD damage is independent of depth 
(p = 0.53 for slope) for UVA1, whereas there is a highly significant (p = 0.0001 for 
slope) reduction in CPD with depth with UVB.  Figure 3.12 shows that repair of 
dermal CPD is slow for UVB. The slope for UVB is not significant (p = 0.62) but is 
significant for UVA1 (p = 0.03). 
 
     
Figure 3.10  CPD dose response in the dermis 
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Figure 3.11  CPD damage according to depth in the dermis after 3MED 
(A) UVA1 (B) UVB CPD 
 
 
Figure 3.12  CPD repair over 48h in the dermis 
 
3.4.4 Combining epidermal and dermal data  
Data for epidermal and dermal CPD and 64PP formed by UVA1 and UVB have 
been combined.  Figure 3.13A shows a statistically significant attenuation of UVB 
induced CPD through the whole skin (p <0.0001) and a statistically significant 
increase in UVA1 induced CPD (p = 0.006).  The regression lines intercept at 
150µm, which implies that beyond this depth, UVA1 induces more CPD than UVB.  
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There is attenuation with UVB induced 64PP (Figure 3.13B) with depth, but UVA1 
does not produce any 64PP at any level.  Figure 3.14 shows attenuation of both UVB 
induced CPD and 64PP with increasing depth with no significant difference between 
the slopes. 
A      B 
       
Figure 3.13  Combined epidermal and dermal photoproducts for UVA1 and UVB 
(A) CPD  (B) 64PP 
 
 
Figure 3.14  UVB induced CPD and 64PP in the skin 
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3.4.5 UVA1 CPD are not repaired at the basal epidermis 
The intensity of CPD staining present at the basal layer of the epidermis 
(melanocytes, identified by TRP1) and basal keratinocytes was examined over 48h 







Figure 3.15  CPD staining in melanocytes and basal epidermal keratinocytes 
(A) example of CPD and TRP1 staining in unirradiated control, 3MED UVB and 
3MED UVA1 (B) quantification of staining with linear regression p values 
 
Unexpectedly UVA1 and UVB repair kinetics are very different at the basal 
epidermis (Figure 3.15C) and although UVA1 produces 3-4 fold fewer CPD, these 








UVA1 basal keratinocytes p=0.35
UVB  melanocytes p<0.0001
UVB basal keratinocytes p=0.002





















Unirradiated control 3MED UVB 3MED UVA1 
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generally do not appear to be repaired (linear regression of slope p = 0.21 for 
melanocytes and p = 0.35 for basal keratinocytes) whereas UVB induced CPDs are 
repaired quickly in melanocytes (p = 0.002) and basal keratinocytes (p =<0.0001) 
over 48h.  Mechanisms are examined in Chapter 4. 
3.5 Discussion 
3.5.1 UVA1 induces CPD, but not 64PP in the epidermis and dermis 
The TT dimer is the most common type of DNA lesion formed by UVB and UVA 
(Douki et al., 2003; Mouret et al., 2006).  UVB forms TT>TC>CT>CC and UVA 
forms TT>TC>CT but not CC dimers (Mouret et al., 2006) in explant skin.  The data 
in this chapter show that at doses which give equivalent erythema, UVA1 readily 
induces TT but not 64PP in human skin in vivo albeit 3-4 times fewer than UVB 
induced TT.  Our maximum doses for UVB (300nm) and UVA1 were 90mJ/cm2 and 
148J/cm2 respectively compared with 20mJ/cm2 and 200J/cm2, used in a large 
comparative study on ex vivo skin (Mouret et al., 2006), where here the UVB source 
was 312 nm.  20mJ/cm2 was sub-erythemal as an MED for skin type I/II at 312nm 
has been shown to be 200–300mJ/cm2 in skin type I/II individuals (Palmer et al., 
2006).  A further study irradiating biopsy samples ex vivo found similar levels of TT 
damage after 1MED of UVB and UVA however their source contained considerable 
amounts of UVA2 (Mouret et al., 2011b).  
 
3.5.2 CPD repair 
An ex vivo study has found that UVA1 induced TT are repaired less well than those 
induced by UVB (Mouret et al., 2006) but doses were not biologically relevant.  
Repair kinetics data in this chapter show in vivo, when the epidermis is examined as 
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a whole, CPD are repaired at the same rate whether they are induced by UVA1 or 
UVB (Figure 3.7), and as UVA1 produced fewer CPD than UVB, repair was almost 
complete at 48h post 3MED UVA1.  Thus it appears that the degree of initial DNA 
damage from an acute exposure determines the amount of damage that remains a day 
or two later.  However, in vitro studies suggest that the rate of CPD repair from a 
single exposure may decrease with higher doses, possibly resulting from damage to 
the DNA repair machinery (Courdavault et al., 2004; Greinert et al., 2000).  The 
situation appears to be different with repeated daily sub-erythemal exposures with 
SSR, which results in the accumulation of TT (Young et al., 2007), although this 
varies with skin type.  Repeated sub-erythemal exposure enhances TT repair in skin 
types III/IV but not in I/II (Sheehan et al., 2002).  In contrast, mice exposed to 
chronic low dose UVB show decreased CPD repair following a challenge dose of 
UVR suggesting that an accumulation of TT had a detrimental effect on repair 
(Mitchell et al., 1999).  Figure 3.11 and Figure 3.12 show there is no evidence of 
repair of UVB induced CPD in the dermis whilst UVA1 induced TT repair is slow 
which has also been shown by others (Bykov et al., 1999; Young et al., 1996) using 
an SSR source.   
 
3.5.3 Location of CPD in the skin 
It is intriguing that UVB predominantly induced TT in the superficial epidermis, 
whereas UVA1 induced TT were more prominent in the lower epidermis (Figure 3.8).  
A similar depth effect has been found with p53 protein staining at 24h (Campbell et 
al., 1993a) post 2MED UVB (300 ± 5 nm) and UVA (350 ± 30 nm) and also at 
1MED but not 2MED doses of UVA1 (Burren et al., 1998).  Overall, skin 
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chromophores absorb primarily in the UVB region.  UVA is known to make up a 
greater percentage of UVR wavelengths that reach the basal layer of the epidermis 
(Miller et al., 1998), and in explant skin (Bruls et al., 1984), 12% of the UVB 
reaches basal Caucasian epidermis compared with >25% UVA.  As well as 
transmittance and scatter, back scattering results in remittance, which provides 
additional opportunity for chromophore absorption during the return pathway.  
Dermal remittance increases between 300 and 400nm (Anderson and Parrish, 1981), 
thus it is possible that the higher number of UVA1 induced TT seen in the basal 
layer is due to dermal back scatter (e.g., from collagen and fibroblasts), as well as 
epidermal forward scatter (Bruls et al., 1984). Irrespective of any mutagenic 
potential for TT, our data suggest that UVA1 preferentially targets the stem cell 
containing basal layer.  
 
Mechanism of CPD production by UVA1  
UVA is poorly absorbed by DNA (Sutherland and Griffin, 1981) and absorption 
beyond 360nm is questionable.  Approximately 3 orders of magnitude more energy 
from UVA1 than UVB is needed to give equivalent erythema (Diffey et al., 1987), 
as also shown with our erythema data: a UVB MED in skin type I/II is 30mJ/cm2 
and a UVA1 MED is 48.8J/cm2.  Direct evidence that DNA is a chromophore for 
erythema has been obtained from animal studies (Ley, 1985), however the similarity 
of the TT and erythema action spectra in vivo especially at 300-340nm range (UVB 
and UVA2) suggests that erythema is a marker of CPD mediated through a common 
chromophore: via DNA (Freeman et al., 1989; Young et al., 1998a).  This has also 
been recently confirmed in a further in vivo study (Mouret et al., 2011b) using UVB 
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and UVA sources where equivalent levels of erythema in skin types II and IV are 
associated with similar levels of TT.  Figure 3.3 shows a lack of correlation between 
an individual’s UVB and UVA1 MED suggesting that UVA1 induced erythema 
likely occurs from at least 2 chromophores one of which is DNA and the other is still 
yet to be identified.  
 
Induction of CPD and 64PP 
With direct absorption of UVB, T (and occasionally C) enters an excited singlet state 
that then undergoes intersystem crossing to an excited triplet state (Cadet and Douki, 
2011).  This energy is transferred to a ground state pyrimidine, causes a formal (2+2) 
cycloaddition between the C5-C6 double bonds of two pyrimidines and the 
formation of a CPD (see Introduction).  Pyrimidines remaining in an excited singlet 
state will form a 64PP.  Varying energy levels achieved by pyrimidines probably 
explains the differing distributions of CPD and 64PP.  CPD are formed by triplet 
energy transfer after direct UVB absorption by thymine or cytosine (Douki, 2013), 
but can also be formed by UVA1.  As 64PP are not produced by UVA1, singlet state 
energy states are likely a UVB mediated phenomenon.  
 
There are currently two schools of thought for TT induction by UVA; either a triplet 
energy transfer mechanism, or an emerging view that they are formed via weak 
direct absorption of UVA by DNA.  Formation of dimers by UVA and UVB is 
summarized in Figure 3.16.   
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Figure 3.16  Mechanism of CPD and 64PP induction by UVA1 and UVB 
 
UVA1 induced CPD formation:  
Indirect mechanism 
UVA1 induced CPD (Cadet et al., 2009) form via triplet energy transfer.  Briefly, 
photons are absorbed by a photosensitizer that enters an excited singlet excited state, 
and then undergoes intersystem crossing to achieve an excited triplet state.  This 
triplet state persists for slightly longer, and enables energy to be transferred to 
thymine predominantly (as it has the lowest triplet energy and can easily absorb this 
energy and initiate new changes).  This causes the formation of TT CPD (90% of 
UVA CPD) (Mouret et al., 2006).  Support for an as yet unidentified endogenous 
photosensitizer comes from work with exogenous photosensitisers (Sauvaigo et al., 






































































































presence of UVA. These include iomefloxacin (Sauvaigo et al., 2001) acetophone 
(Douki et al., 2003),  carprofen (Robinson et al., 2010) and fluoroquinolone 
(Makinen et al., 1997) at UVA doses as low as 5J/cm2.  They act as the excited 
photosensitizer and indirectly transfer UVA photons to DNA.   Interestingly, a recent 
population study showed an increased risk of BCC and SCC by 50% and 80% 
respectively in those patients taking photosensitizing drugs such as psoralens, 
tetracyclines, fluoroquinolones, amiodarone and phenothiazines (Karagas et al., 
2007), possibly due to the increased induction of CPD with UVA exposure. 
 
Direct mechanism 
A few reports discuss the formation of CPD in naked acellular DNA after UVA 
irradiation (Jiang et al., 2009; Kuluncsics et al., 1999; Quaite et al., 1992; Schuch et 
al., 2009), particularly in the absence of a photosensitizer.  Genomic DNA has been 
shown to absorb weakly at UVA wavelengths (Sutherland and Griffin, 1981), but 
this early work may be misleading as cell cultures used had a predominance of G:C 
base pairs which absorbs UVA particularly poorly.  In cultures composed solely of 
A:T (which absorb UVA well) (Mouret et al., 2010), recent experiments show 
(Mouret et al., 2010) that direct UVA (320 – 400nm) absorption by duplex dA:T 
oligomers produce TT dimers at similar proportions to TT produced in cells, 
suggesting that this phenomenon may be occurring through direct absorption in 
keratinocytes.   
 
Generally, photosensitization by other (non-DNA) skin constituents occurs with 
UVA, and may explain why there is less TT induction for equivalent levels of 
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erythema. UVA1 erythema has been shown to be oxygen dependent (Auletta et al., 
1986) likely mediated through ROS (Tyrrell, 2000), whilst UVB erythema is oxygen 
independent.   
 
3.5.4 UVA mutations in skin cancer 
The role of UVA in skin cancer is a growing concern for several reasons.  First, 
UVA was found to be mutagenic in vitro (Drobetsky et al., 1995; Kappes et al., 
2006; Rochette et al., 2003), tumorogenic in mice (de Gruijl and Van der Leun, 
1994; de Laat et al., 1997; van Kranen et al., 1997) and proposed by some authors to 
be involved in the induction of MM (Setlow, 1974; Setlow et al., 1993; Setlow et al., 
1989) although not all have agreed with these findings (De Fabo et al., 2004).  UVA 
forms melanoma through formation of reactive melanin radicals (Wood et al., 2006) 
which has been further confirmed in recent mice studies (Noonan et al., 2012) 
interestingly by a group who previously refuted melanoma induction by UVA (De 
Fabo et al., 2004).  UVA induced melanoma occurs in pigmented but not in albino 
mice (lacking melanin) following production of significant quantities of 8oxodG 
(Noonan et al., 2012), which fundamentally secures a significant role of the G-
C→T-A transversion mutation in melanoma.  Interestingly UVB did not produce 
8oxodG in this study.  These observations are supported by work that shows that 
melanocytes are particularly sensitive to UVA damage (Mitchell and Fernandez, 
2012; Mouret et al., 2011a).  UVA probably acts in a mechanistically different way 
in both SCC and melanoma and although C→T mutations are the predominant 
mutations in p53 in SCC (Benjamin et al., 2008; Brash et al., 1991) and in a 
melanoma cell line (Pleasance et al., 2010), the G→A transversion is the second 
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common mutation in melanoma (Pleasance et al., 2010).   
 
3.5.5 Summary 
Environmental relevance of UVA1 doses 
On a mid summer’s day in the south of France, the maximum ambient daily UVR 
erythemal dose is around 22 MED and the maximum UVA dose is around 137 J/cm2 
(Fourtanier et al., 2012), whilst on average, an indoor worker in Europe is exposed 
to 1,500 J/cm2 UVA per year (Diffey, 1996). In our study we used single UVA1 
doses (24.4, 73.2. 146.4J/cm2 equivalent to 0.5MED, 1.5MED and 3MED), which 
formed TT dimers.  It is known that frequent users of UVA-rich sunlamps increase 
their annual UVA exposure.  In countries such as Norway, the UVA irradiances of 
tanning beds are 3–3.5 times that of summer solar exposure (Nilsen et al., 2008) 
meaning that regular tanning bed users would quadruple their annual UVA 
exposures (Miller et al., 1998).  Cumulative exposure to UVA1 also occurs during 
treatment of certain dermatological skin disorders such as morphea (Andres et al., 
2010; Su et al., 2011) where on average patients receive cumulative doses of 
approximately 900 J/cm2 UVA1 (50 J/cm2, 3 times a week for 6–8 weeks) in one 
year, whilst for treatment for other conditions such as atopic eczema of the hands or 
cutaneous T-cell lymphoma, single doses of up to 100 J/cm2 UVA1 (Kerr et al., 
2012b) mean that cumulative yearly exposures can be up to 1800J/cm2. 
 
Impact on Public Health 
UVA1 is found in very large doses in tanning lamps as it is less erythemogenic and 
hence thought to promote tanning without the potentially painful side effects of 
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sunburn (Mutzhas et al., 1981). It is important to note that approximately 80% of 
tanning lamp emission is UVA1, 18% UVA2 and 2% UVB (personal 
communication from Patrick Tierney) and UVB is more effective than UVA in 
initiating tanning.  Thus, commercial tanning is likely a contribution of both 
UVB/UVA2 delayed tanning and UVA1 immediate photooxidation of melanin.  In 
terms of carcinogenic effects the exact contribution is unknown and skin biopsies 
from chronic tanners have not been examined for molecular changes.  
The trend to use commercial sunlamps for cosmetic pigmentation has increased over 
the past few decades, with 71% of users being women (Swerdlow and Weinstock, 
1998) and 50% under the age of 29 (Coelho and Hearing, 2010).  Melanomas are the 
most prevalent of all cancers in 25-29 year old females, and melanoma incidence is 
higher in young women compared to men (Morris et al., 2009).  
The tanning industry promotes sunbed use as risk free, suggesting that it is a safe 
method for vitamin D synthesis yet there is overwhelming evidence that UVA 
contributes to skin cancers.  A UVB tan provides a small sun protection factor of 2 
(Sheehan et al., 2002), supported by chemical assays that show that UVB increases 
melanin production (Wolber et al., 2008).  UVA causes photooxidation of melanin 
precursors at lower doses than for neomelanogenesis (see Introduction) and there is 
generally no sun protection factor achievable with UVA.  The recent decision of the 
International Agency for Research on Cancer (IARC) to classify artificial UVR 
devices as carcinogens (El Ghissassi et al., 2009) further emphasizes the 
carcinogenic risk associated with UVA, importantly with reference to sunlamps.  
The IARC has shown that there is a 75% increase in melanoma risk (IARC, 2007) 
where the first exposure to a sunbed was before the age of 35. This is also confirmed 
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by a more substantial meta-analysis (Boniol et al., 2012) identifying an 87% higher 
risk of developing melanoma compared to non sunbed users if use began before 35 
years.  Significant risk also occurs with SCC induction, with a 67% increase in 
likelihood compared to non-sunbed users if exposure began under 25 years (Wehner 
et al., 2012).  A recent study in the UK showed that by the age of 55 years the risk of 
SCC induction from sunbed exposure between the ages of 20-35 years is increased 
by 90% (Tierney et al., 2015). 
 
Although there is EU legislation to control sunbed exposures, a recent British study 
showed that in practice this is unregulated: 9 out of 10 sunlamps emit above 
legislation limits for irradiance (Tierney et al., 2013), and more importantly these 
lamps were not manned by health professionals.  Melanoma is triggered by 
intermittent sunburning UVR exposures.  An estimated 18-55% of commercial 
sunlamp users in Europe and North America have reported sunburns (Demko et al., 
2003), with a higher proportion occurring in women (Geller et al., 2002).  This risk 
needs to be emphasized to young adults who are at greatest risk.  
 
Currently, in some US states, minors (under 18) are not allowed to use sunbeds.  In 
practice, the situation is more complex because a nationwide study showed that some 
parents are complicit in allowing their children to engage in tanning.  This is because 
compared to other high-risk behaviours that have potentially serious acute 
consequences, UVR exposure risks are viewed as less serious and the long-term 
consequences are poorly understood (Pichon et al., 2009).  In the UK there is a law 
(Sunbeds Regulation Act 2010) that prohibits sunbed use by those under 18 
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(http://www.legislation.gov.uk/ukpga/2010/20/section/2).  The demographics of 
sunbed use after this legalisation would be useful to look at as sunbed use is 
extremely frequent in the 11-17 year age group in the UK (Thomson et al., 2010). 
 
The work in this chapter has relevance for public health strategies: for consolidating 
legislation of sunbed use as well as stressing the importance of good broadband 
photoprotection which is already increasingly recognized (Osterwalder et al., 2014).  
At present, young fair skinned women, who have the greatest risk for melanoma, are 
heavily targeted by the sunbed industry and younger generations tend to ignore 
warnings in favour of brown, sun-damaged skin, thus extending their potentially 
carcinogenic exposure to UVR.  More CPD are formed the deeper in the skin below 
150μm after UVA1.  CPD contributes to MMP1 formation and increased MMP1 
levels in the dermis might help explain the efficacy of UVA1 in diseases such as 
scleroderma (Kreuter et al., 2006).   UVA1 phototherapy is expensive (~£30,000 per 
machine as opposed to narrowband UVB (TL01) that costs ~£3000-4000) but has 








Chapter 4 UVA1 and UVB have different effects on determinants of 




UVA1 induced CPD in vivo are predominantly formed in the basal epidermis and 
their repair is slow over 48h.  This layer is crucial for epidermal proliferation 
because it is home to epidermal stem cells.  In Chapter 3 we show a lack of repair of 
UVA1 induced CPD in the basal epidermis.  To investigate the slow repair, a series 
of other differentially expressed epidermal markers known to be sensitive to UVR 
(p63, p53, as well as epidermal differentiation markers (involucrin, Keratin (K)1, 
K10, K14) and proliferation marker (Ki67) in the individuals from the DNA repair 
time course study (6 individuals) and from the Protein validation gene study (3 
participants) were assessed.   
UVA1 induced expression of p63 over 48h whilst UVB decreased its expression. 
Only UVB induced p53 expression and SBC (apoptosis) formation.  
CPD recognition, DNA repair and apoptosis are p53 driven processes and both UVB 
and UVA1 induce CPD.  The basal epidermis is relatively more sensitive to UVA1 
than UVB although in total more CPD are produced by UVB across the whole 
epidermis.  The overexpression of p63 at the basal epidermis by UVA1 is likely to 
suppress p53 in this layer and affect the downstream p53 driven processes causing a 
reduction in cellular arrest and apoptosis and may explain why UVA1 CPD are not 
recognised and repaired over a 48h period.  Although 3-4 fold fewer, this might 
mean that UVA1 induced CPD are possibly more mutagenic than UVB CPD.  If this 
is the case, it has implications for the safety of UVA1 phototherapy, tanning lamps 




The mutagenic and carcinogenic potential of UVA1 in vivo at erythemally equivalent 
doses of UVA1 (3MED (~148J/cm2) and UVB (3MED ~90mJ/cm2) was discussed in 
Chapter 3.  Although these doses were high, they are biologically relevant for UVA1 
phototherapy (Kerr et al., 2012a), cumulative tanning lamp exposure and long-term 
outdoor exposure.  This chapter focuses on other markers that are UVR sensitive, 
such as p53 and its recently cloned homologue p63, as well as markers of 
keratinocyte differentiation in order to understand some of the cellular processes in 
the skin in response to UVA1 particularly the lack of repair of UVA1 induced CPD 
at the basal epidermis. 
Tumour protein p53 
Activation of the p53 tumour suppress gene (TSG) and its protein occurs in response 
to cellular stress including DNA damage, oncogenic stimulation and hypoxia.  This 
triggers a G1/S cell cycle arrest and transcriptional activation of NER genes 
(p48XPE and XPC) to enable CPD removal and NER, before onset of scheduled 
DNA synthesis and mitosis (Smith and Fornace, 1997).  p53 also induces apoptosis  
(SBC formation) through Bcl2 (Burns et al., 2002) family members (BAX, PUMA) 
and an upregulation of the death receptor FAS through a caspase associated pathway. 
This process eliminates DNA damaged keratinocytes, that are potential progenitors 




Figure 4.1  Activation of p53 and its downstream consequences 
p53 has dual roles; protective via G1/S arrest and DNA repair and induction of 
apoptosis via Bc2/MDMD2/GADD45a. 
 
The role of p53 in UVR induced apoptosis is clear from mouse studies (Jiang et al., 
1999; Ziegler et al., 1994) in which UV irradiation of p53 wild type mice induced 
the formation of SBC whilst p53 null mice were resistant to such apoptosis and 
accumulated CPD.  The p53 gene is mutated in more than 90% of human SCC and 
about 50% of human BCC (Brash et al., 1991; Ziegler et al., 1993) as explained in 
Chapter 3, and combined analysis of skin cancer mutations (SCC and BCC) showed 
that 90% of the mutations were G:C→A:T in XP patients (Dumaz et al., 1993; 
Kraemer, 1997).  p53 mutations prevent cellular arrest and repair, and through a lack 
of p53 function, these transition mutations are incorporated into further rounds of 
replication with tumour initiation and promotion resulting in SCC and BCC.  UVR 
induced C→T mutations have been found in 80% of p53 mutations in actinic 
keratosis (Ziegler et al., 1993) and 63% of p53 mutations in Bowen’s disease 
(Campbell et al., 1993b).  In sporadic human cancer cases, mutations in p53 occur in 

















p63 is a member of the p53 gene family (Westfall and Pietenpol, 2004) and exists in 
multiple isoforms with varying functions.  All isoforms contain an N terminal (either 
transactivating (TA) or truncated (ΔN)), a C terminal (α, β, γ, δ, ε) and a p53 
response element, which enables interaction with p53.  Two main isoforms: TAp63 
and ΔNp63 exist.  Most work has focused on the ΔNp63 isoform as TAp63 negative 
mice do not display any overt abnormalities.  ΔNp63 is most abundantly expressed 
in human epidermal basal layer (Vanbokhoven et al., 2011).   
The crucial role of p63 (ΔNp63) in the formation of the epidermis is demonstrated 
from studies in knockout mice.  p63 deficient mice have no epidermis, aberrant 
squamous epithelia (cervix and urothelium) and are also devoid of epithelial 
appendages such as hair follicles (Parsa et al., 1999; Yang et al., 1999).  p63 
knockout mice also fail to commit to an epidermal lineage, which results in an 
epidermis with a single cell layer (Mills et al., 1999), and no expression of markers 
of epidermal development and differentiation. As p63 promotes terminal 
differentiation, data regarding upregulation of keratin markers in response to UVB 
and UVA1 is also presented in this chapter.  
 
Terminal differentiation of epidermal keratinocytes 
Keratinocytes undergo a distinct pattern of proliferation and differentiation (Fuchs, 
1990), and upwards migration resulting in the formation and maintenance of the 
stratum corneum (consisting of dead corneocytes and secreted lipids).  This is known 
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as terminal differentiation, and is essential for the skin’s function as a protective 
barrier against entry of environmental chemicals and microbes and protection against 
dehydration (Blanpain and Fuchs, 2006).  
Classically the epidermis comprises 2 cell compartments: one consisting of 
undifferentiated proliferative cells occupying the basal layer and the other consisting 
of differentiated post mitotic cells occupying the suprabasal layers (Lavker and Sun, 
1982, 2000; Regnier et al., 1986).  Work has shown that the basal epidermis is 
actually a heterogeneous cell layer, and as well as the undifferentiated stem cells 
(epidermal stem cells) there are also differentiated post mitotic cells that are 
normally seen in the suprabasal layers (Regnier et al., 1986).   
The stem cell layer continually produces keratinocytes, and also secretes and 
assembles an ECM that constitutes much of the underlying basement membrane as 
well as laminins that hold the epidermis together.  The major structural proteins of 
the epidermis are the keratins, and the expression of different keratin types is related 
to the stage of differentiation. The basal layer is typified by the expression of K5 and 
K14.  When cells are committed they move upwards, switch off integrin and laminin 
expression and execute a terminal differentiation programme where the intermediate 
suprabasal layers express K1 and K10, and filaggrin and loricrin are produced higher 
up in the granular layer.  As keratinocytes commit to terminal differentiation, p63 
expression is lost (Parsa et al., 1999; Westfall and Pietenpol, 2004).  p63 expression 
is needed to sustain K1, K10, loricrin and desmoglein expression (Truong et al., 
2006) and in ΔNp63 null mice the spinous layer of the epithelium fails to develop 
properly as demonstrated by a delay in expression of K1 (Koster and Roop, 2008). 
p63 is needed for epidermal commitment and stratification.  
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Figure 4.2  Markers found in the epidermis according to differentiation stage 
 
Stem cells can be activated by stress events such as wounding when tissue 
regeneration is needed.  The slow-cycling attribute of stem cells conserves the cell's 
proliferative potential until needed and minimizes DNA replication related errors.  
The division of stem cells also gives rise to a further stem cell known as a transit 
amplifying (TA) cell (1:1 ratio) and the TA cell is rapidly proliferating, during which 
it can increase the number of rounds of DNA replication.  Once proliferative 
potential is exhausted TA cells undergo terminal differentiation (Lavker and Sun, 
2000).  
p53 is inducible by UVR and can also be inhibited by the ΔNp63a isoform (Yang et 
al., 1998) as in cell lines the percentage of cell death induced by the ΔNp63 was 
considerably less than those cells expressing p53.  p63 is also UVR responsive 
(Liefer et al., 2000): its down regulation appears to be important for UVB induced 
apoptosis (Liefer et al., 2000).  Transgenic mice constitutively overexpressing 
ΔNp63a exhibit a 40-45% decrease in UVB induced epidermal apoptotic cells 


























4.2  Materials and methods 
Volunteer demographics 
Taken from the Time course DNA damage study (6 individuals) and from the 
Protein validation gene study validation experiments (3 participants) (see Table 4.1). 
Staining 
The types of staining performed are shown in the table below.   
Study group Staining 
3MED: Paraffin embedded sections from 
the DNA damage time course study (n=6) 
p63, CPD, H&E  
Epidermal differentiation: involucrin, 
K1, K10, K14  
Proliferation: Ki67 
1MED: Frozen sections from the gene 
protein validation study (n=3) 
p53 
Table 4.1  Types of immunostaining on treated tissue 
MED refers to 30mJ/cm2 for UVB and 50J/cm2 for UVA1 
 
4.3 Results 










Figure 4.3  Spectra specific effects on basal epidermis 
(A) Example of CPD and p63 co-staining in skin sections at 24h.  Note the 
superimposed blue (DAPI), green (p63) gives a deep aqua colour seen in the 
unirradiated control.  The third superposition of red (CPD) makes the colour more 
purple in the 3MED UVB and UVA1 slides (B) Quantification of p63 at the basal 
epidermis: increase in p63 expression following 3MED UVA1 at the basal 
epidermis compared to 3MED UVB (** p=0.001)  
 
In the basal epidermis, 3MED UVA1 induced a statistically significant increase in 
p63 expression (p =0.047) and 3MED UVB induced a decrease in p63 expression 
(p=0.041). (see Figure 4.3B).  Statistics on the intensity of p63 staining at 48h showed 
a significant difference between UVA1 and UVB  (p=0.001).  
 
4.3.2 UVA1 does not induce p53 protein expression or sunburn cell formation 
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Figure 4.4  p53 and sunburn cell formation 
(A) p53 expression after 1MED UVA1 and 1MED UVB at 10h (** p=0.004) and at 
24h (*** p=0.0008), 3MED doses (B) examples of H&E staining: arrow points to a 
typical SBC (C) mean number of SBC per 500μm epidermis after 3MED.  Error 
bars refer to standard error (SEM). 
 
There was minimal p53 expression with 1MED UVA1 compared to 1 MED UVB at 
10h (p=0.004) and 24h (p=0.0008) see Figure 4.4A.  There was no SBC formation 
with UVA1.  
 
3MED UVA1 at 24h 3MED UVB at 24h 


































4.3.3 Terminal differentiation and proliferation 
In terms of differentiation markers, K14, K1, K10 and involucrin were examined 
after 3MED UVA1 and UVB for any time dependent changes up to 48h (Figure 
4.5A-D).  Only K1 expression (found in suprabasal layers) showed a source specific 
difference at 3h between UVA1 and UVB, and appeared to be upregulated by UVA1 
(p=0.029).  Ki67 staining was found throughout the epidermis, and UVB caused 
increased nuclear proliferation (Ki67) at 3h compared to UVA1 (Figure 4.5E). 
Epidermal thickness was also measured from the H&E sections and was found to be 
notably thicker after UVB than after UVA1 (Figure 4.5F).  
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E  Ki67      F  Epidermal thickness 
  
Figure 4.5  Spectral specific morphological changes to the epidermis 
 (A)-(D) Changes to 4 epidermal markers in response to 3MED UVB and UVA1 
over a period of 48h: increase in UVA1 induced K1 expression at 3h compared to 
UVB (*p=0.03)  (E) increase in cellular proliferation at 3h after UVB compared to 
3MED UVA1 (*p=0.02).  Background control staining has been removed from all 




Increased basal epidermal p63 at 48h Decreased basal epidermal p63 at 
48h 
No/limited p53 production  p53 production 
No SBC SBC formation 
K1 formation (3h) 
No change in K10, K14, involucrin 
No increased Ki67 
No increased K1 formation 
No change in K10, K14, involucrin 
Ki67 expression (3h) 
No increase in epidermal thickness 
over 48h (p=0.71) 
Increased epidermal thickness over 
48h (p=0.01) 
Table 4.2  Summary findings in this chapter 
UVA1 and UVB induced cellular changes over a 48h period in response to 3MED 
UVA1 and UVB. 
 
p63 and terminal differentiation 
The data show that a single 3MED UVA1 exposure induces basal epidermal p63 
expression (ΔNp63α isoform) that reaches maximal levels at 48h (p=0.04), whereas 
UVB decreases p63 expression over the same period of time (p=0.041).  At 48h 
there is a significant difference in UVB and UVA1 p63 levels (p=0.001) (see Figure 
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expression of K5, K14 and loricrin (Parsa et al., 1999) than p63 null mice.  This 
chapter shows a UVR source specific difference only with K1 expression between 
UVA1 and UVB, in that UVA1 induces significantly more K1 than UVB at 3h.  
Involucrin showed peak expression with UVA1 and UVB at 24h but this was not 
significantly different from baseline.  Perhaps we could have expected a statistically 
significant profile pattern of K1, K10 and involucrin expression in conjunction with 
p63 expression pattern in the basal epidermis with UVA1 and UVB.  
Overall epidermal thickness was greater after UVB, which could represent a greater 
responsiveness of the skin to UVB rather than to biologically equal doses of UVA1.  
To support this we saw increased Ki67 expression at 3h by UVB but not UVA1 
which could contribute to increased thickness.   
Previous work however has shown that following 25mJ/cm2 UVB there is increased 
K5 and K14 (as well as K6 and K19) gene expression in vitro however no changes in 
response to up to 20J/cm2 of UVA (Bernerd et al., 2001) have been reported, except 
an increase in K17 gene expression, mutations in which cause a skin and nail 
disorder (pachyonychia congenita (Eliason et al., 2012)).  
p63 associated p53 independent apoptosis 
Both UVA1 and UVB induce CPD, at a given erythemal exposure (see Chapter 3).  
Cell death occurs by 3 mechanism; necrosis (which does not occur after UVR) 
(Godar, 1996; Godar et al., 1994), immediate and delayed apoptosis (Godar et al., 
1994) which can occur following UVR.  Immediate and delayed apoptosis by UVA1 
are mechanistically different to that by UVB (Godar, 1999; Morita and Krutmann, 
2000).  Immediate apoptosis (<4h) (pre-programmed cell death) is UVA1 driven via 
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1O2 damage (Morita et al., 1997) and also superoxide anions (Godar, 1999) likely via 
AP1, and downregulation of Bcl2 (Wang et al., 1998).  There is increased expression 
of Fas Ligand which initiates apoptosis by cross linking the Fas  (Beattie et al., 
2005b).  This is p53 independent (Breuckmann et al., 2001).  
 
UVR induced DNA damage is repaired through a p53 dependent pathway (Eller et 
al., 1997; Smith and Fornace, 1997) and cells which cannot be repaired will undergo 
apoptosis (Sheehan and Young, 2002), which occurs at doses as low as 0.5MED 
UVB (Hofmann-Wellenhof et al., 2004).  Thus the skin also has a p53 dependent 
'guardian-of-the-tissue' response to DNA damage and UVB stimulates induction of 
p53 (Breuckmann et al., 2003; Godar et al., 1994). p53 driven apoptosis produces 
SBC.  Apoptosis then occurs by a common pathway involving FAS/FASL (CD95, 
APO1) and caspases (Yamauchi et al., 2004). 
UVA1 induces CPD in vivo, which needs a p53 dependent pathway for repair.  At 
1MED, our data showed hardly any p53 expression in the epidermis in response to 
UVA1, however at 3MED (data not shown) there was some expression seen by 
immunohistochemistry.  UVA1 did not produce SBC at any dose.  Previous work 
shows p53 formation after 2MED of UVA1 mainly in the basal epidermal (Burren et 
al., 1998; Campbell et al., 1993a), although other studies show a lack of UVA1 
induced p53 or SBC (Beattie et al., 2005b) at 3MED.  Our work shows a lack of 
repair of CPD in the basal epidermis after UVA1. A possible explanation for this is 
that through an upregulation of p63 expression predominantly in the basal epidermis, 
p53 expression is suppressed resulting in the relative lack of downstream effects.  
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p63 mediated p53 suppression by UVA1 
A hypothesis for our observations is shown in Figure 4.6.  Our UVA1 dose 
(146J/cm2), comparable to that used in high dose UVA1 phototherapy, increased p63 
expression in the basal epidermis at 48h, which we feel is suppressing p53 
expression particularly in this layer.  This in turn suppresses apoptosis (seen as a lack 
of SBC) and G1/S arrest, also described by others after UVA (Runger et al., 2012).  
Thus DNA damage is neither removed (by apoptosis) nor repaired.  On the other 
hand, UVB (90mJ/cm2) decreases p63 expression, which enables p53 protein 
expression, apoptosis, cell cycle arrest and CPD repair. Although there are mixed 
views on the carcinogenicity of UVA1 with some work suggesting that it is less 
carcinogenic due to a lack of p53 and SBC formation (Beattie et al., 2005b), this 
chapter suggests that UVA1 may have more damaging effects than UVB in vivo as 
the persistence of CPD at the basal epidermal layer and a lack of p53 mediated 
apoptosis could mean that these CPD could be more likely incorporated as C→T 
mutations in further rounds of replication which over time could lead to skin cancers.  
 




The strong induction of p53 and apoptosis by UVB confirms p53’s role as ‘‘guardian 
of the genome’’ (Ziegler et al., 1993), but the weak induction of p53 and lack of 
apoptosis by UVA increases the probability of mutation by a CPD, especially given 
the lack of DNA repair in the basal layer.  Although this study reports on TT widely 
regarded as non-mutagenic, UVA1 also induces C containing CPD with mutagenic 
potential.  The data presented above suggest that these important differences maybe 
mediated by the differential response to p63 by the two spectra, which may also 
account for differences in the basal layer DNA repair responses.  
These results may be significant in situations where UVA1 is used to achieve a 
biological endpoint such as tanning or a clinical endpoint in phototherapy. They may 
also have implications in sunscreen photoprotection.  DNA repair systems evolved 
under solar radiation where most damage is caused by UVB.  All sunscreens contain 
UVB filters, based on the erythema action spectrum. The data presented above 
suggest that some UVB may be important to trigger basal layer NER and that “over 









Chapter 5 : Downstream molecular changes and their functional 
importance after UVA1 irradiation, with emphasis on matrix 
metalloproteinases 
 
Published paper:  
 
Tewari A, Grys K, Kollet J, Sarkany R, Young AR. 
Upregulation of MMP12 and Its Activity by UVA1 in Human Skin: Potential 
Implications for Photoaging. 








Despite the predominance of terrestrial UVA1, its molecular effects on human skin 
in vivo are surprisingly poorly understood.  In this chapter, time-dependent whole-
genome expression, along with mRNA and protein changes in the skin after 1MED 
of spectrally pure UVA1 (50 J cm2) and 300 nm UVB (30 mJ/cm2) were examined.  
At 6h, genes induced to the greatest extent were those involved in the upregulation 
of the immune response through IL17 signalling for both UVA1 (p=3.148e-7) and 
UVB (p-5.1e-10) with the key upregulated pathways being those involved in 
inflammation, apoptosis and response to hypoxia.  After 24h, the genes induced to 
the greatest extent were those involved in extracellular matrix remodelling (ECM) 
with both UVA1 (P=5.5e−7) and UVB (P=2.9e−22).  There are source specific 
variations within this: UVB induces MMP1, MMP3 and MMP10 mRNA at 24h to a 
much greater extent than UVA1.  Our specific finding was the induction of MMP12 
by UVA1 at 24h.  We saw a dramatic upregulation in the MMP12 microarray 
transcript in all individuals compared to UVB, and these findings were reproduced 
using the quantitative mRNA PCR experiments.  We chose to also assess for the 
presence of MMP12 protein in the skin in a further 3 skin type I/II individuals and 
found MMP12 in human epidermis 24h post 1MED UVA1.  A small amount of 
MMP12 protein was also produced by UVB.  To try and understand its function in 
the skin we used insitu zymography staining techniques and found that UVA1 but 
not UVB induced MMP12 broke down elastin in the skin.  This meant that only 
UVA1 induced MMP12 had elastase activity.  We hypothesize that UVA1 induced 
MMP12 probably mediates some of the photoageing effects in the skin, particularly 
by contributing to elastin degeneration.  We feel this is a process that likely occurs in 
 159 
the later stages of solar elastosis and our results provide a possible mechanism for 
the UVA mediated process known as ‘skin sagging’. We conclude that MMP12 is 





The effects of UVA1 on gene expression in vivo are poorly understood and have 
been much less studied than UVB (Enk et al., 2006; Enk et al., 2004).  This is 
mainly because UVB was previously regarded to be more biologically important, 
and Chapter 3 discussed how this is no longer the case. Experiments to determine 
gene expression after UVA have been performed on reconstructed skin (Marionnet et 
al., 2011; Marionnet et al., 2010) although studies show that gene changes after in 
vitro and in vivo exposure are dissimilar (Enk et al., 2006).  Previous gene 
expression studies in vivo are limited and have primarily focused on expression 
differences between UVA and UVB in the pigmentation pathway (Choi et al., 2010).  
The hallmarks of long-term exposure to solar UVR are photoageing (Yaar and 
Gilchrest, 2007) and photocarcinogenesis (Sage et al., 1996).  In terms of 
photoageing, previous studies with UVB rich sources showed induction of MMP1, 
MMP3, and MMP9 mRNA (Brenneisen et al., 1996; Fisher et al., 1996; Fisher et 
al., 1997) in human skin in vivo (see introduction).  UVA sources have also been 
reported to induce MMP1 expression in fibroblasts (Herrmann et al., 1993; 
Scharffetter et al., 1991), however even <1% UVB contamination of a 
predominantly UVA source can be responsible for most of a given effect such as 
DNA damage (Woollons et al., 1999) and there are few data on the effects of 
spectrally pure UVA1 on MMP in human skin in vivo (Wang et al., 2013).  
 
The aim of this chapter is to understand the molecular processes that lead to long-
term effects of UVA1 on the skin by studying whole genome expression changes 
after a low dose acute exposure of pure UVA1, in comparison to UVB, in skin type 
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I/II individuals.  The most significantly enriched pathway was found to be 
inflammation through Th17 signalling at 6h and extracellular matrix (ECM) 
remodelling at 24h.  Although the mRNA results are discussed in detail, our most 
striking findings occurred with the ECM genes, thus protein and enzyme activity was 
studied for MMP only.  In summary we report the results of a series of experiments 
following a 1MED dose of UVA1 on whole skin and analysis of DNA, RNA and 
protein changes that we believe has identified a novel marker of UVA1 exposure and 
might also explain some of UVA1’s contribution to photoageing. 
 
5.2 Materials and methods 
This is described in detail in Chapter 2. 
In brief 3 studies were performed:  Time course study:  5 volunteers and biopsies 
taken 6h and 24h after 1MED UVA1.  Dose response study: a further 5 volunteers 
and biopsies taken 6h after ¼, ½ and 1MED of UVA1.  UVA1 and UVB comparison 
study: the 5 volunteers in the dose response study also had biopsies taken at 6h and 
24h after 1MED of UVB and also a biopsy taken 24h after 1MED UVA1. 
 
5.3 Results  
5.3.1 Volunteer demographics 
The demographics of volunteers used to study the genetic effects of UVA1 on 
human skin in vivo are shown in Table 2.1 
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5.3.2 Genes upregulated by UVA1 and UVB in human volunteers  
We excluded volunteer 001 from the time course study as he was found to have an 
underlying autoimmune disease (Crohn’s Disease), which skewed our results as 
upregulation of inflammatory genes, were also found at baseline.  Thus the pooled 
intensities (n = 9 for UVA1 and n = 5 for UVB) of upregulated genes compared to 
each individual’s non-irradiated control (p<0.05, fold change ≥2) were analysed for 
enriched pathways using Genego Metacore v7 and biological group known as Gene 
Ontology (GO) groups using Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v 6.7 (Dennis et al., 2003).     
 
The main enriched pathway with low dose (sub-erythemal) UVA1 (12.5J/cm2, 
25J/cm2) was upregulation of the immune response through TH17 signaling.  This 
was also the case after 50J/cm2 UVA1 (1MED), and comparing gene changes with 
30mJ/cm2 UVB (1MED) the main upregulated pathway at 6h was upregulation of the 
immune response through TH17 signalling for UVA1 (p=1.16e-6) and UVB (p=2.1e-
4). Within this, for UVA1, key pathways of upregulated genes include inflammation 
(p=3e-3), apoptosis (p=3.82e-15) and response to hypoxia (p=1.988e-11).  At 24h, 
the main upregulated pathway was ECM remodelling for UVA1 (p=5.5e-7) and 
UVB (p=2.9e-22).  These pathways are part of a bigger network and the schematic 










Figure 5.1  Top molecular signalling events 1MED post UVA1 and UVB 
(A) Immune response through Th17 signalling at 6h showing an upregulation of 
key pathways (B) ECM remodelling at 24h demonstrating upregulation fo MMP1 





































































The upregulated gene lists (p≤0.05, fold change ≥2) were also placed in Venn 
diagrams (Figures 5.2A-C) showing upregulated genes by UVA1, UVB or both at 
the two time points.  Where relevant, these were clustered into Gene Ontology 
groups using DAVID (see Chapter 2 Materials and methods).  24h post UVA1, there 
was striking upregulation of MMP12.  The individualised log2 transformed 
normalised intensity values for MMP12 are plotted in a heat map (Figure 5.3) which 




B      C 
      
Figure 5.2  Venn diagrams demonstrating common and differentially upregulated genes 




Figure 5.3  Heat map showing log2 fold change for MMP12 
Expression values for each individual compared to unirradiated control sample (Red 
is up, green is down).  Brighter intensity of red corresponds to a greater log2 fold 
change. 
 
Figure 5.3A shows that different genes are upregulated by UVA1 at 6h and 24h.  
Figure 5.3B shows that UVA1 and UVB both upregulate apoptotic, inflammatory, 
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presents a variation MMP upregulation by UVB and UVA1 at 24h.  This data 
support the pathway bioinformatics analyses (Figure 5.1). 
5.3.3 Down-regulated genes microarray analysis 
Genes ≤ 2 fold and p≤0.05 were collected and plotted in the Venn diagrams below 
(Figure 5.4).  Of the genes that were downregulated, most were at 24h by UVB (493 
genes as opposed to 147 by UVA1) and UVB was particularly effective at down-
regulating genes in epidermal development.  Specifically these were found to be 
loricrin and filaggrin.  UVB also downregulated MMP16.  The rest of this chapter 
focuses on upregulated, genes and their functional importance. 
A      B 




Figure 5.4  Venn diagrams demonstrating downregulated genes 
(A) UVA1 at 6h and 24h (B) UVA1 and UVB at 6h (C) UVA1 and UVB at 24h.   
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5.3.4 ECM remodelling microarray analysis 
Using the bioinformatics data, a microarray MMP gene expression analysis 
comparison at 6h and 24h was performed against unirradiated control samples.  This 
enabled a numerical comparison of the data in Venn diagram (Figure 5.2C) and shows 
that transcripts encoding MMP1, MMP3, MMP9, MMP10, MMP12 are upregulated 
predominantly at 24h.  MMP1, MMP3 and MMP10 are upregulated predominantly 
by UVB; 10 – 550 fold compared to 2-15 fold by UVA1 (p≤0.05, adjusted p≤0.3) at 
24h.  UVA1 induces MMP12 at 6h ~15fold, whilst UVB does not (~1, no fold 
change) and at 24h MMP12 is upregulated ~43 fold by UVA1 whilst UVB produces  
~11 fold change (p≤0.05, adjusted p≤0.3). 
A      B 
    
Figure 5.5  UVA1 and UVB gene expression changes at 6h (A) and 24h (B) 
 
5.3.5 mRNA validation 
Genes of interest that were validated by RTqPCR are shown below in Table 5.1 and 
were chosen according to generated upregulated pathway lists performed by 
GeneGo.  For inflammation, antioxidant activity, apoptosis and ECM remodelling, 









































































































array plates, Quiagen, Crawley, UK) produced a list of genes that were upregulated 
and could potentially be further examined by RTqPCR.  The fold changes were 
placed in graphs and the top 4-5 genes in each group were chosen. No specific panel 
exists for immunosuppression, and as CD83 has been shown in vitro to positively 
upregulate IL10 expression (Kretschmer et al., 2007) and was significantly 
upregulated in our data set, we decided to validate CD83 as well as IL10.  






































Haem oxygenase 1 
FOS like 1 antigen 
Prostaglandin-endoperoxide synthase 2 
(Prostaglandin G/H synthase and cyclooxygenase) 












Tumour necrosis factor alpha-induced protein 3 
B-cell CLL/lymphoma 2 
MDM2  proto-oncogene, E3 ubiquitin protein ligase  





















Matrix metallopeptidase 1 (interstitial collagenase) 
Matrix metallopeptidase 3 (stromelysin 1) 
Matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) 
Matrix metallopeptidase 10 (stromelysin 2) 
Matrix metallopeptidase 12 (macrophage elastase) 
Matrix metallopeptidase 13 (collagenase 3) 
Table 5.1  Genes of interest for qPCR validation 
 
 
5.3.6 Dose Response Study 
Data below show that incremental doses of UVA1 produced increasing mRNA 
levels, linear regression p values in brackets.  
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A       B 
      
C       D 
    
 
Figure 5.6 Dose response mRNA data 
(A) inflammation (B) immunosuppression (C) antioxidant activity  (D) ECM 
















































































































































5.3.7 Time course study and UVA1 and UVB comparison study 
Results for the time course study are placed together with the UVA1 and UVB 
comparision study (Figure 5.7). Results are presented as an individual fold change 
compared to each individual control (Table 5.2) as well as a mean fold change (Table 




    



































































































B  Immunosuppression 
    
C  Antioxidant activity 











































































































































D  Apoptosis 
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Figure 5.7  mRNA fold change at 6h and 24h post UVA1 and UVB 
For genes involved in (A) inflammation  (B) immunosuppression (C) antioxidant 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Inflammation UVA1 6h UVB 6h UVA1 24h UVB 24h 
IL6 19.1 73.4 6.5 15.3 
IL8 109.1 96.1 28.4 28.9 
TNF 2.6 2.6 1.8 0.9 
IL20 0.8 44.4 29.1 68.9 
Immunosuppression       
CD83 4.3 4.5 4.9 4.4 
IL10 4.9 3.9 4.5 5.2 
Antioxidant activity       
HO-1 1.8 1.3 1.2 0.7 
FOSL1 16.5 66.6 3.5 41.6 
PTGS2 3.9 10.3 1.4 1.4 
NRF2 1.1 0.8 1.1 0.6 
Apoptosis         
TNFAIP3 1.1 2.4 1.3 0.6 
BCL2 0.8 0.5 0.8 0.3 
MDM2 2.0 1.0 1.6 1.2 
TP53 1.0 1.0 1.2 0.7 
Extracellular Matrix       
MMP1 2.9 21.0 8.7 324.8 
MMP3 13.7 2.1 39.2 1734.8 
MMP9 2.4 2.9 3.6 4.6 
MMP10 2.4 2.5 1.5 40.0 
MMP12 20.4 0.8 34.5 6.4 
MMP13 1.0 1.2 1.7 2.4 
Table 5.3  Summary of mean fold changes for all mRNA changes assessed at 6h and 24h 
 
Key gene expression changes at 6h 
Figure 5.7A shows that genes involved in inflammation (IL6, IL8, TNF) are equally 
upregulated by both UVA1 and UVB at 6h.  Erythema is the clinical presentation of 
inflammation, thus with equivalent erythemal doses of UVB and UVA1 we might 
expect similar changes in inflammatory markers. It might be useful repeating 
experiments or increasing volunteer numbers to assess robustness of this finding. 
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The IL20 gene transcript was upregulated at 6h (~45 fold compared to baseline 
unirradiated by both spectra, data not shown).  IL20 mRNA was upregulated by 
UVB at 6h (~50 fold, p=0.03) compared to UVA1, and both sources upregulated 
IL20 at 24h.  IL20 is part of the IL10 subfamily and is upregulated in chronic 
inflammatory conditions such as psoriasis and rheumatoid arthritis (Ouyang et al., 
2011; Wegenka, 2010).  Its upregulation following an erythemal exposure of UVB 
and UVA1 in this chapter probably occurs as part of the inflammatory response to 
UVR.  
One of the key mediators of UVR induced immunosuppression is IL10, produced 
from TH2 cells and also released from Treg cells.  Both UVA1 and UVB appear to 
induce similar immunomodulatory effects as CD83 and IL10 were upregulated to 
similar levels at 6h and 24h (~4-5 fold above baseline unirradiated levels).  If 
erythemally equivalent  doses of UVA1 and UVB result in comparable  upregulation 
of IL10, it might suggest that the erythemal response is a trigger for IL10 induction 
and consequent immunosuppression.  Other work however shows that 3MED UVB 
produced significant amounts of IL10 whilst UVA1 did not (Skov et al., 1998).  The 
impact of immunosuppression by UVB and UVA1 could be further studied by also 
examining IL4, and possibly IL12 levels which we would expect to be lower in 
immunosuppressed states (Krutmann et al., 1992; Krutmann and Morita, 1999; 
Schwarz, 2005). 
A heat map of upregulated AOx and ROS metabolites can be found in Appendix C 
where different AOx response genes are upregulated by both UVA1 and UVB at 6h 
and 24h.  Following UVR exposure, a rapid cellular AOx response is induced in the 
skin after UVR exposure with activation of constituent GPX, SOD1, catalase as well 
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as Haem oxygenase (HO)1 and ferritin (Wondrak et al., 2006).  HO is an essential 
enzyme in haem catabolism and occurs as an inducible HO1 form and a constitutive 
HO2 form (Tyrrell, 2004).  Studies in cultured human skin fibroblasts show the 
induction of a specific stress protein by UVA (at 334-365nm) and near visible 
radiation (405nm) that was minimally induced at shorter UVB wavelengths (Tyrrell, 
2004) and it is felt that HO1 plays a role in the UVA oxidative damage response 
(Kielbassa et al., 1997; Mouret et al., 2006).  Absorption of UVA by haem 
containing chromophores (such as cytochromes and protoporphyrin IX) produces 
free radicals such as 1O2 (Basu-Modak and Tyrrell, 1993; Tyrrell and Pidoux, 1989).  
In order to stabilise the haem ring, energy is transferred to a Nrf2/Keap1 complex 
which then results in HO1 activation.  HO1 transcription can also occur in the dermis 
via haem binding to Bach1 repressor protein.  In our data set, UVA1 appears to 
significantly upregulate both HO1 (6h p=0.007 and 24h p=0.0038) and NRF2 (6h 
p=0.0132 and 24h p=0.0004) compared to UVB although the fold changes were 
small (less than 2.5 fold). 
Our data show that PTGS2 (or cyclooxygenase 2, COX2) is principally upregulated 
by UVB at 6h (see Figure 5.7C), however the large inter-person variability probably 
explains why there is no statistical significance.  PTGS2 is upregulated by UVB 
(Isoherranen et al., 1999) and UVA via p38 MAPK transcription (Bachelor et al., 
2002) and converts arachidonic acid to prostaglandin H2 (PGH2), an important 
precursor of prostaglandins (PGD2, PGE2, PGF2a), prostacyclin (PGI2) and 
thromboxane A2. These play roles in vasodilation and inflammation (Brooke et al., 
2013; Rhodes et al., 2009).  PTGS2 is a mediator of UVR inflammation, as its 
inhibitors such as indomethacin suppress UVR induced erythema (Ibbotson et al., 
 178 
1996).  Elevation of prostaglandin E2 (PGE2) levels are thought to play a role in 
carcinogenesis through inhibition of apoptosis, promotion of angiogenesis and 
increased cell proliferation (Fosslien, 2000).  Arachidonic acid is increased in 
oxidative stress situations (Balboa and Balsinde, 2006) probably explaining how 
PTGS2 is classified as an antioxidant activity gene.  
FOSL1 was strikingly upregulated by UVB compared to UVA1 at 6h  (UVB/UVA1 
fold difference 4, p=0.04) and 24h (UVB/UVA1 fold difference 11 p=0.05).  It is 
upregulated in inflammatory conditions such as psoriasis and binds to c-JUN 
forming the transcription factor complex AP1 that regulates cell proliferation, 
differentiation and MMP transcription.  AP1 transcription is ROS inducible.  Our 
recent findings of FOSL1 expression with biologically significant doses of UVB and 
UVA are novel and suggest a significant contribution from UVB as well as UVA in 
induction of oxidative stress.   
A preliminary mRNA assessment of 4 apoptosis genes (TNFAIP3, MDM2, BCL2 
and TP53) did not show any UVR source specific differences at either 6h or 24h.  
There was minimal upregulation of TP53 mRNA given that in Chapter 4 we 
demonstrate UVB induced p53 protein expression in the epidermis.  Work however 
suggests that p53 protein expression increases following post translational 
modification of the protein (Appella and Anderson, 2001) rather than directly via 
mRNA translation although mRNA levels might otherwise be expressed at different 




UVA1 and UVB induced ECM remodelling 
UVB upregulates more MMP1 mRNA (UVB/UVA1 fold difference 13.2 p=0.0062), 
MMP3 (UVB/UVA1 fold difference 38.7 p=0.0016), and MMP10 (UVB/UVA1 fold 
difference 27.1 p=0.028) at 24h compared to UVA1.  UVA1 upregulates MMP12 
mRNA at 6h (UVA1/UVB fold difference 19.2 p=0.02) and also at 24h 
(UVA1/UVB fold difference 8.26 p=0.22), although at 24h there is large inter-
person variation and the difference is not significant.  Both UVA1 and UVB induce 
MMP9 mRNA at 24h (~5fold compared to baseline) with no statistical difference in 
upregulation (6h p=0.33, 24h p=0.12) (Figure 5.7E).  
 
5.3.7.1 Protein validation Study: Immunofluorescence and in situ zymography 
In a further 3 volunteers (see methods) we chose to study MMP1 and MMP12 
protein in the skin.  MMP1 is the main ECM enzyme found in the dermis: studies 
show that a blocking antibody to MMP1 removed ~ 95% of collagenolytic activity in 
UVR-exposed human skin (Brennan et al., 2003).  Collagen I is the main substrate 
for MMP1 and collagen IV and elastin are substrates for MMP12.  We also 
examined enzyme activity (collagen I, collagen IV and elastin substrate breakdown) 
using in situ zymography (ISZ).   
 
Examples of protein staining (MMP1 and MMP12) and ISZ (DQ™ collagen I and 
IV) are shown in Figures 5.8A and B.  UVB and UVA1 induce similar levels of 
MMP1 protein at 10h and 24h (Figure 5.9A).  DQ™ collagen type I hydrolysis as 
indicated by green fluorescence, occurred predominantly after 1MED UVB at 24h 
compared to 1MED UVA1 (p=0.031) (Figure 5.9B).  As collagen I is also a 
substrate for MMP2, MMP3, MMP9, MMP13 (Yan and Blomme, 2003), we did 
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further immunostaining to assess for MMP2 and MMP9 protein (Figures 5.9C and 
D).  MMP2 is not formed after UVA1 or UVB, and only UVB induces a significant 
upregulation in MMP9 at 24h as shown in previous studies (Fisher et al., 1997).  
UVB and UVA1 induce similar levels of MMP13 mRNA (data not shown), thus the 
spectral difference that we detected for DQ™ collagen type I hydrolysis is indicative 
of MMP1 and also probably some UVB mediated MMP3 and MMP9.  
 
UVA1 preferentially induces MMP12 
MMP12 protein is formed by UVA1 at 24h (p=0.04).  A lesser degree of induction 
of MMP12 protein is seen with UVB at 10h and 24h, despite the absence of MMP12 
mRNA induction at 6 and 24h. UVA1 was more effective than UVB for the 
degradation of DQ collagen type IV in the epidermis (10h, p=0.027).  This is 
primarily a substrate for MMP12, but it is also hydrolyzed by MMP2, MMP7, 
MMP9, and MMP25 (Chakraborti et al., 2003; Yan and Blomme, 2003).  Our data 
showed that these other MMP were not induced by UVA1, thus the induction of 
enzyme activity is most likely to reflect MMP12 activity.  There is some collagen IV 
hydrolysis with UVB at 10h and 24h that could be due to UVB-induced MMP9 
(Figure 5.9F), although without MMP12-blocking enzymes we cannot rule out the 
effects of MMP12.  Figure 5.9G shows that UVA1 induces elastin breakdown that is 
not seen with UVB.  MMP12 is the most important enzyme for the degradation of 
elastin (Gronski et al., 1997; Woessner, 1991) although it shares its elastolytic 
activity with MMP2, MMP7 and MMP9, and breaks down other substrates including 
type IV collagen (as shown here), laminin 1, ﬁbronectin, vitronectin, and 
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Figure 5.9  Epidermal protein and enzyme activity quantification 
(A) MMP1 (B) DQ1 breakdown (C) MMP2  (D) MMP9 (E) MMP12 (F) DQ4 
breakdown (G) Elastin breakdown 
 
Differential expression of MMP1 and MMP12 proteins within the epidermis 
The intensity of MMP1 and MMP12 was examined across the epidermis in order to 
given an insight into mechanism of induction. Figure 5.10A and B show that MMP1 
protein is differentially expressed within the epidermis (upper vs. lower epidermis 
UVB p=0.005 and UVA1 p=0.01) with more produced in the upper layers of the 
skin, but there is no specific pattern of MMP12 expression across the epidermis 








































A  UVA1 MMP1    B  UVB MMP1 
    
 
C  UVA1 MMP12     D  UVB MMP12 
    
 
Figure 5.10  Differential expression of MMP1 and MMP12 across the epidermis 
 
UVR induced MMP and its activity in the dermis 
MMP1 and MMP12 protein formation in the dermis are shown in Figures 5.11A-D.  
Protein expression is significantly greater for UVA1 than UVB for MMP1 and 
MMP12 (A and C) but there are no spectral differences for enzyme activity (B and 
D). Overall, there is a greater abundance of protein and activity for both MMP1 and 









































































A  MMP1 Dermis    B  DQ1  Dermis 
       
 
C  MMP12  Dermis    D  DQ4 Dermis 
 
     
Figure 5.11  Dermal MMP1, MMP12 protein and activity 
 
Macrophages in the skin are a potential source of MMP12  
Figure 5.12 shows significant depletion of dermal macrophages (CD68+) 24h after 
UVB exposure (p=0.01).  In contrast, UVA1 had no effect on dermal macrophage 
numbers (p=0.21) compared with non-irradiated controls.  




































































































Figure 5.12  CD68 staining at 24h post UVA1 and UVB 
 
5.4 Discussion 
Our gene array data, supported by RTqPCR, show that an erythemal exposure of 
UVB and UVA1 readily induce a range of processes at 6h, and MMP predominantly 
at 24h. 
Our RNA studies show that 1MED UVB in skin types I/II individuals induces more 
MMP1 and MMP3 mRNA (350 and 1700 fold) in the epidermis compared to UVA1 
(25 and 40 fold) (Figure 5.7), and our UVA1 data are comparable (given the error 
range in both data sets) to other work where UVA1 increased MMP1 and MMP3 
mRNA by 80- and 50- fold, respectively at 24h (Wang et al., 2013).  Our recent 
study looking at MMP1 mRNA expression at erythemal doses of SSR, UVB and 
UVA showed no difference between UVA and UVB induced MMP1 mRNA (Tewari 
et al., 2012), although the UVA source (UVASUN) emits small amounts of UVA2 








































We found no difference in MMP1 protein levels after UVA1 and UVB, and MMP1 
was predominantly formed in the epidermis, which is expected because of its role in 
tissue homeostasis after UVR injury.  We also show that at 24h, MMP1 and MMP12 
proteins are more readily induced in the dermis by UVA1 than UVB which is 
supported by other work demonstrating the sensitivity of fibroblasts to UVA in vitro 
(Scharffetter-Kochanek et al., 1993) and in vivo (Scharffetter et al., 1991) but is also  
probably due to differential spectral penetration into the skin in vivo (Tewari et al., 
2012; Tewari et al., 2011b).  This may also explain the effectiveness of UVA1 
phototherapy in collagenolysis for diseases such as scleroderma, sclerodermatous 
GVHD, nephrogenic systemic fibrosis, systemic sclerosis and lichen sclerosis (Kerr 
et al., 2012b).  Importantly, we show that UVA1, but not UVB, induces elastin 
degradation at 24h (Figure 5.9G), which can be attributed to the induction of MMP12.  
Interestingly the small amounts of MMP12 produced by UVB did not appear to 
cause elastin breakdown which raises the question of whether UVB induced MMP12 
was either a non specific result or it is produced in insufficient amounts to cause 
elastin breakdown.  This, in association with our data, strongly suggests that MMP12 
is a UVA1 specific biomarker and responsible for elastin breakdown in the skin.   
 
MMP12 producing cells 
MMP12 (macrophage metalloelastase (MME), human macrophage elastase (HME)) 
(Kahari and Saarialho-Kere, 1997) is one of 8 elastases that contribute to elastic 
recoil in skin, blood and lung tissue (Liang et al., 2006).  It is produced 
predominately by macrophages in response to tissue injury (Shapiro, 1998; Shapiro 
et al., 1993) and is also expressed by T cells (Hughes et al., 1998), transformed 
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keratinocytes and keratinocyte derived tumours (Kerkela et al., 2000).  We found 
more macrophages in the dermis after UVA1, as UVB induced significant 
macrophage depletion at 24h (p=0.02) (Figure 5.12), which could contribute to the 
higher levels of UVA1-induced MMP12.  However, its predominant epidermal 
location in our data suggests that after erythemal doses of UVA1 and UVB, 
keratinocytes produce the majority of MMP12 in the skin.  MMP12 stimulates TNFα 
production (Chandler et al., 1996), thus its predominance in the epidermis might be 
important in inflammation.  It is also upregulated in psoriatic tissue (Suomela et al., 
2001), an often described TNF mediated disease. Other work has shown an 
upregulation of MMP12 mRNA in the epidermis and dermis in response to UVR 
(Chung et al., 2002) with a mixed UVA/UVB source. 
 
MMP12 is the major elastinolytic MMP in the skin (Gronski et al., 1997; Senior et 
al., 1991) although other elastinolytic MMP in the skin include MMP2, MMP7 and 
MMP9 (which were not upregulated in our data set after UVA1).  It is a known 
major contributor to remodelling of elastotic tissue in sun-damaged skin (Saarialho-
Kere et al., 1999) as is generally found in areas devoid of normal elastic fibres 
(Vaalamo et al., 1999).  In contrast, MMP9 is found in regions of less damaged 
elastic fibres with morphologically better preserved collagen (Vaalamo et al., 1998), 
whilst MMP2 is seen in more elastin rich areas (Vaalamo et al., 1999) suggesting an 
association of MMP12 and elastin degeneration.  Other work has also shown 
MMP12 accumulation in extensively photoaged dermis (Chung et al., 2002).  
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Other elastases in the skin include neutrophil elastase (NE) and UVR induced NE 
causes ECM breakdown (Li et al., 2013; Takeuchi et al., 2010), but the relative 
contributions of UVA1 and UVB to its formation in the skin is not known.  
Interestingly NE deficient mice are resistant to photoageing (Starcher and Conrad, 
1995; Takeuchi et al., 2010) and SCC formation (Starcher et al., 1996) (Wulf et al., 
1989) suggesting important pathogenic links between the two processes.   
Depth of MMP in the skin 
DNA is a chromophore for MMP1 via CPD formation (Dong et al., 2008).  Our 
recent findings (Tewari et al., 2012; Tewari et al., 2011b) showed attenuation of 
UVB induced CPD with skin (epidermis and dermis) depth due to UVB absorbing 
chromophores in the epidermis.  The attenuation of MMP1 as shown in Figures 
5.10A and B suggests a direct role of UVB in its formation, possibly also mediated 
via CPD.  The distribution of MMP12 is different from MMP1, suggesting a 
different chromophore, with MMP12 probably being mediated by ROS formation 
(Scharffetter-Kochanek et al., 1993; Wlaschek et al., 1995).  Studies show that the 
application of ROS scavengers reduced MMP12 mRNA in human skin (Chung et 
al., 2002). 
Location of MMP in the skin 
In this Chapter we show that MMP protein localises in the epidermis although we 
know that dermal extracellular collagens are degraded by MMP in pathological 
processes such as photoageing.  Other work shows that acute UVR exposures 
produce predominantly epidermal MMP (MMP1, MMP3, MMP9) (Quan et al., 
2013; Quan et al., 2009), which is thought to diffuse into the dermis to degrade 
collagen.  In chronically sun exposed skin such as in studies on photoaged skin, 
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more MMP is found in the dermis than in the epidermis (Chung et al., 2002; Quan et 
al., 2013) which overall suggests that repeated solar UVR exposure results in an 
accumulation of dermal MMP, whether by diffusion from the epidermis or by a 
gradual accumulation of dermally synthesized protein.  It is possible that our 24h 
sampling time was not optimal for MMP12 diffusion from the epidermis into the 
dermis whose peak formation occurs 48h post exposure (Chen et al., 2005). 
 
The role of MMP12 in cancer and disease 
MMP12 is produced by epithelial SCC and BCC, and is found more abundantly in 
less differentiated SCC, whilst premalignant Bowen’s disease and actinic keratosis 
are devoid of MMP12.  Thus it is thought that expression in transformed epithelial 
cells correlates with more aggressive histological changes (Kerkela et al., 2000).  
Keratinocyte derived MMP12 is also found in aggressive vulval SCC (Kerkela et al., 
2002).  Macrophage derived MMP12 however is more common in well-
differentiated vulval tumours and predicts a better clinical outcome (Kerkela et al., 
2002).  Overall, MMP12 plays a role in cell migration past the epidermal and 
vascular basement membrane via collagen IV breakdown (Shipley et al., 1996) 
which might explain its presence in more aggressive cancer subtypes 
MMP12 is also found in in granulomatous skin diseases such as sarcoidosis, 
necrobiosis lipoidica diabeticorum, and granuloma annulare (Vaalamo et al., 1999).  
It is also expressed by subepithelial macrophages in dermatitis herpetitformis 
(Salmela et al., 2001) and duodenal ulcers where its upregulation is probably a 
general response to inflammation and wound healing.  
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The role of MMP12 in photoageing 
Solar Elastosis is the term used to denote tangled degraded elastic fibres, amorphous 
disorganized tropoelastin and fibrillin with reduced amounts of collagen. In addition, 
glycosaminoglycans and proteoglycans increase in photodamaged skin, whereas the 
amount of collagen decreases (Calderone and Fenske, 1995; Yaar and Gilchrest, 
2007).  It can be subtyped into early and late stages.  The early stage is characterised 
by an accumulation of insoluble disorganised elastin and microfibrillar proteins 
(fibronectin) (Chen et al., 1986; Lavker and Kligman, 1988), which is clinically 
evident on the face as a waxy, thickened and furrowed complexion, and the late 
stage is characterised by degeneration of elastin that appears as lucent areas on 
electron microscopy and gives a mottled appearance to the dermis.  This is clinically 
associated with a loss of skin elasticity (likely due to sagging) which been shown to 
be a UVA1 dependent process in hairless mice with a peak at 340nm (Bissett et al., 
1987, 1989) whilst wrinkling is a more UVB mediated process. 
Adding an elastase to external cultures of elastin (Braverman and Fonferko, 1982) 
gives the fibres a mottled appearance that is similar to that seen in late solar 
elastosis.  In fact, this effect can be seen in other laboratory studies (Kumakiri et al., 
1977) with repeated erythemal doses of UVA,  which produces ‘zebra bodies’ in the 
dermis, similar to the mottled appearance in late solar elastosis.  These changes do 
not occur after SSR suggesting that elastin breakdown only occurs after UVA 
irradiation probably via elastase upregulation.  
A hypothetical model for UVA1 induced MMP12-associated photoageing is shown 
below in Figure 5.13. 
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 Figure 5.13  Hypothetical model of UVA1 induced late solar elastosis 
MMP12 is upregulated by UVA1 at 24h and its breakdown of elastin in the dermis 
gives the mottled appearance that is seen on electron microscopy which contributes 
to the appearance of saggy lax skin of late solar elastosis.  
Summary 
Inflammation, immunosuppression, antioxidant activity are important processes that 
occur 6h after an acute erythemal dose of UVB or UVA1. 
The data in this chapter confirms that UVB plays an important role in photoageing 
because of its ability to upregulate a range of MMP.  We show that MMP12 is a 
biomarker of UVA exposure and may be a useful endpoint in photoprotection 
studies.  Solar UVA1 induces the expression of MMP12, which degrades elastin and 
probably contributes to the loss of skin elasticity seen in late solar elastosis.  MMP12 
may also have a role in photocarcinogenesis, as a marker of skin cancer and disease 
but possibly also facilitating skin cancer invasion past the basement membrane. 
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Chapter 6 UVA1 induced cellular and molecular changes in the skin 




DNA repair enzymes can enhance CPD repair and thus downstream consequences of 
the CPD on biological processes can be examined.  In this chapter, a pilot 
experiment showed a reduction of CPD at 6h after a 2MED SSR irradiation in the 
presence of topical DNA repair enzymes (T4N5 and photolyase).  This provides the 
necessary platform to examine specific biological pathways after UVA1 and UVB 
irradiation and topical enzyme. 
6.1 Introduction 
Much of our understanding of the downstream biological responses to DNA damage 
has come from studies using DNA repair enzymes.  The hypothesis that DNA 
damage is thought to initiate UVR induced immunosuppression is based on the 
following evidence: 
(1) UVR induced suppression of CHS in the South American opossum 
(Monodelphis domestica), whose DNA damage is repaired by a visible light-
activated photoreactivating enzyme, was completely prevented by exposing 
opossum skin to visible light immediately after UVB irradiation (Applegate 
et al., 1989) 
(2)  Topical application of T4N5 (bacteriophage T4 endonuclease V, an excision 
repair enzyme for CPD in DNA) to UVB irradiated mouse skin prevented 
UVB induced suppression of DTH and CHS responses and induction of 
suppressor T cells (Kripke et al., 1992)   
(3) IL10, which has been shown to be responsible for systemic 
immunosuppression, is produced by cultured keratinocytes after UVR, but 
not by keratinocytes pretreated with T4N5, suggesting that UV induced DNA 
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damage may trigger the production of soluble immunosuppressive mediators 
like IL10 from keratinocytes (Nishigori et al., 1996). Also CPD affects 
MMP1 (Dong et al., 2008) and TNFα levels  (Walker and Young, 2007). 
The first study in this chapter was a pilot study in order to establish a working 
protocol.   
6.2 Materials and methods 
The liquid enzymes were a gift from Dr Olivier Doucet, Coty-Lancaster, Monaco. 
These were ultrasome (liposome containing T4N5 enzyme) and photosome 
(liposome containing photolyase).  We also had empty liposomes as a control group, 
and 2MED irradiated and unirradiated skin as positive and negative controls.  The 
emission spectrum of the SSR source is shown in Chapter 2 Materials and Methods 
Figure 2.1. 
 
A pilot experiment with two individuals was performed using 2MED SSR with a 
view to first demonstrating a decrease in CPD staining after topical application of 
repair enzymes. Volunteer demographics and MED are shown in the following table: 
 





I M 24 5.4 
002 I M 24 5.4 
Figure 6.1  Volunteer demographics for DNA repair enzyme study 
 
Following 2MED SSR of 4 sites (B, C, D, E), liquid enzyme (~1ml) was placed on 
buttock skin into stainless steel O-rings that were held on the skin with double sided 
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tape.  Volunteers were asked to remain lying down for 30 minutes after irradiation.  
Sites were covered and they then returned 6h later for 4mm punch biopsies, which 
were processed as described in Material and methods.  
The irradiation site map is shown below and all biopsies were taken at 6h.   
Irradiation Site Map:    
 
A B C D 
 E F G 
 
6.3 Results 
In this pilot study we expect significant CPD formation after 2MED SSR, a decrease 
after topical enzyme preparations and possibly minimal changes with the empty 
liposome due to a barrier effect.  There are a series of limiting factors in this 
experiment.  As the topical enzyme preparations are liquids, difficulties arise in 
securing it in place on buttock skin for 6h.  Once participants are mobile, there is a 
possibility that the preparations leaked, merged into each other and contaminated 
results.  Care also had to be taken during application due to the curvature of buttock 
skin to prevent sites merging.  Experimentally this is likely to have occurred with 
volunteer 001 as we found lowest CPD at site B, which was the positive 2MED SSR 
control (data not shown). Therefore we had to discard all data points with this 
volunteer.  Below is example of staining and CPD intensity quantification for 
volunteer 002 (Figure 6.2 and Figure 6.3).  For the quantification, the intensity of 
staining from three slides at each site was averaged. 
A: Unirradiated control  B: 2 MED SSR (positive control) 
C: 2MED SSR+ultrasome  D: 2MED SSR+photosome  





Figure 6.2  Staining for volunteer 002 after application of topical enzymes 
(Note that CPD staining is shown as green)  
 
Graph showing CPD (%) remaining compared to the positive control (put at 100%) 
is shown below. Background staining in the unirradiated control was removed from 
all sections prior to calculations.  
 
Figure 6.3  CPD remaining as % of positive control 






















































In one individual, the biggest decrease in CPD is found after ultrasome (50% 
decrease) which contains T4N5, followed by photosome (45% decrease) containing 
photolyase. This could be that T4N5 is more effective at DNA repair, or that 
photolyase was not fully activated in our study by the UVA content of SSR.  Other 
studies using topical photolyase found maximum CPD after a 30 minute exposure 
with 40-45% fewer CPD produced then the positive control 2MED (288mJ/cm2) 
irradiation (Stege et al., 2000).  Although not directly comparable as we used a 
different UVR source (with a different UVB content) and our exposures were 10 
minutes long we found a similar decrease in CPD after photolyase. There is also a 
slight decrease in CPD formation after topical liposome, which is likely a variation 
of normal as n=1.  Empty liposomes are lipid soluble and although it is known that 
oil increases penetration of UVR through it (Diffey, 2002), the empty liposomes are 
opaque, which reflects visible light and also might change the scattering properties 
of UVR and affect its penetration.  This barrier effect is minimal however and 
insufficient to produce a CPD protection factor, a concept previously introduced as a 
measure of reduction of DNA damage after topical products (Young et al., 2000).  
We see a CPD protection factor of about 2 for photolyase and ultrasome (T4N5).  
Summary  
There is a need for chemoprevention (Yarosh et al., 2001) especially for high risk 
patients such as those with genetic predispositions for DNA damage (XP, basal cell 
naevus syndrome, albinism), organ transplant recipients on immunosuppressive 
therapy, patients who have received large numbers of PUVA treatments as well as 
those with many actinic keratosis (Bath-Hextall et al., 2007).  This is particularly 
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important for XP patients where the first skin cancer typically occurs in children 
younger than 10 years.  The disease is disfiguring and the mainstay of treatment is 
surgery, resulting in many procedures and significant morbidity (pain, recovery time 
and financial strain).  Oral retinoids have been shown to be effective in this patient 
group yet although effective, large doses are required and beneficial effects are not 
apparent once the drug is discontinued (Kraemer et al., 1988).  Also the side effect 
profile is unacceptable.  Ideally, a chemopreventative agent would inhibit skin 
cancer with minimal toxicity to the patient and would preferentially affect 
premalignant or malignant cells leaving normal cells unaffected.  Sunscreens are 
effective against cutaneous SCC and seem to have no effect on BCC (Green et al., 
1999; van der Pols et al., 2006) although they have been shown to reduce UVR 
induced p53 expression (Ananthaswamy et al., 1997) and TT damage (Young et al., 
2007).  Use with topical DNA repair enzymes (photolyase, endonuclease (T4N5), 
and 8oxoguanine glycosylase) shows a reduction in CPD but not 8oxodG (Emanuele 
et al., 2014) compared to sunscreen alone suggesting benefit of a product with dual 












30 years ago UVA1 was suggested as a potential UVR source to deliver a ‘safe’ dark 
tan as following irradiation, the skin appeared normal on histology with no SBC 
(Mutzhas et al., 1981; Plewig et al., 1978).  Apoptosis (SBC formation in the 
epidermis) is an established photoprotective skin response, as is tanning where 
UVA1 is 3 orders less effective than UVB (300nm) at producing new melanin in 
order to attenuate further UVR and its damaging effects on the skin (Parrish et al., 
1982).  The majority of UVA1 ‘tanning’ occurs via a redistribution of oxidised 
melanin within the skin, which is not photoprotective.  UVA1 also has a range of 
immunomodulatory effects and UVA1 phototherapy is used for treatment of certain 
skin diseases.  In this thesis we studied the cellular and molecular effects of UVA1 
on the skin primarily focussing on DNA damage, possible mechanisms of 
carcinogenesis and pathogenesis of UVA1 photoageing, using a biological human 
model based on skin type I/II individuals (who have the highest susceptibility to 
UVR induced biological effects).  
 
7.2 Conclusions 
Main findings from thesis 
1) UVA1 is probably more carcinogenic than previously thought.  In Chapter 3 
we show, for the first time in vivo that compared to erythemally equivalent 
doses of UVB, UVA1 produces 3-4 times fewer CPD and preferentially these 
are produced in human skin basal epidermis. This is the location of 
keratinocyte stem cells and melanocytes. The quantity of UVA1 induced 
CPD increases with skin depth, and beyond 150μm (i.e. in the dermis) they 
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are found in larger amounts than with UVB.  Overall the repair rate of 
epidermal UVA1 and UVB CPD is the same, however repair in the basal 
epidermis, including in melanocytes, is extremely slow after UVA1.   
2) We lack data on UVR transmission through the skin in vivo. Most studies 
have been done ex vivo (Bruls et al., 1984) and have required the chemical 
separation of the epidermis from the dermis, which is likely to compromise 
the skin’s optical properties.  The CPD studies can also be used as an 
indicator of UVB and UVA1 transmission/exposure in the different layers of 
the skin. The data suggest that the basal layer and the dermis are particularly 
susceptible to a wide range of damage induced by UVA1, for example 
oxidative damage to DNA, membranes and proteins. Also, although we have 
assessed for TT, which is not mutagenic, some C containing dimers will be 
formed at these sites which can potentially form C-T transitions if 
unrepaired. 
3) A lack of UVA1 induced p53 apoptosis.  In Chapter 4 we show that a lack of 
CPD repair in the basal epidermis is probably due to an upregulation of p63 
by UVA1 that contributes to the lack of p53 driven apoptosis and DNA repair 
in this layer.  The fact that this occurs in rapidly dividing epidermal stem cell 
layer is particularly worrying as it might suggest how a UVA1 CPD is 
possibly more carcinogenic than a UVB CPD, as they are more likely to 
persist and be incorporated in the next cell cycle division.   
4) UVA1 and UVB induce an upregulation of genes involved in the same 
pathways at 6h and 24h 
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At 6h we show that both UVA1 and UVB upregulate the immune response 
(inflammation, apoptosis, immunosuppression and antioxidant activity) 
through IL17 signalling and at 24h, both sources induce genes in the ECM 
pathway. 
5) UVA1 induced MMP12 has elastolytic activity.  Chapter 5 demonstrates the 
identification of a novel UVA1 marker through a series of gene, mRNA and 
protein studies.  Functional work identifies its possible role in photoageing in 
late solar elastosis.  Elastase activity also synergistically plays a role in 
carcinogenesis.  Studies in neutrophil elastase deficient mice showed that 
they had less ‘saggy’ skin and did not produce SCC in response to UVB 
(Starcher et al., 1996).  MMP12 is also upregulated by epithelial SCC 
(Kerkela et al., 2000).  Thus, although not identified in this thesis UVA1 
induced MMP12 likely also plays a role in human photocarcinogenesis.  
6) Topical application of T4N5 or photolyase reduces CPD after SSR to human 
skin.  Chapter 6 is a pilot study demonstrating that compared to the positive 
SSR irradiated control (2 MED) there is enhanced CPD repair 6h following 
topical photolyase or T4N5 application and SSR.  
 
7.3 Further perspectives 
Oxidative DNA damage: location and repair: 8oxoGua is primarily felt to be a 
UVA induced photoproduct in the skin which is thought to be mutagenic if 
unrepaired.  It was not possible to get 8oxoGua staining to work reliably for this 
thesis, despite multiple attempts with different protocols, antibody clones, and 
treated tissue types (frozen, paraffin embedded tissue).  This work however, has been 
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taken over by another PhD student, using the tissue from the DNA damage dose 
response and time course studies (see Chapter 3).  Our work suggests that following 
UVA1 the basal epidermis is less well protected from CPD damage than expected.  
Previous work has found similar CPD levels in melanocytes and keratinocytes 
(Mouret et al., 2012; Young et al., 1998b) but an increased sensitivity of 
melanocytes to 8oxodG (2.2 fold higher than in keratinocytes) possibly due to its 
accumulation mediated by melanin oxidation (Wood et al., 2006).  It would be 
useful to assess 8oxodG production in the skin particularly in the basal layer where it 
is thought to accumulate (Agar et al., 2004).  Previous work has also found a lack of 
8oxodG and CPD repair in melanocyte cultures (Wang et al., 2010a).  
Stem cells: The basal layer, particularly in the deep rete ridges, contains the inter-
follicular epidermis (IFE) stem cells (Blanpain and Fuchs, 2006; Kaur, 2006), which 
work towards tissue renewal.  Other stem cells include the melanocyte stem cells, 
which can be recruited during wound healing to repair the epidermis.  It would be 
important to look at UVA1 induced DNA damage and repair in stem cells in 
comparison to erythemally equivalent doses of UVB as UVR induced apoptosis of 
stem cells in the basal layer and hair bulge is postulated to result in epidermal 
atrophy, slow wound healing, and depigmented pseudoscars, whereas the greater 
melanin production observed in senescent melanocytes in response to trauma 
(Bandyopadhyay and Medrano, 2000) may be responsible for ‘‘bronzing,’’ the 
permanent ‘‘tan’’ observed in photoaged skin of some darker-skinned individuals.  
  
Gene array studies:  We anticipated some clear differences between UVB and 
UVA1 because of reported differences in mechanisms of action but overall this did 
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not seem to be the case.  The current “dogma” is that UVB effects are caused by 
direct damage to chromophores and that UVA1 effects are indirect via ROS.  We 
suggest that this may be too simple, especially as we show that UVB also induces 
oxidative stress.  We also suggest that even though pathway responses in the skin 
following UVB and UVA1 are broadly similar, individual gene expression changes 
in immunomodulation, apoptosis, antioxidant pathways and p63 contribute to the 
distinct differences with UVB and UVA1.  It is possible that indirect or direct effect 
may depend on UVR dose and that thresholds may vary from gene to gene.  
There are a host of other processes not examined in detail in this thesis including 
DNA repair (BER, NER) genes and those for epidermal differentiation.  It would be 
important to study these further for any source specific differences. 
Our protein validation study was proof of concept work in 3 skin type I/II of similar 
photosensitivity, where we demonstrated MMP12 protein induction and elastase 
activity by UVA1.  Our results could be expanded in 3 further individuals to increase 
robustness of the data. 
Repeated sub-erythemal exposure: Although our UVA1 doses were single (low to 
high) dose UVA1 (12.5-148J/cm2), we have made conclusions on the potential 
chronic effects in the skin.  An obvious extension to the work would be to examine 
the skin after multiple daily suberythemal UVA1 doses with reference to CPD 
induction and repair the basal epidermis.  MMP1 induction in human skin after 
multiple UVA1 doses has recently been studied and shown to occur predominantly 
in the dermis without a concomitant increase in collagen synthesis (type 1 collagen 
fibrils) (Wang et al., 2013).  This is probably a more realistic interpretation of 
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chronic UVA1 exposure, either via high dose UVA1 tanning lamps or chronic UVA 
exposure using predominantly UVB sunscreens.  MMP1 and MMP12 also 
accumulate in the dermis in photoaged skin (Chung et al., 2002; Quan et al., 2013; 
Quan et al., 2009; Wang et al., 2013).  A new study giving multiple erythemally 
equivalent doses of UVA1 and UVB would be a unique opportunity to assess the 
upregulation and location of MMP1 and MMP12 and might help determine 
contribution of each source to chronic UVR induced damage.  MMP12 is highly 
inducible, its mRNA is upregulated ~20-35 fold at 6h and 24h after UVA1, and we 
feel that also studying dose and repair kinetics would give us a deeper understanding 
of the nature of this enzyme.  Previous work shows that MMP12 mRNA reaches a 4-
fold maximum 48h post heat exposure (90minutes at 40-42°C) (Chen et al., 2005) 
thus not only would it be useful to extend our time points but also assess 
contribution from the infrared emitted from our UVA1 source.  
Role of CPD in biological responses:  Finally, preliminary evidence of CPD 
removal using topical T4N5 and photolyase after SSR has been demonstrated in 
Chapter 6.  Expansion of the number of volunteers was not possible in the time span 
of the thesis, but CPD repair enhancement technology allows the determination of 
the biological consequences of the CPD. This has been done in vitro, in animal 
studies and in human skin.  In a further set of 5 individuals it would be important to 
assess downstream cellular endpoints as examined in Chapter 5; for example 
inflammation (IL1, IL6, IL8 mRNA expression), antioxidant activity (FOSL1, 
PTGS2, HO1 mRNA expression) as well as immunosuppression (IL10 mRNA 
expression) to give an indication of the nature of the processes triggered by UVA1 
ROS and UVB/UVA1 CPD induction.  
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7.3.1 Impact to human health 
Phototherapy 
There are a lot of data on the long-term risks of PUVA and UVB phototherapy.  
Most authors report that patients with ≥ 200 PUVA treatments have a 10–30 fold 
increased risk of developing SCC and up to 5 fold increase of BCC (Bruynzeel et al., 
1991; Lindelof et al., 1991; Stern et al., 1998).  There is also a 286 fold increase in 
genital SCC following PUVA treatment.  The risk of MM is approximately 5 fold 
increased in patients who have received > 250 treatments (Stern et al., 1997).   
In the case of broadband UVB therapy, a matched analysis revealed that exposure to 
>300 treatments increased the risk of genital SCC by about 4 fold (Stern, 1990), 
which is different to early studies that reported no significant cancer risk (Maughan 
et al., 1980; Studniberg and Weller, 1993).  A recent study in 4000 patients treated 
with NBUVB showed no increased risk of BCC, SCC or MM after a mean of 29 
treatments, with approximately 10% having greater than 100 treatments (Hearn et 
al., 2008).  However these results need to be interpreted with caution as most 
patients only had 2 cycles of phototherapy.  Concomitant PUVA therapy increases 
the risk of BCC.   Based on these studies, most photodermatology centres set an 
upper limit of 200 treatments of PUVA and 300 treatments for NBUVB 
phototherapy and protection to eyes and genitals. 
Currently there are no published data on the risks of NMSC and MM after UVA1 
therapy. This thesis provides evidence that UVA1 is potentially mutagenic and 
carcinogenic, and contributory to photoageing.  This thesis also provides an 
objective assessment for likely MMP1 depth effect in the skin as at erythemal doses 
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we show more induction by UVA1 of dermal MMP1 compared to UVB (300nm) 
(Chapter 5) after 150μm.  Our findings of UVA1 induced MMP12 with elastase 
specificity is novel and might explain the contribution of UVA1 in late solar 
elastosis.  Current anti-ageing strategies involve the use of topical antioxidants and 
DNA repair enzymes, and strategies with the use of topical anti-MMP have not yet 
been targeted although MMP affect a large number of metabolic processes and its 
use in the treatment of cancer has been controversial (Zucker and Cao, 2009).  
Topical anti-MMP12 encapsulated in liposomes might be a future strategy in patients 
exhibiting late stages of photoageing.  It is also important to note that combating 
photoageing is likely to also indirectly combat photocarcinogenesis. 
 
Sunbed use 
UVR is classified as a carcinogen (El Ghissassi et al., 2009) and there is a 75% 
increase in melanoma risk (IARC, 2007) when first exposure to a sunbed is before 
35 years of age.  9 out of 10 sunlamps emit above the legislation limits for irradiance 
(Tierney et al., 2013) and in the UK there is a law prohibiting sunbed use by those 
under 18 of age. The data in this thesis provide additional support for these 
restrictions, given that the major output of sunbeds is in the UVA1 spectral region. 
 
Photoprotection 
The role of UVA in MM remains controversial. Some epidemiological analyses, 
based on differential latitude gradients for UVB and UVA, provide evidence for an 
important role of UVA (Moan et al., 2012a).  It has been suggested that the lack of 
good UVA protection in early sunscreens (Diffey and Farr, 1989) may explain the 
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positive association between MM and sunscreen use reported in some studies (Autier 
et al., 2011; Gorham et al., 2007; Westerdahl et al., 1995).  This could be due to 
increased sunshine exposure particularly at doses below the sunburn threshold 
(Autier et al., 1999; Autier et al., 2000; Young, 2000) and whilst this has been 
extensively debated (Huncharek and Kupelnick, 2002) a recent RCT showed a 
significant decrease in the incidence of melanoma with the regular use of a broad 
band SPF15 sunscreen (Green et al., 2011).  Lack of UVA protection may also be a 
factor in poor immunoprotection by sunscreens (see Introduction for discussion on 
CPD and UVR induced immunosuppression) (Kelly et al., 2003; Poon et al., 2003; 
Ullrich et al., 1999), which if verified, would support enhanced UVA protection by 
sunscreens.  
 
There has been a recent trend for greater UVA1 protection in sunscreens and several 
regulatory authorities now require minimum levels of UVA protection (Osterwalder 
et al., 2014).  The consequence of this is reduced UVB protection for a given SPF.  
In general, this trend has not had a biological basis, and indeed UVA protection has 
been widely assessed by PPD, which has no known biological significance, or by 
arbitrary spectral properties (e.g. critical wavelength or Boots star rating).  In the US, 
the FDA regulates sunscreens as drugs and it is more difficult than Europe (where 
sunscreens are treated as cosmetics) to obtain approval for new filters.  One 
consequence of this is a lack of sunscreens with good UVA1 protection.  The data 
generated in this thesis support enhanced UVA1 protection by sunscreens especially 
in relation to damage to the basal layer and the dermis and also for 
immunoprotection.  Furthermore, UVA1 exposure is much less dependent on 
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latitude, season and time of day than UVB exposure.  Thus, UVA1 protection may 
be more important than UVB protection under certain conditions (particularly at the 
end of day and in temperate latitudes), but this remains to be established. 
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Appendix C    Heat map showing gene expression profiles of UVA1 and UVB at 
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Upregulation of MMP12 and Its Activity by UVA1
in Human Skin: Potential Implications for Photoaging
Angela Tewari1, Katarzyna Grys2, Jutta Kollet3, Robert Sarkany1 and Antony R. Young1
UVA1 constitutes around 75% of the terrestrial UV radiation, and most of the output of artificial tanning sources.
However, the molecular effects of UVA1 in human skin in vivo are surprisingly poorly understood. We have
examined time-dependent whole-genome expression, along with mRNA and protein changes in the skin after
one minimal erythema dose of spectrally pure UVA1 (50 J cm 2) and 300nm UVB (30mJ cm 2). After 24hours, the
genes induced to the greatest extent were those involved in extracellular matrix remodeling with both UVA1
(P¼ 5.5e 7) and UVB (P¼ 2.9e 22). UVA1 and UVB caused different effects on matrix metalloproteinase (MMP)
expression: UVB induced MMP1, MMP3, and MMP10 mRNA at 24hours to a much greater extent than UVA1.
MMP12 induction by UVA1 at 6hours is marked and much greater than that by UVB. We have found that MMP12
mRNA induction by UVA1 resulted in expression of MMP12 protein, which is functional as an elastase. This
induction of elastase activity did not occur with UVB. We hypothesize that the UVA1 induction of MMP12
mediates some of its photoaging effects, particularly by contributing to elastin degeneration in late solar elastosis.
MMP12 is a good marker of UVA1 exposure.
Journal of Investigative Dermatology advance online publication, 8 May 2014; doi:10.1038/jid.2014.173
INTRODUCTION
Terrestrial solar UV radiation (UVR) comprises o5% UVB
(B295–315 nm) and 495% UVA (315–400 nm), the
majority (B75%) of which is UVA1 (340–400 nm). UVA1
also makes up most (B80%) of the spectral output of sunbeds
and is used at high doses as a specialist form of photo-
therapy (Kerr et al., 2012). However, the acute effects of
UVA1 in vivo, including its effects on gene expression, are
much less well understood than those of UVB (Enk et al.,
2004; Enk et al., 2006). As it is now clear that UVA1 is
biologically active and mutagenic in human skin in vivo
(Mouret et al., 2006; Tewari et al., 2012), it is clinically
important to understand the biological effects of UVA1 in the
skin. Previous studies on the effects of UVA1 on whole-
genome expression in vivo have been limited and have
primarily focused on understanding mechanisms of pigmenta-
tion (Choi et al., 2010).
The hallmarks of long-term exposure to solar UVR are
photoaging (Yaar and Gilchrest, 2007) and photocarcino-
genesis (Sage et al., 1996). Photoaging is characterized by
the induction of extracellular matrix-degrading proteolytic
enzymes (matrix metalloproteinases, MMPs) without a
parallel induction of inhibitors of proteolysis (tissue inhibitor
of metalloproteinases). The resulting pathological remodeling
process involves the degradation of collagen and the
accumulation of abnormal elastin in the superficial dermis,
resulting in the characteristic changes of solar elastosis (Chen
et al., 1986; Uitto, 2008). Previous studies with UVR sources
rich in UVB showed induction of MMP1, MMP3, and MMP9
mRNA (Brenneisen et al., 1996; Fisher et al., 1996; Fisher
et al., 1997) in human skin in vivo. UVA sources have also
been reported to induce MMP1 expression in fibroblasts
(Scharffetter et al., 1991; Herrmann et al., 1993). There are
few data on the effects of spectrally pure UVA1 on MMPs in
human skin in vivo (Wang et al., 2013).
MMP activity is required both in normal physiological pro-
cesses such as wound healing and angiogenesis (Chakraborti
et al., 2003) and in the pathological tissue destruction that
occurs in chronic wounds, dermal photoaging, bullous skin
disease, cancer invasion, and metastasis (Kerkela and
Saarialho-Kere, 2003). The mechanisms by which UVR
induces MMPs are poorly understood. Some studies have
reported that this occurs via the generation of reactive oxygen
species (Scharffetter-Kochanek et al., 1993; Fisher et al.,
2009), whereas others have suggested that DNA is a major
chromophore and that MMPs are triggered by the formation of
cyclobutane pyrimidine dimers (CPDs) (Dong et al., 2008).
MMPs may also be induced by mediators such as tumor
necrosis factor a (Steenport et al., 2009), which is also readily
induced in the skin by UVR, probably via the induction of
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CPDs (Walker and Young, 2007) and IL6 (Wlaschek et al.,
1994).
It is widely considered that UVA has a larger role than UVB
in photoaging, both because of the deeper penetration of
UVA into the dermis (Bruls et al., 1984) and because of
the sensitivity of fibroblasts to UVA-induced MMPs
(Scharffetter et al., 1991; Herrmann et al., 1993). There are
inherent problems with previous studies that relate to spectral
purity of the source of UVR. UVB sources often also emit a
considerable amount of UVA and it is not possible to attribute
an effect to UVB without knowledge of the action spectrum of
the end point under investigation. Even minor contamination
of a nominal UVA source with very small amounts of UVB
may give misleading results because o1% UVB
contamination can be responsible for most of a given effect,
e.g., DNA damage (Woollons et al., 1999). Also, UVA2 (315–
340 nm) and UVA1 are biologically and mechanistically
different. Thus, we have concentrated our studies on the
biological effects of spectrally pure UVB (300 nm) and UVA1.
In a recent work, we reported that solar UVB exposure was
probably the most important factor in MMP1 induction from
an environmentally relevant perspective (Tewari et al., 2012).
In this study, we compare the effects in vivo of erythemally
equivalent and biologically relevant doses of spectrally pure
UVA1 and UVB on whole genome expression, mRNA, and
protein and enzyme activity of the most significantly enriched
pathway at 24 hours (extracellular matrix remodeling). We
have used this approach because erythema is the widely used
end point in clinical and experimental photodermatology. We
chose 300 nm because it is in the region of the peaks of the
action spectra both for erythema and for CPD induction in
human skin in vivo (Young et al., 1998) and its photo-
biological effects are likely to be mechanistically different
from UVA1. Furthermore, erythemal exposure, quantified
by the standard erythema dose, is increasingly used as a
measure of UVR exposure in clinical and epidemiological
studies.
RESULTS
Extracellular matrix remodeling genes are induced to a greater
extent than other pathways, both by UVA1 and by UVB 24hours
after exposure.
We used Genego Metacore v7 on our microarray data to
identify upregulated pathways at 6 and 24 hours using the
pooled intensities (n¼9 for UVA1 and n¼5 for UVB) of
upregulated genes compared with each individual’s nonirra-
diated control (Po0.05, fold change X2). At 6 hours, the most
significantly enriched pathway was inflammation through
Th17 signaling for erythemally equivalent doses of UVA1
(P¼ 1.16e6) and UVB (P¼ 2.1e4). At 24 hours, the most
significantly enriched pathway was extracellular matrix remo-
deling for UVA1 (P¼5.5e7) and UVB (P¼2.9e22).
Many other groups of genes were induced to lesser extents
but this paper will focus on the MMPs, given their striking
degree of induction.
Whole-skin microarray analysis at 6 (Figure 1a) and
24 hours (Figure 1b) after exposure indicated that genes
encoding MMP1, MMP3, MMP9, MMP10, and MMP12 are
induced predominantly at 24 hours. MMP1, MMP3, and
MMP10 (10–550-fold, Pp0.05, adjusted Pp0.3) were
induced to a greater extent by UVB, whereas UVA1 induced
a 15-fold increase in MMP12 gene expression at 6 hours
(Pp0.05, adjusted Pp0.3) that increased to around 30-fold at
24 hours (Pp0.05, adjusted Pp0.3).
Key UVA1 and UVB mRNA expression differences
Specific genes assessed by reverse transcription quantitative
PCR (qPCR) at 6 and 24 hours are shown in Figure 1c–h.
At 24 hours, UVB was more effective than UVA1 at inducing
MMP1 (P¼ 0.0062, UVB/UVA1 fold difference 13.2)
(Figure 1c), MMP3 (P¼0.0016, UVB/UVA1 fold difference
38.7) (Figure 1d), and MMP10 (P¼ 0.028, UVB/UVA1 fold
difference 27.1) (Figure 1e). Both UVA1 and UVB induce
MMP9 mRNA to an equal extent (at 6 and 24 hours post
exposure (Figure 1f); P¼0.33 at 6 hours, P¼0.12 at 24 hours).
UVA1 was more effective than UVB at inducing MMP12
mRNA at 6 (P¼0.02, UVA1/UVB fold difference 19.2) and
24 hours (P¼0.22, UVA1/UVB fold difference 8.26). How-
ever, the large interindividual variation at 24 hours means that
the difference is not significant (Figure 1g). UVA1 did not
induce MMP3 or MMP10.
UVR-induced MMP1 protein and its activity in the epidermis
Typical MMP1 and MMP12 protein staining (red fluorescence)
and enzyme activity (in situ zymography shown by green
fluorescence) are shown in Figure 2a and b, respectively.
UVB and UVA1 induce MMP1 protein (at 10 and 24 hours
(Figure 2c)) to a similar extent. Enzyme activity is preferentially
induced by UVB at 24 hours compared with UVA1 (P¼ 0.031)
(Figure 2d). DQ collagen type I is a substrate for MMP1,
MMP2, MMP3, MMP9, and MMP13 (Yan and Blomme, 2003).
Figure 3a shows that MMP2 protein was not induced by either
spectrum at 24 hours. However, as shown in Figure 3b, UVB
induced an increase in MMP9 protein at 24 hours.
UVA1 preferentially induces MMP12
MMP12 protein is predominantly formed by UVA1 at 24 hours
(P¼ 0.04) (Figure 2e). A lesser degree of induction of MMP12
protein is seen with UVB at 10 and 24 hours, despite the
absence of MMP12 mRNA induction by UVB at 6 and 24hours.
There is significantly (P¼ 0.027) more MMP12 activity at
10 hours after UVA1 exposure than after UVB (Figure 2f).
Location of MMP1 and MMP12 proteins within the epidermis
Figure 2g and h show that MMP1 protein is mainly induced
in the upper epidermis (upper versus lower epidermis UVB
P¼0.005 and UVA1 P¼0.01), whereas MMP12 is equally
induced throughout the epidermis (Figure 2i and j) (upper vs.
lower epidermis UVB P¼ 0.20, UVA1 P¼ 0.42).
UVR-induced MMPs and their activity in the dermis
Expression of MMP1 and MMP12 proteins in the dermis are
higher with UVA1 than UVB (Figure 4a and c), but there are
no spectral differences in the enzyme activities (Figure 4b
and d). Overall, both MMP protein and enzyme activity are
higher in the epidermis than in the dermis. Figure 5a shows
A Tewari et al.
UVA1 Induces MMP12






























































































































































































Figure 1. Key UVA1 and UVB gene expression differences in extracellular matrix remodeling: RNA changes. Nine skin type I/II participants for UVA1
and five skin type I/II participants for UVB, RNA extracted and converted to cRNA, and hybridized to Agilent 4 44 K microarray chips. Normalized gene
expression ratios (log2) compared with each individual’s nonirradiated control at (a) 6 hours and (b) 24 hours were used for calculations. The individual values were
plotted (Pp0.05, adjusted Pp0.3). Validation with reverse transcriptase (RT) quantitative (PCR) qPCR (DDCT method) using Taqman probes and
GAPDH housekeeping gene to produce a relative fold change: (c) MMP1, (d) MMP3, (e) MMP10, (f) MMP9, (g) MMP12, (h) MMP13. *Pp0.05, **Pp0.01.
Microarray and qPCR were performed on samples from all nine volunteers.
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that UVA1, but not UVB, induces elastin breakdown in the
epidermal region.
Macrophages are a potential source of UVA1-induced MMP12
Figure 5b shows significant depletion of dermal macrophages
(CD68þ ) 24 hours after UVB exposure. In contrast, UVA1 had
no effect on dermal macrophage numbers (P¼0.21) com-
pared with nonirradiated controls.
DISCUSSION
We have compared UVR-induced MMPs using spectrally pure
UVB (300 nm) and UVA1 on the same individuals, which is
likely to reduce the impact of interpersonal variation. Our
UVA1 doses are physiologically relevant; 50 J cm 2 would
be a typical dose received from a 2.5 hour exposure to the
tropical Australian sun (19 1S) (Bernhard et al., 1997) and
higher doses are regularly given for treatment of sclerosing
skin conditions (Kerr et al., 2012).
Baseline expression of MMPs is usually low in human
tissue, including skin. Our gene array data (supported by
qPCR) show that erythemally equivalent doses of UVB and
UVA1 induce many MMPs. There was no increase in tissue
inhibitor of metalloproteinases 1–4 with either spectrum
assessed by microarray (data not shown). For most MMPs,
induction by UVB peaked at 24 hours, although some expres-
sion is seen at 6 hours with some MMPs. MMP12 gene and
mRNA expression by UVA1 is seen at 6 hours but primarily at
24 hours. The most striking fold increases with UVB were for
MMP1 and MMP3 with array and qPCR technology. There
was also an impressive increase of MMP10 mRNA with qPCR.
Neither UVB nor UVA1 had any effect on MMP2 assessed
by microarray, mRNA (data not shown), and protein. The most
striking effect of UVA1 was on MMP12, as assessed by the
three techniques. In contrast, UVB had little effect on MMP12
expression. There was modest or no evidence of any UVA1
induction of MMP3 or MMP10 by qPCR. MMP12 mRNA
expression has been reported in human skin in vivo at 16 and
24 hours by others (Chung et al., 2002), after a 2 minimal
erythema dose (MED) exposure from a broad-spectrum






UVA1 10 hours UVB 10 hours UVA1 24 hours UVB 24 hours
Unirradiated UVA1 10 hours UVB 10 hours UVA1 24 hours UVB 24 hours
Figure 2. UVA1 induces more epidermal matrix metalloproteinase (MMP)12 protein (immunofluorescence) and enzyme activity (in situ zymography)
than UVB. MMP1 and MMP12 protein (antibodies from Abcam) immunofluorescence in one representative individual detected by (a) alexafluor 555
(red fluorescence) for 30 mJ cm2 UVB (B1 minimal erythema dose (MED)) at 10 and 24 hours and 50 J cm2 (B1MED) of UVA1 at 10 and 24 hours and
(b) DQ collagen type I (DQ1), substrate for MMP1, MMP2, and MMP9, and DQ collagen type IV (DQ4), substrate for MMP2, MMP7, MMP9, MMP12,
and MMP25, were used to detect enzyme activity via fluorescein (green fluorescence), quantification of (c) epidermal MMP1, (d) epidermal DQ1,
(e) epidermal MMP12, and (f) epidermal DQ4. Distribution of MMP1 and MMP12 within the epidermis, (g) UVB-induced MMP1, (h) UVA1-induced MMP1,
(i) UVB-induced MMP12, and (j) UVA1-induced MMP12. *Pp0.05, **Pp0.01; n¼ 3. Scale bar¼50mm.
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detected after exposure to UVA1 or broad-spectrum UVR
(UVB with UVA) for three consecutive days (Saarialho-Kere
et al., 1999).
Recently, it was shown that 40 J cm2 UVA1 in human skin
in vivo increased MMP1 and MMP3 mRNA byB80- and 50-
fold, respectively, at 24 hours (Wang et al., 2013). These data
are comparable to the responses we see to 50 J cm2 UVA1
(especially for MMP3), which are 25- and 45-fold compared
to nonirradiated control tissue for MMP1 and MMP3,
respectively (see Figure 1c and d), given the error range in
both data sets. Repeated (4 ) low-dose UVA1 on human skin
in vivo results in an accumulation of MMP1 and MMP3
mRNA expression (Wang et al, 2013).
Our protein studies show that UVR-induced MMPs are
predominantly expressed in the epidermis, which is expected
because of their role in epithelial tissue homeostasis after UVR
Epidermal MMP12 Epidermal DQ4
UVB MMP1 UVA1 MMP1
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Figure 2. Continued.
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injury. Other studies support this observation (MMP1, MMP3,
and MMP9 mRNA and MMP1 activity) after exposure to
solar-simulating radiation (Quan et al, 2009). However, we
believe that our data demonstrate MMP1 protein/activity by
spectrally pure UVB and UVA1.
There are eight elastases in human skin (Liang et al., 2006),
of which human macrophage elastase (HME) or MMP12
(Shapiro, 1998; Shapiro et al., 1993), and neutrophil-derived
(neutrophil elastase (NE)) are induced by UVR (Lee et al.,
2008). NE has long-term photobiological significance,
because NE-deficient mice are resistant to photoaging
(Starcher and Conrad, 1995; Takeuchi et al., 2010) and
squamous cell carcinoma formation (Starcher et al., 1996)
after exposure to a source containing 10% UVB and 90%
UVA. This suggests that elastase may be linked to these two
long-term consequences of UVR exposure.
MMP12 protein has been detected in ‘‘a few stromal
fibroblast/macrophage-like cells’’ after exposure to UVA1
(Saarialho-Kere et al., 1999). A modest induction of dermal
fibroblast MMP12 (but not in macrophages) has also been
reported in human skin in vivo after a 2 MED exposure from
a broad-spectrum UVB–UVA source (Chung et al., 2002;
Saarialho-Kere et al., 1999). UVB induced significantly greater
(P¼ 0.02) depletion of papillary dermal macrophages than did
UVA1 (Figure 5b). Thus MMP12 could be explained by the
larger presence of activated macrophages in the dermis after
UVA1. MMP12-negative macrophages cannot penetrate the
dermal/epidermal junction (Shipley et al., 1996), and we
found no evidence of epidermal macrophages. We did not
stain for NE, but dermal neutrophil infiltration (and likely NE
release) is a predominantly UVB-driven process (Lee et al.,
2008) and is therefore unlikely to explain our UVA1 data.
MMP12 is also produced by activated T cells (Hughes et al.,
1998), transformed keratinocytes, and keratinocyte-derived
tumors (Kerkela et al., 2000). Given that we found MMP12
primarily in the epidermis, irrespective of spectrum, we
suggest that it is mainly derived from normal keratinocytes.
However, we cannot exclude the possibility that some
MMP12 may be derived from dermal cells such as
fibroblasts and macrophages.
UVB and UVA1 induced the degradation of DQ collagen
type I. The assessment of specific MMP function by in situ
zymography is complicated by cross-reactivity. DQ collagen
type I is primarily a substrate for MMP1 but is also degraded
by MMP2, MMP3, MMP9, and MMP13 (Yan and Blomme,
2003). There is no UVR induction of MMP2 mRNA or protein
(Figure 3a) at 24 hours but there is a small (B20%) significant
increase in MMP9 protein by UVB (Figure 3b). This has been
previously reported (as 92 kd gelatinase) (Fisher et al., 1997)
with a broad-spectrum UVB–UVA source. As UVB and UVA1
induce MMP13 mRNA to similar extents (Figure 1h), it is
possible that the UVB-induced collagen I hydrolytic activity is
also mediated via MMP3 and MMP9. We did not measure
MMP3 protein, but UVB resulted in a very large increase in its
mRNA that was not seen with UVA1. However, MMP3
protein (stromelysin-1) has been shown to increase after
exposure to a UVB–UVA source (Fisher et al., 1997).
UVA1 was more effective than UVB for the degradation of
DQ collagen type IV in the epidermis (10 hours). This is
primarily a substrate for MMP12, but it is also hydrolyzed by
MMP2, MMP7, MMP9, and MMP25 (Yan and Blomme,
2003). As MMP2, MMP7, MMP9, and MMP25 mRNAs were
not induced by UVA1, the induction of enzyme activity is
more likely to reflect the induction of MMP12. This is also
supported by the lack of UVA1 effects on MMP2 and MMP9
protein expression. There is some collagen IV hydrolysis with
UVB at 10 and 24 hours that could be due to UVB-induced
MMP9 (Figure 3b), although without MMP12-blocking
enzymes we cannot rule out the effects of MMP12.
UVB was significantly more effective than UVA1 at indu-
cing epidermal MMP1 activity at 24 hours. In contrast, UVA1
was more potent at induction of epidermal MMP12 protein
(24 hours) and its activity (10 hours) against DQ collagen type
IV. It was also significantly better at the induction of dermal
MMP1 and MMP12 proteins at 24 hours. This difference is
likely to be due to greater UVA1 dermal penetration/scattering
(Tewari et al., 2011; Tewari et al., 2012). Interestingly,
we found no spectral differences for dermal MMP1 and
MMP12 activity against their respective collagen substrates,
but there was large interpersonal variation. There was some
UVB-induced MMP12 protein, predominantly in the









































Figure 3. Effects of UVA1 and UVB on matrix metalloproteinase (MMP)2
and MMP9 expression in the epidermis. Using immunofluorescence there
was (a) no differential MMP2 expression at 24 hours following 1 minimal
erythema dose of UVA1 and UVB; (b) UVB induces significantly more
MMP9 than UVA1 at 24 h. *Pp0.05; n¼ 3.
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The small amount (relative to epidermis) of UVA1-induced
MMP12 in the dermis, maybe insufficient to degrade elastin at
24 hours because no elastase activity was detected in the
dermal region, although this was considerable in the epider-
mal region. This may be attributed to greater MMP12 protein
induction in the epidermis. This is also supported by the in situ
zymography data for degradation of collagen IV. Essentially,
the degradation of two substrates by MMP12 was an epider-
mal phenomenon in which UVA1 was more effective
than UVB.
Dermal extracellular collagens are degraded in photoaging.
Quan et al (2009) have suggested that epidermal MMP1,
MMP3, and MMP9 (where they report the majority is
synthesized), diffuse into the dermis to degrade collagen
(Quan et al., 2009). However, studies on photoaged skin
show more MMPs in the dermis than in the epidermis (Chung
et al., 2002; Quan et al., 2013). Overall, this suggests that
repeated solar UVR exposure results in an accumulation of
dermal MMP, whether by diffusion from the epidermis or by a
gradual accumulation of dermally synthesized protein. It is
also possible that our 24-hour sampling time was not optimal
for MMP12 diffusion from the epidermis into the dermis and
the degradation of elastin.
Light microscopy shows that the papillary dermis of photo-
aged skin contains an accumulation of amorphous
disorganized elastin fibrils, which is known as ‘‘solar elasto-
sis’’ (Calderone and Fenske, 1995; Yaar and Gilchrest, 2007).
In its early stages, there is an accumulation of insoluble disor-
ganized elastin and microfibrillar proteins (fibronectin) (Chen
et al., 1986; Lavker and Kligman, 1988), seen clinically as
waxy, thickened, and furrowed facial skin. In more advanced
solar elastosis, degeneration of dermal elastin results in a
mottled appearance that is clinically associated with a loss of
skin elasticity. The addition of an elastase to an elastin culture
(Braverman and Fonferko, 1982) results in a mottled
appearance that is similar to that seen in late solar elastosis.
This appearance, termed ‘‘zebra bodies’’, can also be induced
by repeated erythemal doses of UVA, but not by solar-
simulated radiation (Kumakiri et al., 1977).
Our data with gene array, qPCR, and protein activity
strongly suggest that UVA1 preferentially induces MMP12.
We acknowledge that our protein studies are based on small
sample sizes (n¼3). However, they generally correlate with
the mRNA data, and the protein expression and activity data
are mutually consistent. Our elastase activity data (Figure 5)
are particularly striking. MMP12 protein has been observed in
the upper dermis of patients with solar elastosis and actinic
keratosis (Saarialho-Kere et al., 1999; Chung et al., 2002).
Chung et al. (2002) suggest that MMP12 has a role in elastin
remodeling in solar elastosis of the face. We suggest that solar
Dermal MMP1 Dermal DQ1














































































































Figure 4. UVA1 induces more dermal metalloproteinase (MMP) protein than UVB. Using immunofluorescence and in situ zymography (a) there was
more UVA1-induced MMP1 than UVB-induced MMP1 at 24 hours, (b) there were no spectral differences for the degradation of dermal DQ1, (c) there was
more UVA1-induced MMP12 than UVB-induced MMP12 at 24 hours, and (d) there were no spectral differences for the degradation of dermal DQ4.
Scale bar¼ 50mm. *Pp0.05, **Pp0.01; n¼3.
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elastosis, and its association with MMP12, may be explained
by our studies because MMP12 is the major enzyme for the
degradation of elastin (Gronski et al., 1997; Woessner, 1991).
However, we cannot exclude other MMPs having a role in the
pathogenesis of solar elastosis, because MMP2, MMP7, and
MMP9 also have elastolytic activity and may be induced by
UVB (e.g., MMP9 as shown in Figure 3b). In addition, MMP12
degrades other substrates apart from type IV collagen includ-
ing laminin 1, fibronectin, vitronectin, and proteoglycans
(Gronski et al., 1997).
We hypothesize that solar UVA1 induces the expression of
MMP12, which then degrades elastin, contributing to the loss
of skin elasticity seen in late solar elastosis. This may occur, as
suggested by Quan et al (2009), by diffusion of the MMPs
from the epidermis to the upper dermis. The resultant loss
of elasticity, termed ‘‘sagging’’, has been shown to be a
UVA1-dependent process in hairless mice, with an action
spectrum peak at 340 nm (Bissett et al., 1987, 1989). This
suggests that UVA1 has important implications for photoaging
and also possibly photocarcinogenesis (Starcher and Conrad,
1995; Starcher et al., 1996). This is supported by studies
that show that people habitually exposed to UVA through
glass on one side of the face show more signs of photoaging
and skin cancer on the exposed side (Butler and Fosko,
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Figure 5. (a) UVA1, but not UVB, initiates DQ elastin degradation. In situ zymography showing fluorescence proportional to elastin breakdown at 24 hours
after a 1 minimal erythema dose exposure. (b) No UVA1 induced depletion of macrophages. Immunofluorescence shows higher numbers of CD68þ macrophages
present in the dermis at 24 hours after UVA1 than UVB, (c) examples of CD68-positive staining in one individual. *Pp0.05, **Pp0.01; n¼ 3. Scale bar¼ 50mm.
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A reduction of photoaging in an intense solar environment
has been observed with the long-term discretionary use of a
sunscreen (SPF 15þ )(Hughes et al., 2013). Its formulation is
not photostable, and would have lost most of its UVA1
protection within 1 hour (Dr B Herzog, personal commu-
nication). Our MMP12 data support the inclusion of good
photostable UVA1 protection in sunscreens to enhance their
ability to inhibit photoaging. Furthermore, our data suggest
that the inhibition of MMP12 may be a future strategy for
protecting against photoaging.
The absorption of UVR by chromophores mediates all
photobiological reactions. UVB absorbed by DNA results in
CPD formation, the action spectrum of which peaks at 300 nm
in human skin in vivo (Young et al., 1998). There is evidence
that DNA is a chromophore for MMP1 via CPD formation
(Dong et al., 2008). Our recent findings (Tewari et al., 2012;
Tewari et al., 2011) showed considerable attenuation of UVB-
induced CPDs with skin (epidermis and dermis) depth, which
was not the case with UVA1. Thus, we would expect to see
marked attenuation of UVB-induced MMP1 with skin depth,
as shown in Figures 2g and 4a, if DNA were the putative
chromophore. In contrast, epidermal depth has no effect on
the distribution of MMP12 induced by UVB or UVA1
(Figure 2i and j). This suggests that they have different
chromophores. We therefore propose that UVA1 induces
MMP12 via a non-DNA chromophore that generates reactive
oxygen species (Scharffetter-Kochanek et al., 1993; Wlaschek
et al., 1995). This is supported by studies that showed that
topical reactive oxygen species scavengers reduced MMP12
mRNA in human skin (Chung et al., 2002). UVA1 did not
induce MMP3 or MMP10 when assessed by qPCR. Our
erythemal dose of UVA1 (50 J cm2) does induce CPDs,
although at one-fourth to one-third times lower levels than
after an erythemally equivalent exposure to UVB (Tewari,
Sarkany et al., 2011). This suggests that these enzymes may
not only have a CPD threshold but may also have non-DNA
chromophores that are required for their induction.
MATERIALS AND METHODS
Volunteers
The studies were approved by the St Thomas’ Hospital, London, UK
Ethics Committee (Ref: 09/H0802/98) in accordance with the declara-
tion of Helsinki. The details of the 12 healthy skin type I/II volunteers
are shown in Table 1. Participants gave written informed consent
before taking part in the study.
Irradiation
UVR sources, dosimetry, and irradiation protocol. Emission
spectra and irradiances of the UVA1 and UVB sources, and
assessment of MED are previously described (Tewari et al., 2011).
Table 1 shows that the mean MEDs for 12 volunteers were
29.2±5.8 mJ cm 2 (UVB) and 58.6±7.9 J cm 2 (UVA1).
Experimental protocol. (i) ‘‘UVA1 time course’’: four skin type
I/II volunteers were irradiated over a 1-cm2 area on previously
unexposed buttock skin with 50 J cm 2 UVA1 and 4-mm punch
biopsies were taken under local anesthesia 6 and 24 hours later.
This wasB1MED (minimal erythema dose) and was based on our
previous work (Tewari et al., 2011). (ii) ‘‘UVA1 and UVB
comparison’’: five skin type I/II participants were exposed to
50 J cm 2 UVA1 and 30 mJ cm 2 (B1MED) UVB and biopsies
were taken at 6 and at 24 hours. (iii) ‘‘Protein validation’’:
Table 1. Volunteer demographics and their just-perceptible MED
Study Skin type Sex Age MED UVA1 (J cm 2) MED UVB (mJ cm 2)
UVA1 time course I M 27 48.8 30.0
II M 21 48.8 30.0
I F 21 61.8 37.0
I F 21 61.8 23.0
Mean±SD Mþ F 22.5±2.6 55.3±6.5 30.0±4.9
UVA1 and UVB comparision I M 20 61.1 19.0
I M 21 61.1 23.0
II F 23 61.1 30.0
I F 22 61.1 23.0
II F 28 76.2 30.0
Mean±SD Mþ F 22.8±3.1 64.1±6.8 25.0±4.8
Protein validation II F 24 61.1 37.0
II F 27 61.1 37.0
I F 22 48.8 30
Mean±SD 24.3±2.5 57.0±7.1 34.7±4.0
Combined mean±SD 7I, 5II 4M, 8F 23.0±2.8 59.4±7.7 29.1±6.1
Abbreviations: F, female; M, male; MED, minimal erythema dose.
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a further three skin type I/II individuals were recruited, had UVR
sensitivity tested as above, and received UVB and UVA1
irradiations equivalent to B1MED (30 mJ cm 2 UVB and
50 J cm 2 UVA1). Biopsies were taken at 10 and 24 hours
along with an nonirradiated control biopsy.
Microarray. A single color hybridization on Agilent Whole
Human Genome Oligo Microarrays (Agilent Technologies, Wald-
bronn, Germany) (4 44 K) and bioinformatics was performed
(Milteyni Biotech, Bergisch Gladbach, Germany). Briefly, biopsies
were snap-frozen in liquid nitrogen and RNA was extracted
(Trizol, Sigma, St Louis, MO) and quality checked (Agilent 2100
bioanalyzer platform; Agilent Technologies). cRNA was pro-
duced, Cy3 labeled, and hybridized overnight (B17 hours,
65 1C) to Agilent Whole Genome Oligo Microarray chips
(4 44 K) using the Agilent Gene Expression Hybridzation Kit
(Agilent Technologies). Fluorescence signals were detected using
Agilent’s Microarray Scanner system, Agilent Feature Extraction
Software was used to process intensities. Raw intensity data were
extracted from Feature Extraction output files using Rosetta
Resolver software (Rosetta, Inpharmatics, Kirkland, WA). Back-
ground-corrected intensity values were normalized between
arrays using quantile normalization (Bolstad et al., 2003). Log2-
transformed normalized intensity values were used for sub-
sequent statistical analysis. Quality controls include comparison
of intensity profiles and a global correlation analysis. The
microarray data is deposited at NCBI GEO with accession
number GSE45493.
Quantitative real-time PCR
Total RNA was converted to cDNA (Applied Biosystems, Paisley, UK)
and quality controlled using reverse transcription PCR with b-actin as
the housekeeping gene. cDNA was visualized as characteristic bands
on a 3% agarose gel under UVR. qPCR was performed using Taqman
Gene Expression Assays (Applied Biosystems) according to the
manufacturer’s protocol with the following TaqMan DNA probes
(Applied Biosystems), FAM (6-carboxyfluorescein) labeled, and GAPDH
(Applied Biosystems) housekeeping gene, VIC labeled. Probes
used (gene name and reference no): MMP1 Hs00899658_m1,
MMP3 Hs00968305_m1, MMP9 Hs00234579_m1, MMP10
Hs00233987_m1, MMP12 Hs00899668_m1. Fold change was
calculated using the DDCT method.
Protein validation
Biopsies were placed in OCT (VWR Chemicals, Leuven, Belgium),
embedded in isopentane (VWR Chemicals, Fontenay-sous-Bois,
France), and once placed in cryovials were then frozen in liquid
nitrogen. 5–7mm sections were mounted on Superfrost plus slides and
stored at  80 1C. Sections were placed at room temperature
(10 minutes), fixed in cold acetone (10 minutes), then rinsed in
phosphate-buffered saline (PBS) for 5 minutes. (i) Immunofluorese-
cence: sections were incubated with blocking buffer for 20 minutes
(10% goat serum (DAKO, Cambridge, UK) 0.1% BSA, 0.1% Tween-
20 in PBS), washed in PBS, incubated for 90 minutes with MMP1
(1:100), MMP12 (1:400) (recognizes the proactive and active forms of
MMP12), rabbit antihuman antibodies (Abcam, UK), CD68 (1:100)
mouse antihuman antibody (Abcam, Cambridge, UK) washed in PBS,
and incubated with either Alexa Fluor goat antirabbit 555 or goat
antimouse 555 (Invitrogen, Paisley, UK) at 1:200 for 30 minutes,
counterstained with prolong gold antifade with DAPI (Molecular
Probes, Paisley, UK), coverslipped, and stored away from light.
Imaging was performed with a Zeiss Axiophot microscope (Harpen-
den, UK) and Nikon DS-U2 camera (Kingston upon Thames, UK).
Images were captured in 2560 1920 format, gain  1.00, 4 second
exposure. (ii) in situ zymography: slides were incubated with 60ml
substrate (low-gelling agarose (Sigma, Dorset, UK) (1 g dissolved in
500 ml PBS)), with four drops of 40,6-diamidino-2-phenylindole with
antigold fade (Invitrogen) and DQ-collagen 1, DQ-collagen 4, or DQ
elastin (all from Molecular Probes) at 1:10 forB18 hours in the dark.
Fluorescent imaging for fluorescein (green) and 40,6-diamidino-2-
phenylindole (blue) was performed. Images were obtained as above
and captured in 2560 1920 format, gain  1.00, 1 second expo-
sure. Analysis was performed using NIS elements BRv2 software
package as previously described (Tewari et al., 2011) after removing
background control intensity. For the spread of MMP1 and MMP12
across the epidermis, thresholding was set to capture red intensity,
and upper epidermis and lower epidermis were visually gated to give
mean intensity values corresponding to MMP amount.
Data analysis
For microarray data, bioinformatical analysis was based on normal-
ized Log2 intensities using R/Bioconductor and software packages
therein (http://www.R-project.org; http://www.bioconductor.org).
Analysis of variance with repeated measurements followed by Tukey
post hoc tests was used to test for expression differences among the
groups. The UVA1 time course was as follows: UVA1 6 hours versus
UVA1 24 hours (50 J cm 2 doses), UVA1 versus UVB at 6 hours, and
UVA1 versus UVB at 24 hours. All P-values were adjusted for
multiple testing (Benjamini and Hochberg, 1995). Differentially
expressed genes were considered if both the analysis of variance
and Tukey post hoc test P-values were p0.05 (adjusted P-value or
false discovery rate p0.3) and the expression difference was at least
twofold.
Functional analysis of candidate genes was performed using DAVID
(Database for Annotation, Visualization and Integrated Discovery)
v6.7 (Dennis et al., 2003) to identify biological clusters and GeneGo
Metacore v7 to identify key pathways. Briefly, gene ratio lists for
pooled individuals (fold changeX2, Pp0.05) from the 6- and 24-hour
biopsies were uploaded to the software program, which generated
pathway maps and P-values associating the statistical likelihood of a
sequence of genes with a particular pathway. All graphs were
generated using the Graphpad Prism v4 statistics package.
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UVA1 is skin deep: molecular and clinical implications†
Angela Tewari,*a Mette M. L. Grage,b Graham I. Harrison,a Robert Sarkanya and
Antony R. Younga
Long wavelength UVA1 (340–400 nm) is the main component of
terrestrial UVR and is increasingly used in skin phototherapy. Its
damage to critical biomolecules such as DNA has been widely
attributed to its ability to generate reactive oxygen species (ROS)
via other chromophores. However recent studies in vitro and
in vivo have shown that UVA1 has a speciﬁc ability to generate
cyclobutane pyrimidine dimers (CPD), especially thymine dimers
(T<>T), and that this is probably due to direct absorption of UVR.
The CPD has been implicated in many aspects of skin cancer.
Measuring UVB-induced CPD in the epidermis and dermis in vivo
shows that, as expected, the skin attenuates UVB. In contrast, our
data show that this is not the case with UVA1: in fact there is more
damage with increased skin depth. This suggests that the basal
layer, which contains keratinocyte stem cells and melanocytes, is
more vulnerable to the carcinogenic eﬀects of UVA1 than would
be predicted by mouse models. These data support the continuing
trend for better UVA1 protection by sunscreens.
Erythema as a biological measure of
exposure to solar UVR
Ultraviolet radiation (UVR) is electromagnetic radiation
spanning 100–400 nm and is oﬃcially divided into UVC
(100–280 nm), UVB (280–315 nm) and UVA (315–400 nm), with
UVA being sub-classified into UVA2 (315–340 nm) and UVA1
(340–400 nm). However, a UVB–UVA cutoﬀ at 320 nm is widely
used in photodermatology. Since stratospheric ozone absorbs
all UVR below ∼295 nm, terrestrial sunlight contains only UVB
(5–10% of total UVR) and UVA (90–95% of total UVR), the latter
being primarily UVA1 (∼75%). The precise ratio of UVB to UVA
varies with the solar zenith angle that is determined by
latitude, season and time of day. This is demonstrated by
Fig. 1a, which shows the monthly variation of UVA and UVB
irradiance at Chilton, UK (51.6°N), in which a radiative trans-
fer model (SMARTS)1 generated the data taking total ozone
into account.2 Similarly, Fig. 1b shows the daily variation of
Fig. 1 Variation of UVB and UVA irradiance at Chilton, UK (a) monthly at noon
on the 21st day of each month (b) daily at summer and winter solstices. These
data have been modeled taking total ozone into account.2
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UVA and UVB taken in mid-summer (21st June) and mid-
winter (21st December) at the same location.
Erythema is widely used as a clinical measure of UVR
exposure. Thus, the data in Fig. 1a and 1b have been weighted
with the CIE erythema action spectrum3 to produce erythe-
mally eﬀective energy (EEE) as shown in Fig. 2a and 2b respecti-
vely. Fig. 2a shows that in mid-summer, UVA at temperate
latitudes contributes about 25% of EEE of solar UVR. However,
this decreases either side of this period such that the ratio is
approximately 50 : 50 from December through to January.
Fig. 2b shows that UVA contributes to a maximum of about
25% of EEE at noon in mid-summer, but that in mid-winter
the relative contributions of UVB and UVA to erythema are
independent of time of day, i.e. erythemal exposure is achieved
equally by UVB and UVA. In this context, it must be remem-
bered that considerable molecular and cellular damage can be
done in human skin in vivo by single and repeated sub-
erythemal exposure,4 irrespective of spectrum. Furthermore,
suppression of the skin’s immune function can occur with
about 25% of the minimal erythema dose (MED).5
The standard erythema dose (SED)6 is increasingly used as
a measure of human exposure, especially in epidemiological
studies. Unlike the MED, the SED is independent of individual
UVR sensitivity. During mid-summer in Chilton at midday it
would take approximately 9.5 minutes to receive a full UVR
spectrum SED (unpublished data) which is approximately 1/3
of a minimal erythema dose (MED) in a skin type I/II person.7
It would take approximately 4 times longer to get an SED from
the UVA component alone. These data show considerable
potential exposure to UVA whether determined by physical or
erythemal exposure parameters.
UVR and skin cancer
There has been a dramatic increase in incidence of skin
cancers in Europe and the USA, especially malignant mela-
noma (MM), in the past 25 years.8,9 This has increased the
urgency of identifying and protecting against the causative
factors of which UVR has emerged as the most important. This
conclusion has resulted from classic epidemiology and more
recently, by molecular epidemiology that identifies UVR-
specific mutations in skin cancers. The focus has been largely
on UVB because of a combination of action spectrum data
from a mouse model of squamous cell carcinoma (SCC)10,11
and the well-established finding that UVB readily induces the
production of DNA photoproducts (see section below) associ-
ated with skin cancer.12–14 However, a combination of factors
has arisen in recent years that implies that UVA plays a more
significant role than was previously thought. First, epidemiolo-
gical data have shown that MM shows a better latitude corre-
lation with UVA than with UVB15,16 and that the use of
artificial tanning devices (which mainly emit UVA) increases
the risk of skin cancer, especially MM.17 UVA artificial tanning
devices are widely used,18 especially by the young, and use
under the age of 35 confers the greatest risk.19 Second, it has
become increasingly clear that UVA1 is not photochemically or
biologically inactive, and that UVA1 is a potent inducer of reac-
tive oxygen species (ROS),20 which are thought to play a role in
skin cancer.21,22 The question of whether UVA1 is a significant
carcinogen has become more important as exposure of the
human population to UVA has significantly increased. Until
relatively recently, sunscreens were primarily UVB absorbing
products that enabled prolonged sunbathing without much
protection against UVA, paradoxically increasing exposure to
UVA in sunbathers.23,24 This can occur to the extent that
erythema from repeated sub-erythemal exposure can be caused
by UVA.25 Finally UVA1 phototherapy has been developed in
the last 20 years and is used to treat a variety of dermatological
diseases26 with comparable eﬃcacy to other types of photo-
therapy (TLO1 or narrowband UVB) for some conditions.
Although the action spectrum for induction of SCC in mice is
predominantly in the UVB waveband, the action spectrum for
induction of MM in mammalian skin is still unknown.
Mechanistically, the proven mutagenicity and carcinogenicity
of UVB has led to the dogma that UVB is the only significant
cause of skin cancer.
Fig. 2 Variation of UVB and UVA EEE at Chilton, UK (a) monthly at noon on the
21st day of each month (b) daily at summer and winter solstices. These data are
based on the data in Fig. 1.
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The rest of this review will focus on what is currently known
about UVA1 photodamage of DNA, the significance of this
damage in terms of mutagenicity and carcinogenicity, and the
clinical and public health implications of these new findings.
UVR-induced DNA damage
DNA is susceptible to modification by UVR which may result
in mutation if not successfully repaired. There are many
diﬀerent types of DNA photolesions, which show wavelength
dependence in their formation. Some are formed by the direct
absorption of UVR and others are formed indirectly as
described below.
(i) Di-pyrimidine photolesions
UVR is absorbed by skin chromophores27 and DNA pyrimidine
bases are primarily chromophores for UVB (thymine, cytosine
and the minor 5 methylcytosine),28 but also weakly absorb
UVA. The direct excitation of these nucleobases by UVB in an
oxygen independent manner induces two main classes of
photolesions in the DNA of skin fibroblasts and keratino-
cytes.29 These are cyclobutane pyrimidine dimers (CPD) and
6-4 pyrimidine pyrimidone adducts (6-4PP) (which make up
65% and 35% of the UVB induced DNA lesions respecti-
vely.30,31 The CPD arises by linkage of two adjacent pyrimidine
bases of which the T<>T type is the most common.32
Until recently the presence of CPD-induced “fingerprint”
mutations (e.g. C→T) in skin cancers was taken as a priori
evidence for a causal role for UVB, even though it has been
known for some time that UVA, including UVA1, induces CPD
in human skin in vivo.33,34 More recent studies have confirmed
that UVA1 induces CPD in vitro, ex vivo and in vivo32,35 but not
6-4PP,32,35 these being predominantly (but not exclusively)
T<>T at frequencies comparable to or exceeding that of
oxidative damage to DNA (see below) but at several orders of
magnitude lower eﬃciency than UVB. The dogma that C→T
mutations are only caused by UVB has been recently
challenged.36
Distribution of UVB and UVA1-induced CPD in human skin
in vivo. Fig. 3 shows the distribution of CPD and 6-4PP in the
epidermis and dermis when biopsies were taken immediately
after erythemally equivalent does of UVA1 (Fig. 3a) and mono-
chromatic UVB at 300 nm (Fig. 3b); the latter wavelength was
chosen because it approximately corresponds to the peak for
the action spectra for both erythema and CPD.33 Fig. 3b shows
that both types of UVB-induced-damage are attenuated with
increasing skin depth, as would be expected because of
the presence of UVB absorbing chromophores in the skin. In
contrast, Fig. 3a shows a significant increase in CPD with skin
depth with UVA1 and no evidence for 6-4PP. These figures
show that UVB and UVA1 can cause significant DNA damage to
dermal cells; such damage has been largely neglected in the
past, especially with UVB. Assessments of the epidermis
showed that UVA1 induces at least twice as much DNA damage
in the basal layer than the upper epidermis.35 Thus, the extent
of CPD damage varies with spectrum and epidermal location.
UVA1 is less well absorbed by the upper layers of the epider-
mis than UVB and hence can penetrate deeper into tissue, but
the reasons for the “reverse attenuation” with UVA1 are not
known. One possibility is that UVA1 photons are preferentially
scattered by the epidermis and dermis, in a forward or back-
ward direction, rather than absorbed by chromophores.37,38
Back scattering results in remittance (a type of “reflection”),
which provides additional opportunity for chromophore
Fig. 3 (a) Linear regression for UVA1-induced CPD (p = 0.0006 for slope) and
6-4PP (p = 0.56 for slope) in the epidermis and dermis in vivo immediately after
a 3MED exposure. More CPD appear to be induced as depth increases through
the epidermis and dermis. Note the lack of UVA1 induced 6-4PP. (b) Linear
regression for UVB (300 nm)-induced CPD (p = <0.0001 for slope) and 6-4PP
(p = 0.0006 for slope) in the epidermis and dermis in vivo immediately after a
3MED exposure.
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absorption during the return pathway. Dermal remittance
increases between 300 and 400 nm.37 Thus, it is possible that
the higher number of UVA1-induced CPD seen in the basal
layer is due to dermal back scatter (e.g., from collagen), as well
as epidermal forward scatter.39
Although we have only measured CPD and 6-4PP, these can
be used as a surrogate for UVR penetration into skin and can
inform about the possibility of generating other types of DNA
and bio-molecule damage. Overall, our data demonstrate that
the basal layer, which contains melanocytes and proliferating
keratinocytes, is especially sensitive to UVA1 induced DNA
damage, and they challenge the paradigm that UVB is the only
important spectral region for skin cancer. This is supported by
studies on engineered human skin show that, in contrast to
UVB, UVA-induced mutations were mainly located in the basal
layer.40
The photochemical mechanisms of UVA1 CPD induction.
The photochemical mechanisms, by which UVA1 selectively
induces CPD, especially T<>T, and not 6-4PP (see Fig. 3a)
in vivo, remains unknown. UVA activation of some photo-
sensitizers such as fluoroquinolones41 and carprofen42 can
induce CPD in vitro, suggesting that unidentified endogenous
photosensitizers in human skin in vivo may have a role in the
induction of CPD by UVA1, possibly via photosensitizer
mediated triplet energy transfer.43,44 More recently a direct
UVR absorption photochemical reaction45,46 has been pro-
posed from in vitro studies. For example, double-stranded base
sequences (e.g., dA.dT) increase UVA absorption compared
with the same monomeric molecules.46
(ii) Oxidative damage
DNA damage also occurs indirectly through the formation
of ROS.44,47 These are generated by the absorption of UVA by
non-DNA endogenous chromophores (photosensitizers) such
as porphyrins, flavins and NADH/NADPH44,48 which can be
excited to a triplet state. Damage can occur via a type 1 photo-
sensitization reaction which can cause DNA strand breaks by
the generation of superoxide anions, hydrogen peroxide and
hydroxyl radicals, the latter being very reactive with all DNA
bases.47 There are also type 2 photosensitization reactions
where energy is transferred to molecular oxygen giving rise to
singlet O2 (
1O2). This species specifically reacts with guanine
residues49 producing 8-oxo-7,8-dihydro-2′deoxyguanosine
(8oxodG) and is thought to be important in UVA induced cell
death.50 Few studies have reported the detection of UVR-
induced oxidative damage to DNA in vivo, but this has been
reported in mice51 and in human skin.22,52 8oxodG has also
been reported in urine after the exposure of human skin to
UVA.53
When UVB (300 nm) and UVA1 doses are given to produce
comparable levels of erythema in human skin (1MED ∼ 30 mJ
cm−2 and ∼50 J cm−2 respectively), UVA1 induces 3–4 fold
fewer T<>T than UVB implying other non-DNA chromophores
have an important role in UVA1 erythema, and it is possible
that this is mediated via oxidative damage to DNA. Unlike UVB
erythema, UVA erythema is oxygen dependent,54 implying a
role for ROS in UVA erythema. Diﬀerent mechanisms for UVB
and UVA1 erythema are supported by a lack of correlation
between UVB and UVA1 induced MED on the same individuals
(Fig. 4). A detailed laser action spectrum for human erythema
showed a peak at 300 nm but also identified a minor UVA1
peak (at approximately 360 nm)55 which also suggests that
more than one chromophore is important (Fig. 5).
Consequences of UVR induced DNA damage
in human skin
(i) Non-genetic
The action spectra for CPD and erythema (inflammation) are
similar (especially between 280–340 nm) suggesting that DNA
is a chromophore for erythema33 which is also supported
in studies in the marsupial Monodelphis domestica in which
the MED was reduced by a factor of approximately four
after enhanced CPD repair induced by UVA activation of
Fig. 4 Lack of relationship between a given individual’s UVB and UVA1 MED
(n = 22 with some data points overlapping). jp = just perceptible.
Fig. 5 Erythema action spectrum55 showing small peak at approximately
360 nm (raw data obtained from the late Dr Anders) normalized at 300 nm
with the CIE action spectrum.3
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endogenous photolyase which is not present in placental
mammals.56 In other words the CPD triggers inflammation
of the skin. Inflammation plays a role in many types of
cancer57,58 by fostering tumour progression, and UVR-induced
erythema is a risk factor for MM and possibly BCC.59
Persistent erythema is also found in xeroderma pigmentosum
patients who are unable to repair CPD and who are also
2000–10 000 times more likely to present with melanomas and
non-melanoma type skin cancers.12,60
Apart from erythema, the CPD has been shown to trigger
pro-inflammatory cytokine release and immunosuppression
that are thought to play a role in skin cancer.61,62 We have
recently shown that 3 SED, irrespective of spectrum (including
UVA1), is predictive of the suppression of the sensitization
phase of the contact hypersensitivity (CHS) response, which is
regarded as a model for the immunological events in non-
melanoma skin cancer (manuscript in preparation). In con-
clusion, there is considerable evidence that DNA damage,
especially the CPD, causes inflammation/immunosuppression
that may play a role in skin cancer. Recently published work
also suggested that erythema is predictive of photoageing
induced by matrix metalloproteinase 1 (MMP1) via the CPD.63
Oxidative damage and immunosuppression
The CPD and urocanic acid have been identified as possible
chromophores for UVR-induced immunosuppression.64,65
However several studies in the mouse66,67 have shown that
antioxidants can inhibit UVR-induced immunosuppression,
which suggests other possibly UVA absorbing chromophores.
In addition, antioxidants have been shown to inhibit mouse
photocarcinogenesis.68,69 However, there is no direct evidence
that oxidative damage to DNA is a trigger for UVA-induced
immunosuppression.
(ii) Genetic
Di-pyrimidine lesions. Di-pyrimidine lesions containing a
cytosine are thought to lead to a C→T transition (C:G to A:T
transition) which are commonly found in UVR induced skin
cancer (SCC, basal cell carcinoma (BCC)),14 and the majority of
mutations in a melanoma cell line70 but rarely in non-UVR-
induced internal cancers. Thus cytosine-containing photopro-
ducts are thought to be more mutagenic. C→T transitions can
be induced by both CPD and 6-4PP. However in mammalian
cells, 6-4PP are repaired quickly71,72 whilst the CPD is believed
to be the major mutagenic lesion owing to its high level of
induction, slow repair by nucleotide excision repair (NER) and
eﬃcient replication bypass.73 Transgenic mouse studies
have shown that the CPD is much more important for non-
melanoma skin cancer than the 6-4PP.74
Faithful NER of CPD is crucial for the prevention of skin
cancer. One study on ex vivo skin suggested poorer repair of
UVA1-induced CPD compared with those induced by UVB32
but our data did not support this when the epidermis was
assessed in total.35 However, a subsequent analysis of repair in
the basal layer alone suggests that repair of UVA induced
CPD is less eﬃcient than that with UVB (unpublished). UVA
can induce a G2/S block in melanocytes and melanoma cells
suggesting that the DNA damage induced by UVA can have
potent eﬀects as they may not be easily repaired at the
basal epidermis.75 Recent work76,77 suggests that UVB initiates
melanoma and that both UVB and UVA are involved in the
progression of the disease.
ROS-induced lesions. 8oxodG can induce G→T transver-
sions which are potentially mutagenic,78,79 but because ROS-
mediated base damage is low compared to direct damage
and because this type of damage is rapidly repaired80 the
importance of these lesions in skin carcinogenesis is less
clear.32,43,81
Oxidative damage to DNA results in what have been termed
“UVA fingerprint mutations” via G:C→A:T transversions which
have been detected in human SCC and actinic keratosis,
especially in the basal layer.22 These were found to be more
prominent than C→T, transitions21 but p53 gene mutations do
not contain UVA specific T and G transversions implying that
although UVA causes oxidative DNA damage, such lesions may
not contribute to the generation of p53 mutations.82 Also, the
UVA mutation spectrum in mammalian cells does not exhibit a
predominance of G:C→T:A transversions83 which, combined
with the lack of increase in mutation rate in cells deficient in
repair of 8oxodG,84 suggests that other lesions are involved in
UVA mutagenesis. New work in mice85 examined UVB and UVA
induced DNA damage and their contribution to melanoma.
UVB induced melanoma was independent of melanin, but
UVA-induced melanoma required melanin. UVA, but not UVB,
induced oxidative DNA damage in melanocytes of pigmented
mice. These data support other work that suggests that
melanocytes are particularly sensitive to UVA.86
Clinical implications of UVA1 DNA
photodamage in the skin
As discussed earlier, potential exposure to solar UVA1 is sub-
stantial, even in temperate UK climates. Further south, on a
summer’s day in the south of France the maximum ambient
daily UVR dose is ∼22MED and the maximum UVA dose is
∼137 J cm−2,23 of which the majority is UVA1. The accumu-
lation of high UVA1 doses also occurs during the treatment of
dermatological skin disorders such as morphea87,88 and atopic
eczema89 where on average patients receive cumulative doses
of approximately 900 J cm−2 UVA1 (for example 50 J cm−2
3 times a week for 6–8 weeks) and some conditions such as
atopic eczema of the hands or cutaneous T-cell lymphoma
receiving single doses of up to 100 J cm−2 UVA1.90 The long-
term consequences of such exposures are not known. We have
shown that repeated daily exposure to sub-erythemal doses
of solar simulated radiation (SSR) results in an accumulation
of CPD4,25 probably because repair of this lesion is relatively
slow. To the best of our knowledge, the eﬀects of repeated
UVA1 sub-erythemal exposure on CPD has not been studied.
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A recent study91 demonstrated that uncontrolled activation
of a major mediator of the Hedgehog pathway signalling can
lead to the development of nodular BCC from hair follicle
stem cells and superficial BCC-like tumours from the basal
cell compartment of the epidermis. Such cells may also thus
be vulnerable to UVA1 because of its skin penetration
properties.
Increasing recognition of the possible long-term harmful
eﬀects of solar UVA exposure and development of better UVA
sunscreens is now required by regulatory bodies in Europe and
the USA.23 Recent government regulation in the UK and other
countries and prohibits the use of sunbeds for those under 18
years of age.
Conclusions
Our data, and those of others, show that the basal epidermis
of human skin is especially vulnerable to UVA1-induced CPD,
and ROS-induced mutations and therefore suggests that the
carcinogenic potential of this spectral region, which is the
major UVR component of sunlight, may be much greater than
has been estimated for SCC in the albino mouse, which has a
very thin epidermis and unlikely to show much evidence of
diﬀerential UVA1 induced damage in the epidermis.
The UVA1 sensitive basal layer is the location of proliferat-
ing keratinocytes and melanocytes. The action spectrum for
MM in mammalian skin is unknown, but there are epidemio-
logical data to suggest a greater role for UVA for MM compared
to non-melanoma skin cancer, furthermore recent mouse data
suggest that melanocyte DNA is especially sensitive to oxidative
damage.85 Overall, the data support the use of broad-spectrum
sunscreen protection.
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Human erythema and matrix metalloproteinase-1 mRNA induction, in vivo,
share an action spectrum which suggests common chromophores†
Angela Tewari,‡a Christine Lahmann,‡§b Robert Sarkany,a Jo¨rg Bergemann¶b and Antony R. Younga
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Matrix metalloproteinase 1 (MMP-1) is widely regarded as a biomarker of photoageing. We tested the
hypothesis that MMP-1 mRNA expression and erythema share a common action spectrum by
comparing the effects of erythemally equivalent doses of UVB, UVA1 and solar simulated radiation
(SSR) on acute MMP-1 mRNA expression in whole human skin in vivo. Our results show comparable
MMP-1 expression with all three spectra, which supports our hypothesis. The sharing of an action
spectrum implies common chromophores, one of which is likely to be DNA. We have previously shown
that all spectra that we used readily induce cyclobutane thymine dimers (T<>T) in human epidermis
in vivo but we lack quantitative data on damage to dermal DNA. This is important because we do not
know if dermal MMP-1 induction occurs via direct damage to the dermis, or indirectly via damage to
the epidermis. Our results show that UVB induces about 3 times more T<>T compared with
erythemally equivalent doses of UVA1, which is similar to our published epidermal data. This supports
previously published work that also implicates an unknown UVA1 chromophore for erythema and
MMP-1 induction. However, the distribution of the dermal DNA damage varies considerably with
spectrum. In the case of UVB it is primarily in the upper dermis, but with UVA1 it is evenly distributed.
Thus, irrespective of chromophores, MMP-1 induction by direct dermal damage by both spectra is
possible. The practical conclusions of our data are that the small (<5%) UVB content of solar UVR is
likely to be the main cause of photoageing, at least in terms of MMP-1 expression. Furthermore,
prevention of erythema by sunscreen use is likely to result in reduced MMP-1 expression.
Introduction
Photoageing and skin cancer are the normal long term conse-
quences of exposure to solar ultraviolet radiation (UVR: ~295–
400 nm), especially in sun sensitive skin types I and II. Skin
cancer is a major health problem and has been subject to
extensive epidemiological and basic research. There has been
relatively limited research into photoageing, even though this is
often associated with skin cancer, and mouse studies have shown
that neutrophil elastase deﬁcient hairless mice are resistant to
photoageing and UVR-induced squamous cell carcinoma (SCC),
suggesting a mechanistic link.1
The vast majority (>95%) of solar UVR is UVA (320–400 nm),
of which UVA1 (340–400 nm) is the major (~75%) component,
but action spectroscopy has shown that the much smaller (<5%)
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UVB (~295–320 nm) component is responsible for the majority
of DNA photodamage (thymine dimers; T<>T) in human skin
in vivo and sunburn;2 this has led to the conclusion that DNA is an
important chromophore for erythema. It is also widely accepted
that UVB is the main cause of skin cancer,3 though some have
advocated an important role for UVA, especially for malignant
melanoma.4,5 UVA1 is increasingly used in high dose phototherapy
for skin disorders6 and is typically the major spectral component
of tanning devices.7
Most research on the effects of UVR on skin in vivo has
focused on the epidermis because it is the target tissue for
photocarcinogenesis. The dermis is also an important target,
especially in the context of inﬂammation and photoageing.8 The
structural integrity and function of the dermis are dependent on
its extracellular matrix (ECM), which is mainly composed of type
I and type II collagen.9 Collagen turnover is mediated by matrix
metalloproteinases (MMP)10 and their inhibitors (TIMP).MMP-1
is highly induced byUVR in resident keratinocytes and ﬁbroblasts,
as well asMMP-3 andMMP-9 in vivo.10–12 Photoageing is thought
to be caused by UVR-induced hydrolysis of the dermal ECM that
is initiated by MMP-1; a blocking antibody to MMP-1 removed
95 ± 4% of collagenolytic activity fromUVR-exposed human skin,
strongly implicating MMP-1 as a major enzyme responsible for
collagen degradation in photoageing.13































































It is often stated without much evidence that UVA is more
important than UVB for photoageing as it penetrates deep into
the dermis, unlike UVB. Such statements ignore the possibility
that epidermally derived factors may inﬂuence dermal ECM, and
indeed there is evidence that cytokines/TNFa, readily induced by
UVR,14,15 can induceMMP synthesis.16,17 Furthermore, there have
been very few studies that have investigated UVR penetration of
the skin, and studies that have done this have used physical, rather
than biological techniques, often on disrupted isolated skin.18,19
There are no human data on the action spectrum for photoage-
ing. Mouse studies20 have suggested that the action spectrum
for elastosis, a hallmark of photoageing, is similar to that for
erythema, in whichUVB is 3–4 orders of magnitudemore effective
than UVA. Chronic UVA exposure in hairless mice is capable of
inducing photodamage like UVB21 and, given the high quantity of
UVA in sunlight, there is reason to believe that UVA could make
a signiﬁcant contribution to photoageing.22 One study evaluated
skin cancer and elastosis inmice exposed to narrowbandUVBand
UVA;20 UVB induced SCC and elastosis whereas UVA induced
elastosis only but was less effective than UVB.
The aim of this study was to test the hypothesis that UVR-
induced erythema andMMP-1mRNA induction share a common
action spectrum. We approached this by giving exposures from 3
UVR sources that resulted in equal erythemal responses observed
at 24 h after irradiation. The sources were UVB (300 nm), UVA1
and solar simulated radiation (SSR). If our hypothesis were
correct, we would predict comparable MMP-1 mRNA expression
with comparably effective erythemal exposures. In this context
we also assessed the expression of tissue inhibitor of matrix
metalloproteinase-1 (TIMP-1).
A common action spectrum for erythema and MMP-1 mRNA
induction would suggest common chromophores. There is indirect
human in vivo evidence that epidermal DNA is an important
chromophore for erythema,2 and in vitro and in vivo evidence that
DNA is a chromophore for the induction of MMP-1 mRNA and
protein.23 UVR-induced MMP-1 is expressed in the epidermis
and dermis at the mRNA and protein level.11,12 It is not known
whether the dermal mRNA induction is due to factors released
by the epidermal cells, or the result of direct UVR effects on
dermal cells, such as ﬁbroblasts. Little is known about dermal
DNA photodamage so we also investigated the effects of UVA1
and UVB on the induction and location of dermal T<>T and its
repair.
Results
UVA1, UVB and SSR induce comparable expression of MMP-1
mRNA
Fig. 1 shows the induction of mRNA MMP-1 expression by
(1a) UVA1 and (1b) UVB. A linear regression model showed
substantial dose-response effects for UVB and UVA1 and a
substantial subject level effect as can seen by the large inter-
person variation in the ﬁgures. Overall, the increase is 80.6
times higher (compared to baseline) with UVA1 and 34.3 times
higher with UVB, giving a ratio of 2.35 (95% CI 0.44 to 12.6,
p = 0.32) which is not signiﬁcantly different from 1. A non-
linear model that we used also allowed for arbitrary non-linear
effects of dose and this indicated a threshold of 1 MED for
Fig. 1 Effect of (a) UVA1 and (b) UVB on MMP-1 mRNA expression
in comparison with 2MED SSR. The horizontal bars represent median
values. A linear regression model showed a highly signiﬁcant effect of
UVA1 and UVB dose, but that these dose-response curves were not
signiﬁcantly different from each other.
a signiﬁcant effect for both spectra. The level of SSR-induced
mRNA expression is comparable in the two groups of volunteers
(p= 0.1) and comparisons of 2MEDSSR,UVBandUVA1 showed
no differences (p > 0.1).
UVA1 induces more TIMP-1 mRNA expression than UVB
Fig. 2 shows the induction of mRNA TIMP-1 expression by (2a)
UVA1and (2b)UVB.The inductionofTIMP-1 ismuch lower than
for MMP-1, as we have previously reported for SSR.12 The linear
model showed a signiﬁcant effect of dose for UVB and UVA1 but
there was no subject level effect. The overall increase for UVA1
was 2.2 and 1.5 for UVB from baseline, giving a ratio of 1.48 (95%
CI 1.09–2.01, p = 0.01), which means that UVA1 is signiﬁcantly
more effective than UVB at inducing TIMP-1 expression. The
level of SSR-induced mRNA expression is comparable in the two
groups of volunteers (p = 0.08). There is no difference between
2MED UVA1 and 2 MED SSR (p = 0.59), but signiﬁcantly more
TIMP-1 was induced with 2MED SSR compared with 2 MED
UVB (p = 0.03). The dose-response results and those from the 2
MED comparisons are consistent given that UVA1 is the major
component of SSR.































































Fig. 2 Effect of (a) UVA1 and (b) UVB on TIMP-1 mRNA expression
in comparison with 2 MED SSR. The horizontal bars represent median
values. A linear regression model showed a highly signiﬁcant effect of
UVA1 and UVB dose, with UVA1 being more effective than UVB.
The effect of dermal depth on UVA1 and UVB-induced T<>T
staining
Examples of epidermal and dermal T<>T staining for UVA1 and
UVB are shown in Fig. 3a and 3b, respectively. Fig. 4a and 4b
show the relationship between T<>T staining and depth from the
basal epidermis for UVA1 and UVB, respectively. The data show
the degree of T<>T is independent of depth (p = 0.53 for slope)
for UVA1, whereas there is a highly signiﬁcant (p = 0.0001 for
slope) loss of stain with depth with UVB.
Dose response and repair kinetics for dermal T<>T with UVA1
and UVB
Fig. 5 shows a dose-dependent increase in T<>T for UVA1 (slope
p = 0.009) andUVB (slope p< 0.0001). Themaximal damage with
UVB is about 3 fold greater that UVA1, which is similar to what
we have reported in the epidermis.24 Fig. 6 shows that repair of
dermal T<>T is slow. The slope for UVA1 is signiﬁcant (p = 0.03)
but that for UVB is not signiﬁcant (p = 0.62).
Discussion
We have previously shown that SSR induced MMP-1 mRNA in a
dose dependent way with maximal expression at 24 h;12 with high
Fig. 3 Staining of dermal nuclei for T<>T, 3 notionalMED (a)UVA1 (b)
UVB.The red stain is indicative of T<>T.Biopsieswere taken immediately
after exposure. See Tewari et al.24 for quantiﬁcation of epidermal data that
allows comparisons with Fig. 4, 5 and 6.
levels following 2 MED. In contrast, the effect on TIMP-1 was
very modest. Comparable levels of mRNA expression of MMP-1
were seen in the epidermis and dermis with SSR, whereas TIMP-1
was only seen in the dermis.12
In the current study, our results are for mRNA only, but other
groups have shown that UVB also induces MMP-1 protein and
its activity in the dermis and epidermis.10,11 We used 2MED SSR
as a positive control in UVB and UVA1 dose-response studies
with comparable erythemal exposure. Our data show considerable
inter-personal variation in MMP-1 mRNA expression, which has
been reported by us12 and others,23 one reason for which may
be different single-nucleotide polymorphisms (SNPs) that may
inﬂuence gene transcription.25 However, the dose-response curves
(as MED fractions) for UVB and UVA1-induced MMP-1 were
not signiﬁcantly different, and there was no statistical difference
between MMP-1 mRNA expression levels with 2MED by three
different spectra. This provides evidence that the action spectra
for erythema and MMP-1 mRNA induction are the same or very
similar. However, it should be noted that the conﬁdence limits on































































Fig. 4 Inﬂuence of dermal depthonT<>Tstaining after 3 notionalMED
(a) UVA1 and (b) UVB. A total 50 nuclei for each spectrumwere examined
from 12 volunteers. Biopsies taken immediately after exposure and the
data have been analyzed by linear regression and p values refer to slopes
of regression lines. The mean T<>T staining (vertical axis) represents the
“red intensity” of each nucleus. This is calculated from the average intensity
of each pixel within a nucleus and corresponds to the amount of T<>T
present.
Fig. 5 Dose response for dermal T<>T induced by UVA1 and UVB.
Both slopes are signiﬁcant (p < 0.01). The mean T<>T staining (vertical
axis) represents the average “red intensity” of nuclei of a given volunteer
at a given dose.
which this conclusion is based are high, due to large inter-person
variability.
This similarity of action spectra suggests common chro-
mophores. Two main photochemical events have been proposed
for the induction of MMP-1: i) the formation of cyclobutane
pyrimidine dimers (CPD)23 and ii) UVR induced reactive oxygen
species (ROS), primarily by UVA via chromophores that have yet
to be identiﬁed.26 Until recently, DNA was primarily regarded as
Fig. 6 Repair of dermal T<>T after exposure to 3 notional MEDUVA1
and UVB. The slope (p 0.03) of UVA1 is signiﬁcant, but this is not the case
for UVB (p = 0.62). The mean T<>T staining (vertical axis) represents
the average “red intensity” of the nuclei of a given volunteer at a given
post-irradiation time.
a UVB chromophore, but studies show that UVA1 induces more
CPD, especially T<>T, than expected.27,28 To date, the focus on
UVA has primarily been on its ability to generate ROS. This yields
oxidized bases, such as 8-oxo-7,8-dihydro-guanine (8-oxoGua),
and DNA strand breaks.29 DNA, resulting in the formation
of CPD, has been proposed as an important chromophore for
erythema2 and TNFa15 (which may initiate MMP-1 induction).
Laser action spectroscopy for human erythema has identiﬁed
a minor independent UVA1 absorbing chromophore.30 UVB-
induced erythema is oxygen independent but UVA1 induced
erythema requires oxygen.31 Overall, these data suggest a role
for ROS in UVA1-induced erythema. Thus, our MMP-1 data are
consistent with the hypothesis that DNA and an unknown UVA1
absorbing molecule, that probably generates ROS, are shared
chromophores for erythema and MMP-1 induction. Support for
an important role for DNA comes from human skin in vivo studies
in which skin was exposed to 1 MED UVB. Post-irradiation
treatment with an activated CPD photolyase reduced MMP-
1 mRNA expression as well as epidermal and dermal MMP-1
protein visualized by immunohistology.23
Interpreting action spectroscopy in the skin is difﬁcult because
UVR penetration is wavelength dependent and the location of the
chromophore and the biological outcome of its activation may
be different. Erythema and collagen degradation by MMP-1 are
both dermal events that are possibly initiated by photochemical
activity in the epidermis; for example, the transfer of media from
UVB-irradiated human keratinocytes induces MMP-1 mRNA
and protein expression in unirradiated human ﬁbroblasts.23 The
dose-range that we used in the MMP-1 studies readily induces
dermal T<>T, especially with UVB as shown in Fig. 5, but Fig. 3
and 4 show that the location of the damage is spectrally dependent.
UVB-induced lesions are focused in the upper dermis whereas
UVA1 induced lesions, although fewer in number (characterised by
less red intensity), are evenly spread throughout the dermis. Thus,
our data suggest that direct dermal UVR-induced expression of
MMP-1 mRNA is possible. Enhanced repair of CPD in skin cells
in vitro and in vivo has been shown to inhibit MMP-1 mRNA and
protein.23 We have previously shown that epidermal repair of SSR
and UVA1-induced T<>T is slow 24,32,33 and Fig. 6 shows that this
is also the case in the dermis; indeed there was no evidence for the































































repair of UVB-induced lesions. Thus persistent lesions may well
initiate dermal MMP-1 expression.
As with SSR, the effects of UVB and UVA1 on TIMP-1, which
is only expressed in the dermis, are relatively modest.12 However,
there was a signiﬁcant dose-response with UVB and UVA1 but
the effects of the latter were signiﬁcantly greater than the former.
In addition, 2 MED SSR was signiﬁcantly more effective than 2
MED UVB, whereas the effects of 2 MED UVA1 and 2 MED
SSR (mostly UVA1) were the same. One reason for the greater
efﬁcacy ofUVA1may be its better penetration into the dermis. The
relationship between UVR-induced MMP-1 and TIMP-1 mRNA
and protein/activity is not known.
It is often stated that UVA is the main cause of photoageing.
However, irrespective of chromophores, if the SSR spectrum that
we used is weighted with the CIE action spectrum for erythema,34
we can state that 87% ofMMP-1 induction is due toUVB (deﬁned
as 280–320 nm). A comparable weighting for London (51◦N)
noon summer sun would result in 80% ofMMP-1 induction being
due to UVB. Even assuming that our hypothesis is false, and
that UVA1 is 2.35 times more effective than UVB at comparable
erythemal exposures, we would still conclude that solar UVB is
the main cause of photoageing. These conclusions are based on
acute exposures and do not account for any photoadaptation,
which has been reported after repeat exposure studies for some
endpoints.35 An action spectrum for solar elastosis in hairless mice
was also similar to that for human erythema,36 which would also
implicate UVB as the most important spectral region in practice.
Most action spectra for photoageing markers in mice have shown
UVB to bemore important thanUVAapart from skin “sagging”.22
Sunscreens inhibit erythema, as measured by their sun pro-
tection factors (SPF). Comparable SPFs can be obtained with
different ratios of UVB:UVA protection, which can predict
protection from SSR-induced epidermal T<>T.37 Our results
suggest that the inhibition of erythema by sunscreen use of a
given labelled SPF should comparably inhibit MMP-1 expression.
However, we have also reported that SPF in practice will decrease
with lower solar UVB content (dependent on latitude, time of day,
etc) with a primarily UVB sunscreen.38 This is not the case with
broad spectrum sunscreens in which actual SPF is independent of
solar UVB content. Overall, it is better to have a robust index of
protection, and we therefore advocate the use of broad spectrum
protection with comparable levels of UVB and UVA protection.
Conclusions
Although we have not done a conventional action spectrum
study with dose-response curves at different monochromatic
wavelengths, our analyses suggests that the action spectra for
erythema and acuteMMP-1mRNA expression are the same. This
suggests common chromophores and we propose DNA and an
unknown UVA1 absorber that may mediate its effects by ROS.
In contrast, the action spectra for erythema and TIMP-1 mRNA
expression are different, with UVA1 being relatively more effective
than UVB. This could mean that the chromophores for MMP-1
and TIMP-1 are different, but it could also reﬂect the different
location of the chromophores within the skin.
Maximal ambient exposure during a clear sky summer’s day in
the UK is about 45 standard erythema doses (SED), of which the
UVA1 contribution is approximately 7%; equivalent to 3 SED or
~1 MED in a skin type I/II person.39 Thus, assuming that the
action spectra for erythema andMMP-1 induction are similar, the
UVA1 contribution to photoageing in practice is likely to beminor.
We can conclude that solarUVB is themain cause of photoageing.
Experimental
Volunteers
The studies were approved by the St Thomas’ Hospital, London,
UK Ethics Committee (Ref: EC00/006 and Ref: 09/H0802/98)
Table 1 Volunteer demographics and just perceptibleMED forMMP-1/TIMP-1 studies. 95.1% of the EEE of the UVA1 source was UVA1, 4.1%UVA2
and 0.8% UVB. In the case of SSR 87.1% EEE was UVB, 5.1% UVA1 and 7.8% UVA2. There was no signiﬁcant difference in age (p = 0.10) or SSR
MED (p = 0.10) between the UVA1 and UVB groups. 4(25%) volunteers were smokers, but this did not have an impact on control (i.e. no UVR) MMP-1
expression (p = 0.17)
Study Skin type Sex Age SSR MED (J cm-2) UVA1 MED (J cm-2)
UVA1 and SSR I F 19 5.1 100
I F 33 2.9 25
I M 36 4.9 70.7
II F 33 5.8 50
I M 35 4.9 35.4
II F 19 5.1 100
Totals and mean ± SD 4I + 2II 2M + 4F 29.3 ± 7.7 4.8 ± 0.97 63.5 ± 32.2
Study Skin type Sex Age SSR MED (J cm-2) UVB MED (mJ cm-2)
UVB and SSR II M 26 6.1 14
II M 22 6.1 20
II F 22 6.1 28
I/II M 22 3.9 28
II M 27 4.9 40
I/II M 24 6.1 14
II M 31 5.3 40
II F 29 3.9 28
II F 21 4.9 20
II M 20 3.9 14
Totals and mean ± SD 2I/II +
8II
7M + 3F 24.4 ± 3.7 5.1 ± 0.98 24.6 ± 9.9































































Table 2 Volunteer demographics and just perceptible MED for dose-response and time-course T<>T studies. 99.3% of the erythemally effective energy
(EEE) of the UVA1 source was UVA1 and 0.7% was UVA2. There was no signiﬁcant different in age (p = 0.89) between the two study groups. The mean
UVA1 MED in the dose-response group was higher than in the time-course group (p = 0.03) but there was no difference in the UVB MED (p = 0.40)
Study Skin type Sex Age UVA1 MED (J cm-2) UVB MED (mJ cm-2)
Dose-response I F 28 48.8 30.0
I F 25 48.8 30.0
II M 20 48.8 30.0
II F 21 53.0 30.0
I F 22 48.8 23.0
I M 34 61.1 19.0
Totals and mean ± SD 4I + 2II 2M + 4F 25 ± 5.3 51.6 ± 4.9 27.0 ± 4.8
Time-course I F 28 31.3 19
I F 28 31.3 30
I M 22 48.8 23
II F 24 31.3 30
I M 23 48.8 23
II F 23 48.8 23
Totals and mean ± SD 4I + 2II 2M + 4F 24.7 ± 2.7 40.1 ± 9.6 24.7 ± 4.4
Combined 8I + 4II 4M + 8F 24.8 ± 4.0 45.8 ± 9.4 25.8 ± 4.6
and done in accordance with the declaration of Helsinki. Normal
healthy skin type I–II young adults gave written informed consent
before taking part. The demographic details of the 16 volunteers
for the MMP-1/TIMP-1 studies and the 12 volunteers for the
T<>T studies are similar and are shown in Tables 1 and 2,
respectively.
UVR sources and dosimetry
The emission spectra of the UVR sources are shown in Fig. 7
(UVB1 source forMMP-1/TIMP-1 data, UVB2 for T<>T data).
Thesewere determinedwith aDM150BCdouble-monochromator
spectroradiometer (Bentham Instruments, Reading, UK) using
an integration sphere and gratings blazed at 250 nm. The
spectroradiometer was calibrated against national UK standards.
Fig. 7 Emission spectra of the sources used. UVB1 corresponds to the
spectrum for Fig. 1–2 andUVB2 corresponds to the spectrum for Fig. 3–6.
SSR was produced by an Oriel solar simulator (Model 81292,
L.O.T Oriel, Leatherhead, UK) with a 1-kW xenon arc lamp with
two dichroic mirrors, a collimator, and a 1-mm WG320 ﬁlter.
Irradiance was routinely measured by a wide-band thermopile
radiometer (Medical Physics, Dryburn Hospital, Durham, UK)
that had been calibrated against the spectroradiometric measure-
ments. This was typically 15 mW cm-2 at skin surface (11 cm from
source).
TwoUVA1 sourceswere used. For theMMP-1/TIMP-1 studies,
this was a UVASun 2000 (Mutzhas, Munich, Germany). Routine
dosimetry was done with a radiometer (Model IL442A (with a
UVA sensor), International Light technologies, Massachusetts,
USA), after calibration against the spectroradiometric measure-
ments. Irradiance was 70–75 mW cm-2 at the skin surface (11 cm
from the source). For the T<>T studies, this was a Sellamed 3000
Dr Sellmeier (Sellas, Gevelsberg, Germany) phototherapy device.
Irradiance was routinely measured with a radiometer (Model
IL1400A, International Light technologies,Massachusetts,USA),
after calibration against the spectroradiometric measurements,
and was typically ~74 mW cm-2 at skin surface (24.5 cm from
source).
NarrowbandUVB (300nm)was producedby amonochromator
(L.O.T. Oriel, Newport, USA: 1-kW xenon arc; grating blazed at
250 nm; slits set for 3 nm full width at half maximum (FWHM)
bandwidth) and 2.5 nm FWHM UVB was delivered with a liquid
light guide (Oriel), exit diameter 5 mm, in direct contact with
the skin. In the studies described in Table 1, irradiance (typi-
cally 0.3mW cm-2) was measured with a wide-band thermopile
radiometer (Medical Physics, Dryburn Hospital, Durham, UK).
In the case of studies in Table 2, irradiance (typically ~0.5 mW
cm-2) was measured with an SEL623 thermopile (International
Light Technologies,Massachusetts,USA) attached to an IL1400A
photometer calibrated by the United Kingdom Accreditation





2 for the MMP-1/TIMP-1 study and ¥1.25, for
the T<>T study) series of doses was given over 1 cm2 areas of
previously unexposed buttock skin or over the 5 mm exit diameter
of the liquid light guide in the case of 300 nm. A visual assessment
of the exposed sites was made 24 h after exposure and the ‘just
perceptibleMED’was determined as it is amore reliable threshold
endpoint than ‘erythema with a deﬁnite border’.40
Previously unirradiated buttock skin of the MMP-1/TIMP-1
study volunteers (Table 1) was given 0.2, 0.5, 1 and 2 MED of
UVB or UVA and 2 MED of SSR, based on their individual































































MED and 4 mm punch biopsies were taken 24 h after exposure.
This time was based on our previous time-course studies with SSR
for MMP-1 and TIMP-1.12
The dose protocols in the T<>T studies were based on
“notional MED”. These were derived from the MED from 3
individuals: mean values 48.8 J (SD ± 0) cm-2 for UVA1 and
30.0 (SD ± 0) mJ cm-2 for UVB and the mean MEDs given
in Table 2 were within 1–2 SD of these values. Table 2 shows
the demographics of the volunteers in the dose response and
repair studies. In the former, 6 volunteers were given 0.5, 1.5 and
3 notional MED of UVB and UVA1 on previously unexposed
buttock skin and biopsies were taken immediately afterwards. In
the latter, 6 volunteers were given 3 notional MED of UVA1 and
UVB and biopsies taken at 3 time-points from: immediate, 3, 6, 24
and 48 h (times varied from person to person because of ethical
restrictions: all had biopsies at 0 and 24 h, except for 2 UVB sites
on 2 volunteers. A non-irradiated control biopsy was taken from
all 12 volunteers).
Immunostaining and image analysis
Full details are given in our previous studies.24 Brieﬂy 5 mm
parafﬁn sections were stained with the monoclonal antibody
incubation: CPD TDM-2 (CosmoBio, Tokyo, Japan) at 1 : 2000
(antibody speciﬁcity to UVR induced T<>T 41) and isotype
control IgG2a (DAKO, Cambridge, UK) for 90 min at room
temperature. Fluorescent imaging was done for AlexaFluor555
(red) and DAPI (nuclear DNA stain; blue) with a Zeiss Axiophot
microscope (Harpenden, UK), Nikon DS-U2 camera (Kingston-
upon-Thames, UK) with ¥20 magniﬁcation (and ¥1.25 eyepiece
objective). Using NIS elements BR v3 software package, images
acquired in 2560 ¥ 1920 format and exposed to 20S (gain 1.40¥
for AlexaFluor555 with 1.5 s exposure, gain 1.40¥ for DAPI).
The contrast setting was the same for all images. DAPI stained
nuclei were gated and mean red intensity (Alexa Fluor 555)
assessed within each of the nuclei in the dermis.Mean background
intensity from the unirradiated control was subtracted from the
irradiated samples to control for nonspeciﬁc nuclear staining
(typically for T<>:T: 10.0 ± 6.4(SD) as previously reported33).
Settings for nuclei capture (circularity and diameter of nuclei)
were kept constant, and sections subjectively assessed. It was not
possible to stain and assess all slides in a single batch. To assess
the reproducibility of the techniques, the same positive controls
(3 MED UVB and UVA1) were processed with each staining and
image analysis run, as well as a non-irradiated control and an
isotype control in each case.
RT-PCR
Weused the TaqManTM method, with probes forMMP-1, TIMP-1
andGAPDH(housekeeping), as described indetail in our previous
studies.12 RNA was extracted from whole skin 4 mm punch
biopsies. The raw CT data were converted using the comparative
DDCT method.
Statistics
Statistical analyses were done using Stata (StataCorp LP, College
Station, Texas) using a mixed-effects random effects maximum
likelihoodmodel (REML) allowing for grouping by subject. Log10
gene expression datawere analysed using a simple linear regression
dose response to UVB and UVA1, as well as a non-linear model.
The latter allowed for possible arbitrary non-linear effects of dose
by ﬁtting dummy variables to account for the four-dose (MED
fraction) levels. The two models gave very similar results, so
unless otherwise stated the results are based on the linear model.
Graphpad Prism v4 was used for two-tailed paired and unpaired
(as appropriate) T tests to compare volunteers’ ages, MED and
MMP-1 and TIMP-1 mRNA expression. In the case of data from
Fig. 1, 2 MED UVB and 2 MED UVA were compared by using
the individual volunteer SSR D values. Graphpad Prism v4 was
also used for linear regression analysis of the T<>T data.
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UVA1 Induces Cyclobutane Pyrimidine Dimers
but Not 6-4 Photoproducts in Human Skin In Vivo
Angela Tewari1, Robert P. Sarkany1 and Antony R. Young1
UVB readily induces cyclobutane pyrimidine dimers, mainly thymine dimers (TTs), and pyrimidine (6-4)
pyrimidone photoproducts (6-4PPs) in DNA. These lesions result in ‘‘UVB signature mutations’’ found in skin
cancers. We have investigated the induction of TTs and 6-4PPs in human skin in vivo by broadband UVA1, and
have compared this with comparable erythemal doses of monochromatic UVB (300 nm). In vitro and ex vivo
studies have shown the production of TTs, without 6-4PPs, by UVA1. We show that UVA1 induces TTs, without
6-4PPs, in the epidermis of healthy volunteers in vivo, whereas UVB induced both photoproducts. UVB induced
more TTs than UVA1 for the same level of erythema. The level of UVA1-induced TTs increased with epidermal
depth in contrast to a decrease that was seen with UVB. UVA1- and UVB-induced TTs were repaired in epidermal
cells at a similar rate. The mechanism by which UVA1 induces TTs is unknown, but a lack of intra-individual
correlation between our subjects’ UVB and UVA1 minimal erythema doses implies that UVA1 and UVB erythema
occur by different mechanisms. Our data suggest that UVA1 may be more carcinogenic than has previously
been thought.
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INTRODUCTION
Solar UVR is the main cause of skin cancer (Armstrong and
Kricker, 2001), and UVB (290–320nm) has generally been
thought of as the major carcinogen. However, UVA
(320–400nm) is 20 times more abundant than UVB in
terrestrial UVR, and around 75% of solar UVA is UVA1
(340–400nm). On average, an indoor worker is exposed to
1,500 J cm2 UVA exposure per year (Diffey, 1996). UVA is
the predominant waveband emitted by sunbeds despite
recent classification as a carcinogen to humans (El Ghissassi
et al., 2009), and UVA1 is increasingly used for phototherapy
for skin diseases (Dawe, 2003; York and Jacobe, 2010).
Although the action spectrum for induction of squamous
cell carcinoma in mice has a major UVB peak, there is also
a smaller peak in the UVA1 region (de Gruijl et al., 1993).
It has been reported that UVA causes melanoma precursors
in Monodelphis domestica (Ley, 1997), and melanoma in
Xiphophorus fish (Setlow, 1974; Setlow et al., 1993), but this
has been recently refuted (Mitchell et al., 2010). A role for
UVA in human skin cancer has been proposed (Drobetsky
et al., 1995; Agar et al., 2004), which is supported by some
epidemiological data for melanoma (Garland et al., 2003).
DNA absorbs UVB, and UVA to a smaller degree (Setlow,
1974; Sutherland and Griffin, 1981; Young et al., 1996).
Absorption of UVB causes the formation of cyclobutane
pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone
photoproducts (6-4PPs). These lesions are repaired by the
excision repair pathway, but when unrepaired can form the
classic ‘‘UVB signature’’ mutations: C-T or CC-TT (Ziegler
et al., 1996), which are found in skin cancers.
UVA is also mutagenic, but its genetic effects have
been mainly attributed to UVA excitation of non-DNA
chromophores, resulting in reactive oxygen species-induced
base oxidation to form products such as 8-oxo-7,8-dihydro-
guanine, as well as DNA single-strand breaks (Cadet et al.,
2009). UVB also induces 8-oxo-7,8-dihydroguanine (Ravanat
et al., 2001).
Unexpectedly, studies in cultured cells and whole explant
skin have shown that CPDs are induced by UVA1 in larger
amounts than oxidatively generated lesions (Douki et al.,
2003; Mouret et al., 2006). In addition, the classic CPD-
induced ‘‘UVB signature’’ mutation C:G-T:A has been
found to be the most common mutation induced by UVA
(41% of mutations; Rochette et al., 2003; Kappes et al.,
2006). This has raised doubts about the relative mutagenicity
and carcinogenicity of UVA and UVB in human skin as the
‘‘UVB signature’’ mutations found in skin cancers, including
melanoma, may also be caused by UVA.
Interestingly, unlike UVB, UVA1 produces cyclobutane
thymine dimers (TTs) in vitro and ex vivo but few CC, CT, and
no 6-4PP or their Dewar isomers (Douki et al., 2003; Mouret
et al., 2006). An indirect photosensitized triplet energy
transfer mechanism with UVA1 was originally suggested to
explain this (Cadet et al., 2009), but this is no longer thought
& 2011 The Society for Investigative Dermatology www.jidonline.org 1
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to be the case (see discussion). UVA1 induction of CPDs has
been studied in vitro and ex vivo (Mouret et al., 2006).
However, the important issue of the role of UVA1 in CPD
formation in vivo has not been studied.
We therefore aimed to measure the formation of TTs and
6-4PPs in humans in vivo by comparable erythemal doses
of UVA1 and UVB (300nm). Erythema was used as the
comparator because it is a key response to UV damage, and
human action spectroscopy has specifically implicated TT
formation as a trigger for erythema (Young et al., 1998). In
addition to induction, we assessed the repair of photoproducts
with UVA1 and UVB in vivo, because it has been reported
that TT repair is slower ex vivo after UVA1 than UVB, which is
relevant to the formation of mutations (Mouret et al., 2006).
RESULTS
Erythema
Comparable levels of erythema were achieved for the
same multiple of the notional minimal erythema dose
(MED; see Material and Methods for definition) for both
UVB and UVA1 (Figure 1a). This is a fixed physical dose
based on the mean MED of three individuals (see Materials
and Methods). The slope for UVB was steeper than that for
UVA1 (P¼ 0.0006); there was no correlation between a given
individual’s UVB and UVA1 MED (Figure 1b).
Epidermal localization of TT and quantification of depth of
staining
Figure 2a and b shows anti-TT antibody staining after UVA1
and UVB, immediately after exposure to three notional








































Figure 1. UVA1- and UVB-induced erythema. (a) Quantitative erythema
dose responses for UVB (300 nm) and UVA1. These data were obtained from
the individual MED assessments series and are plotted against notional MED
fractions. The slopes for both spectra are highly significant (Po0.001).
(b) Lack of relationship between a given individual’s UVB and UVA1 MED,
n¼ 12: note numbers on the figure correspond to the number of volunteers























Figure 2. Immunostaining of UV-irradiated epidermis. Typical microscope
images of (a) UVA1 and (b) UVB assessed immediately after exposure to three
notional MEDs. Note more intense red (cyclobutane thymine dimer, TT)
staining at basal epidermis with UVA1 and more intense red staining in upper
epidermis with UVB. (c) Quantification of TT staining on a nucleus-per-
nucleus basis with epidermal depth for 12 volunteers. The lines were
generated by linear regression and both slopes were significant (Pp0.01).
Bars¼ 50 mm (a) and 50 mm (b). MED, minimal erythema dose.
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MEDs. All isotype controls were negative (data not shown).
UVA1 caused more intense staining in the lower epidermis,
whereas UVB led to more intense upper epidermal staining.
We quantified the relationship between staining intensity and
epidermal depth by linear regression analysis to a depth of
10 nuclei (Figure 2c, n¼12). With UVB there was a
significant (P¼0.01) reduction in TT staining with increased
epidermal depth. In contrast, for UVA1, there was a
significant (Po0.001) increase in staining with increased
depth.
Dose dependence of photoproduct formation
For a given multiple of notional MED, UVA1 produced fewer
TTs than UVB (Figure 3): the slope for UVB is 3.4-fold steeper
than that with UVA1 (P¼0.00096). Immediately after
exposure to UVB, 4.4 times more TTs were found than with
a comparable dose of UVA1 (Figure 4a). 6-4PPs are induced
by UVB in a dose-dependent manner but no 6-4PPs at all are
induced with UVA1 at any dose in vivo (Figure 3).
Repair kinetics of CPD and 6-4PP
The slopes for the loss of UVB- and UVA1-induced TTs with
time are not significantly different (P¼0.71). By 48 hours,
the majority of the UVA1-induced TTs had disappeared
(Figure 4a). However, UVB-induced TTs are still present
because 3MED UVB induces more TTs than 3MED UVA1.
Repair of UVB-induced 6-4PPs was very fast (Figure 4b), as
we previously reported in vivo (Young et al., 1996; Bykov
et al., 1999) for UVB using solar-simulated radiation.
The comparable repair rate for TTs induced by both
spectra suggests that the same host repair machinery is used.
Our data are different from published ex vivo studies (Mouret
et al., 2006) that suggest that UVB-induced TTs were repaired
faster than those induced by UVA1.
DISCUSSION
We have shown that UVA1 readily induces TTs but not
6-4PPs in human skin in vivo. To our knowledge this is
previously unreported in humans in vivo, as is the compar-
ison of the effects of UVA1 to erythemally equivalent doses of
UVB. Our maximum doses for UVB (300 nm) and UVA1
were 90mJ cm2 and 148 J cm2 compared with 20mJ cm2
and 200 J cm2, respectively, used in the previous study using
ex vivo skin (Mouret et al., 2006). As the UVB in that study
was primarily at 312 nm, those exposures would have been
sub-erythemal as MEDs for skin type I/II at 312 nm are
200–300mJ cm2 (Palmer et al., 2006); thus, previous ex vivo
studies have not used UVA1 and UVB doses with comparable
erythemal potential. Erythema is widely accepted as the
biologically relevant measure of acute UVR exposure (e.g., a
sunscreen’s sun protection factor is measured by its protective
effect against erythema). Our data show comparable levels
of erythema for UVA1 and UVB for a given notional
MED fraction (Figure 1a), although the dose response for
UVB is significantly steeper. The absence of any correlation
(Figure 1b) between an individual’s UVB and UVA1 MED
suggests that UVA1 erythema may involve a different
mechanism. Epidermal DNA is thought to be an important
chromophore for UVB erythema induction (Young et al.,
1998). When it produces approximately the same intensity of
erythema, UVA1 induces 3- to 4-fold fewer TTs than UVB.
This implies that other chromophores may be important for
UVA1 erythema. The second UVA1 peak identified in one
action spectrum of human erythema also points to the
100 CPD    300 nm
6-4PP  300 nm
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Figure 3. Dose responses for cyclobutane thymine dimer and 6-4PP with
UVB (300 nm) and UVA1. The lines were generated by linear regression.
Note: in one case the volunteer was inadvertently given a different dose
series. 6-4PP, pyrimidine (6-4) pyrimidone photoproduct; CPD, cyclobutane





































Figure 4. Repair of epidermal photolesions. (a) Repair kinetics of
cyclobutane thymine dimer and (b) pyrimidine (6-4) pyrimidone
photoproduct after three notional MEDs UVB (300 nm) and UVA1.
The lines were generated by linear regression and the slopes are not
significantly different (P¼ 0.71).
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chromophores possibly being different for UVA1 (Anders
et al., 1995). UVB-induced erythema is oxygen independent,
whereas UVA erythema is oxygen dependent (Auletta et al.,
1986), implying a role for reactive oxygen species in UVA
erythema.
The majority of CPDs induced by UVA1 are TTs (Mouret
et al., 2006), and we show the presence of UVA1-induced
TTs using an antibody technique, although it is possible that
some cytosine-containing CPDs were also induced because
the antibody is not 100% TT specific (see Materials and
Methods). TTs are much less mutagenic than CC and CT
(Pfeifer et al., 2005), but are more persistent in human skin
in vivo because of slower repair than CC (Bykov et al., 1999;
Xu et al., 2000). However, in vitro studies have shown that
UVA1 readily induces C-T transitions, widely associated
with UVB-induced CPDs (Kappes et al., 2006; Runger and
Kappes, 2008), which is probably the result of UVA1-induced
cytosine-containing CPDs (Mouret et al., 2006).
An ex vivo study found that UVA1-induced TTs are
repaired less well than those induced by UVB (Mouret et al.,
2006), as with our study there were about four times more
TTs with UVB compared with UVA1. Our repair kinetics data
show that this is not the case in vivo. UVA1-induced TTs
were repaired at the same rate as those induced by UVB
(Figure 4a). As UVA1 produced fewer CPDs than UVB, repair
was almost complete after 48 hours. These data suggest that
the degree of initial DNA damage, from an acute exposure,
determines the amount of damage that remains a day or
two later. However, in vitro studies suggest that the rate of
CPD repair from a single exposure may decrease with
higher doses, possibly resulting from damage to the DNA
repair machinery (Greinert et al., 2000; Courdavault
et al., 2004). The situation may be different with repeated
daily sub-erythemal exposure, which results in the accumu-
lation of TTs (Young et al., 2007). Limited evidence exists
that repeated sub-erythemal exposure enhances TT repair
in skin types III/IV but not in I/II (Sheehan et al., 2002).
In contrast, mice exposed to chronic low-dose UVB show
decreased CPD repair in response to a challenge dose
(Mitchell et al., 1999).
The photochemical mechanism by which UVA1 selec-
tively induces TTs remains unknown. UVA activation of some
photosensitizers such as fluoroquinolones (Makinen et al.,
1997) and carprofen (Robinson et al., 2010) can induce
CPDs in vitro, suggesting that unidentified endogenous
photosensitizers might have a role in the induction of TTs
by UVA1. However, double-stranded base sequences
(e.g., dA.dT) increase UVA absorption compared with the
same monomeric molecules (Mouret et al., 2010) and UVA
induction of TTs seems to be due to a direct photochemical
mechanism without involvement of a cellular photosensitizer
(Jiang et al., 2009; Mouret et al., 2010). The lack of 6-4PPs
with UVA suggests that the photochemical process is different
from that with UVB and UVC; however, this remains to be
elucidated.
It is intriguing that UVB predominantly induced TTs in the
superficial epidermis, whereas UVA1-induced TTs were more
prominent in the lower epidermis (Figure 2). A similar depth
effect has been found in staining for p53 protein expression at
24 hours (Campbell et al., 1993) with UVB (300±5 nm) and
UVA (350±30 nm). There are very few data on the optical
properties of skin in the UVR region. Such photons may be
absorbed by chromophores (e.g., DNA) or scattered by the
epidermis and dermis in a forward or backward direction,
and scattering may be considered more important than
absorption (Anderson and Parrish, 1981; van Gemert et al.,
1989). Overall, skin chromophores absorb primarily in the
UVB region. Back scattering results in remittance (a type of
‘‘reflection’’), which provides additional opportunity for
chromophore absorption during the return pathway. Dermal
remittance increases between 300 and 400nm (Anderson
and Parrish, 1981). Thus, it is possible that the higher
number of UVA1-induced To4T seen in the basal layer is
due to dermal back scatter (e.g., from collagen), as well as
epidermal forward scatter (Bruls and van der Leun, 1984).
Irrespective of any mutagenic potential for TTs, our data
suggest that UVA1 preferentially targets the stem cell-
containing basal layer. This may be significant for skin
cancer because more UVA fingerprint mutations are found in
the basal layer compared with the suprabasal layer in
squamous cell carcinomas and actinic keratoses (Agar
et al., 2004). Furthermore, studies on engineered human
skin show that, in contrast to UVB, UVA-induced muta-
tions were mainly located in the basal layer (Huang et al.,
2009).
In summary, we have demonstrated that erythemally
equivalent doses of UVA1 and UVB induce TTs in human
buttock skin in vivo, but that 6-4PPs are induced by UVB
only. UVB induced more TTs than UVA1 for a given
erythemal exposure. This, along with the lack of correlation
between UVB and UVA1 MED, adds support to the
hypothesis that the chromophores and the mechanism for
UVB and UVA1 erythema are different, although presumably
TTs contribute to UVA1 erythema. Our data suggest that the
basal layer is particularly vulnerable to UVA1-induced
damage and this is supported by some mutagenesis studies.
This has implications for public health policies, particularly
the need for broader waveband population photoprotection.
MATERIALS AND METHODS
Irradiation
UVR sources and dosimetry. Emission spectra and irradiances of
the UVA1 and UVB sources were determined with a DM150BC
double-monochromator spectroradiometer (Bentham Instruments,
Reading, UK) using an integration sphere and gratings blazed at
250 nm (see Figure 5). The UVA1 source was a Sellamed 3000
Dr Sellmeier (Sellas, Gevelsberg, Germany) irradiation device.
Irradiance was routinely measured with a radiometer (Model
IL1400A, International Light Technologies, Peabody, MA), after
calibration against the spectroradiometric measurements, and was
typically about 74mWcm2 at the skin surface, which was 24.5 cm
from the source. Narrowband UVB (300 nm) was produced by a
monochromator (Oriel, Irvine, CA: 1-kW xenon arc; grating blazed
at 250 nm; slits set for 3 nm full width at half maximum bandwidth).
UVB was delivered with a liquid light guide (Oriel), with an exit
diameter of 5mm, in direct contact with the skin. Irradiance
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(B0.5mWcm2) was measured with an SEL623 thermopile (Inter-
national Light Technologies) attached to an IL1400A radiometer
(details as above; detector and meter calibrated by the United
Kingdom Accreditation Service-accredited Guy’s and St Thomas’
Hospitals Trust UVR laboratory).
Volunteers. The studies were approved by the St Thomas’ Hospital,
London, UK, Ethics Committee (ref: 09/H0802/98), and conducted in
accordance with the Declaration of Helsinki Principles. The details
of the 12 healthy skin type I/II (Fitzpatrick, 1988) volunteers are
shown in Table 1. Participants gave written informed consent before
taking part in the study.
Irradiation protocol. A geometric ( 1.25) series of eight doses
was given over 1 cm2 areas of previously unexposed buttock skin.
A visual assessment of the exposed sites was made 24 hours after
exposure and the ‘‘just perceptible MED’’ was determined, a more
reliable threshold end point than ‘‘erythema with a definite border’’
(Quinn et al., 1994). Quantitative reflective spectroscopy to quantify
erythema (erythema meter, Dia-Stron, Andover, UK) was carried out
three times per test site per volunteer, and the mean of the three
measurements calculated. The difference between the measurement
from the test site and that from an adjacent nonirradiated control site
is the D erythema index value.
MEDs were measured in three individuals: mean values 30.0
(SD±0)mJ cm2 for UVB and 48.8 (SD±0) J cm2 for UVA1. These
were defined as the ‘‘notional MED’’ subsequently given to each
volunteer. Table 1 shows that the mean MED for 12 volunteers
were 25.8±4.6mJ cm2 (UVB) and 45.8±9.4 J cm2 (UVA1): the
notional MEDs are within one SD of these values. Punch biopsies
(4mm) were taken under local anesthesia in two studies: (i) ‘‘dose
response’’: six participants were given 0.5, 1.5, and 3 notional MEDs
of UVB and UVA1 and biopsies taken immediately afterward;
(ii) ‘‘time course’’: six participants were given three notional MEDs
of UVA1 and UVB and seven biopsies then taken at three time
points, per spectrum, from each volunteer within the ranges
immediate, 3, 6, 24, and 48 hours. Times varied because of ethical
considerations: all had biopsies at 0 and 24 hours, except for two
UVB sites on two volunteers. A nonirradiated control biopsy was
taken from all volunteers.
Immunostaining. Biopsies were fixed in 10% formalin overnight
(B16hours), embedded in paraffin, and sectioned at 4mm. Sections
were deparaffinized with xylene and incubated with 0.1% trypsin
(Gibco, Paisley, UK) at 37 1C for 30minutes; slides were washed twice
in phosphate-buffered saline (PBS) and incubated in 0.6% H202 and
0.1% triton X-100 in PBS for 10minutes. After washing in tap water,
DNA was denatured with 70mM NaOH in 70% ethanol for 4minutes.
Table 1. Volunteer demographics and their just perceptible MED
Study Skin type Sex Age (years) MED UVA1 (J cm2) MED UVB (mJ cm2)
Dose response I F 28 48.8 30.0
I F 25 48.8 30.0
II M 20 48.8 30.0
II F 21 53.0 30.0
I F 22 48.8 23.0
I M 34 61.1 19.0
Mean±SD M+F 25±5.3 51.6±4.9 27.0±4.8
Time course I F 28 31.3 19
I F 28 31.3 30
I M 22 48.8 23
II F 24 31.3 30
I M 23 48.8 23
II F 23 48.8 23
Mean±SD M+F 24.7±2.7 40.1±9.6 24.7±4.4
Combined I (8), II (4) M (4), F (8) 24.8±4.0 45.8±9.4 25.8±4.6
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Figure 5. Emission spectra of UVB (300 nm) and UVA1 sources. Note the
very clean separation of the spectra with 3–4 orders of magnitude difference
between peaks and spectral crossover. The UVA2 (230–340nm) content
of the UVA1 source was 0.2%, which is equivalent to 0.6% of the overall
erythemally effective energy when the emission spectrum is weighted with
the action spectrum for erythema (CIE, 1998).
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Slides were washed twice with PBS and incubated for 20minutes in
blocking buffer (10% goat serum, 0.1% bovine serum albumin, and
0.1% Tween-20 in PBS), followed by monoclonal antibody incuba-
tion for 90minutes at room temperature. The antibodies were TDM-2
(CosmoBio, Tokyo, Japan) at 1:2,000, which has primary specificity to
TTs but also can recognize other CPDs (Mori et al., 1991), and 64M2
(CosmoBio) at 1:300, which has primary specificity to TT 6-4PPs but
also recognizes other 6-4PPs (Mori et al., 1991). In addition, an
isotype control IgG2a (DAKO, Cambridge, UK) was used. After
washing twice in PBS, slides were incubated with Alexa Fluor goat
anti-mouse 555 (Invitrogen, Paisley, UK) at 1:200 for 30minutes,
counterstained with prolong gold antifade with DAPI (Molecular
Probes, Paisley, UK), coverslipped, and stored away from light.
Isotype controls, to exclude nonspecific antibody staining, were
negative in every experiment. The reproducibility of staining and
image analysis was measured for both the dose–response and time-
course studies. Thus, three notional MEDs of UVB or UVA1 (taken
immediately after exposure) were stained with each staining run within
both experiments. Mean nuclear intensities for TTs were (mean±SD)
117.8±7.8 for UVB and 22.4±6.6 for UVA1 (dose response), and
99.6±3.1 for UVB and 36.7±3.1 for UVA1 (time response). For
6-4PPs, the comparable values for the dose response were 29.8±14.2
for UVB and 0±0 for UVA1, and for the time response were
34.9±14.1 for UVB and 0±0 for UVA1. These data indicate that the
staining and imaging analysis techniques were reproducible within a
given experiment.
CPD and 6-4PP quantification by immunofluorescence image
analysis. Fluorescent imaging was done for Alexa Fluor 555 (red) and
DAPI (nuclear DNA stain; blue): Zeiss Axiophot microscope
(Harpenden, UK) and Nikon DS-U2 camera (Kingston upon Thames,
UK) with  20 magnification (and  1.25 eyepiece objective). Images
were acquired in 2,560 1,920 format and exposed to 20S (gain
 1.40 for Alexa Fluor5 55 with 1.5 seconds exposure, gain  1.40
for DAPI). Contrast setting was the same for all images. Epidermis
analysis was done using NIS elements BR v3 software package
(Melville, NY). DAPI-stained nuclei were gated and mean red intensity
(Alexa Fluor 555) assessed within each of at least 200 nuclei. Mean
background intensity from the nonirradiated control also calculated
for over 200 nuclei and subtracted from the irradiated samples to
control for nonspecific nuclear staining (typically higher for 6-4PPs:
44.9±36.7 than TTs: 12.6±6.4 as previously reported (Young et al.,
1996)). Settings for nuclei capture (circularity and diameter of nuclei)
were maintained constant, sections subjectively assessed, and nuclei
‘‘separated and smoothed’’ as necessary. For each biopsy, the mean
intensity value for nuclei in the epidermis was calculated.
Quantification of the distribution of epidermal TT staining.
The ‘‘3MED’’ UVA1 and UVB biopsies, 0 hour, from 12 volunteers
were assessed for nuclear staining intensity on a line perpendicular
to the surface over the thickest section of the epidermis. DAPI-
stained epidermal nuclei were gated and red staining of each
nucleus on the line was individually gated and measured.
Reproducibility of staining and image analysis. It was not
possible to stain and assess all slides in a single batch. To assess the
reproducibility of the techniques, sections prepared from one
individual exposed to three notional MED UVB and UVA1 were
processed with each staining and image analysis run, as well as a
nonirradiated control and an isotype control in each case.
Data analysis
Linear regression analysis was used to study correlation between
UVR dose and outcome. Statistical tests used Graphpad Prism v4
statistics package (La Jolla, CA).
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Although erythropoietic protoporphyria (EPP) is relatively uncommon, affecting
approximately 1 in 140 000 individuals in the U.K., it is an important disease
not to miss owing to the risk of acute severe liver disease in 2% of cases. EPP
occurs with clinical and histological changes in the skin associated with free-
radical-associated dermal vascular damage. This also mediates the painful photo-
sensitivity. Severe and disfiguring hyaline deposition is extremely rare. We
demonstrate that severe EPP can cause disfiguring hyaline infiltration of the skin
on the hands and face, which sheds light on the mechanism of photosensitivity
in EPP; it must also be differentiated from conditions such as lipoid proteinosis.
What’s already known about this topic?
• Erythropoietic protoporphyria (EPP) is an important disease not to miss owing to
the risk of acute severe liver disease in 2% of cases.
• Severe and disfiguring hyaline deposition is extremely rare.
What does this study add?
• We show how severe EPP can cause disfiguring hyaline infiltration of the skin on
the hands and face.
• This must be differentiated from conditions such as lipoid proteinosis.
Case report
A 59-year-old woman presented with lifelong severe photo-
sensitivity due to erythropoietic protoporphyria (EPP). From
early childhood she had suffered bouts of burning pain
affecting the skin of the face, neck and hands. The bouts
were triggered by 3 min of exposure to summer sunshine,
and were associated with visible swelling that lasted
2–3 days. The diagnosis of EPP was confirmed by an
increased erythrocyte-free protoporphyrin concentration of
59 lmol L1 (normal range < 02). Over the previous
2 years there had been progressive disfiguring, furrowing
and thickening of the skin of the face and hands (Fig. 1).
Histology of a forehead skin biopsy revealed deposits of
amorphous eosinophilic material throughout the papillary
and mid-dermis, centred around and compressing dermal
capillaries (Fig. 2). Periodic acid–Schiff (PAS) staining of this
hyaline material was positive, but amyloid stains (Congo red
and thioflavin T) were negative. This pattern of hyaline
deposition is not seen in lipoid proteinosis, in which there is
additional involvement of eccrine glands or colloid milium,
which has a characteristic fissured appearance on histology. A
diagnosis of lipoid proteinosis was excluded from the clinical
history as there was an absence of symptoms manifesting in
childhood, such as a hoarse voice, hair loss or neuropsychiat-
ric symptoms. The disfigurement was found solely on photo-
exposed skin, and there was no evidence of moniliform
blepharosis or plaques at any trauma sites.
Normally, exposed skin in EPP contains small amounts of
PAS-positive eosinophilic deposits of hyaline in a perivascular
distribution in the upper dermis.1 Clinically, this is reflected
in the classical findings of a waxy appearance of facial skin,
perioral radial fine linear scars, fine linear and crateriform
scarring on the cheeks, and thickening of the skin over the
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knuckles.2 In EPP, these hyaline deposits have been shown on
immunohistochemistry and electron microscopy to contain
plasma proteins, including fibrinogen and immunoglobulins.1
This reflects the pathogenesis of the painful photosensitivity in
EPP, which involves free-radical-mediated necrosis of upper
dermal small blood vessel endothelium, with hyaline accumu-
lating as a result of repeated episodes of damage and plasma
leaking through vessel walls into the surrounding dermal tis-
sue.3 The resulting regeneration of the basement membrane
causes the characteristic reduplication seen on electron micros-
copy.1
The exaggerated, extensive and clinically disfiguring hyaline
deposition seen in this patient is unusual. Clinically, it resem-
bles lipoid proteinosis. We postulate that the extensive deposi-
tion of hyaline reflects the severe nature of the patient’s EPP
photosensitivity; 3–4 min of U.K. summer sun is an unusually
small dose of light to trigger a bout of pain in EPP.2 The
severity of the photosensitivity is also clear from the repeated
formation of crusts (Fig. 3), a classical feature of severe bouts
of EPP photosensitivity. Although EPP has been recognized in
large numbers of patients worldwide since it was first
described in 1961,4 this type of disfigurement and extensive
deposition of hyaline in the skin has been described in only
five patients.5,6 Therapeutically, options are limited and patient
education on photoprotection from visible light is important.
In this patient, despite sun avoidance strategies and the use of
photoprotection, there is still extensive skin disfigurement.
The hyaline deposits are too deep for resurfacing procedures
to be carried out without causing scarring. In an attempt to
reduce the prominence of the furrowing, the patient is cur-
rently being treated with dermal hyaluronic acid injections.
This rare and disfiguring complication of EPP highlights the
pathogenetic mechanism of photosensitivity in EPP.
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Fig 1. Extensive thickening and furrowing of facial skin secondary to
dermal hyaline infiltration in a patient with erythropoietic
protoporphyria.
Fig 2. Forehead skin biopsy showing amorphous eosinophilic material
accumulating in the papillary dermis (circled). This is far more
extensive than the accumulation usually seen in erythropoietic
protoporphyria.
Fig 3. Crusts on the malar and right lateral aspect of the nose during
a severe bout of photosensitivity in our patient.
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Oral cholestyramine is not an effective
treatment for uncomplicated erythropoietic















Fig 1. A, Plasma porphyrin levels for each of the 3
patients. B, Red cell protoporphyrin levels for each of
the 3 patients.
3protoporphyria
To the Editor: Erythropoietic protoporphyria (EPP) is
an inherited disease in which protoporphyrin accu-
mulates in erythrocytes, causing lifelong painful
photosensitivity. There is currently no effective
treatment.
One therapy that has been reported in isolated
cases of EPP is the use of cholestyramine. This anion
exchange resin binds to porphyrins and has been
shown to disrupt enterohepatic recirculation of bile
acids.1 It has been suggested that cholestyramine
might increase biliary excretion of protoporphyrin
by interrupting its enterohepatic recirculation.1 In
one patient with EPP,1 cholestyramine increased
fecal excretion of the porphyrin, and although there
was concurrent improvement in liver function tests,
these are isolated reports. Unexpectedly, it has also
been observed to increase urine porphyrin excretion
in 3 patients with EPP.2 Activated charcoal, an alter-
native porphyrin chelator, has also been tried in
EPP,3 although it has no effect in patients with
congenital erythropoietic porphyria(CEP)4 and
causes a paradoxical clinical and biochemical dete-
rioration in variegate porphyria.5
The absence of effective treatment for EPP makes
it important to establish whether a treatment such as
cholestyramine is effective or not. Since red cell and
plasma protoporphyrin concentrations are the path-
ologically relevant measures, we assayed these in 3
EPP patients before, during, and after treatment with
oral cholestyramine. We chose to study 3 adult
patients with EPP (with classic and severe photo-
sensitivity from childhood, and without evidence of
liver dysfunction) as this number gives statistical
significance to our data.
The study was conducted in compliance with the
principles of the Declaration of Helsinki under the
regulation of the Medicines and Healthcare products
Regulatory Agency. Red cell and plasma protopor-
phyrin were measured monthly during the 3 months
of therapy with cholestyramine (12 grams daily) and
for 2 months before and after the treatment.
Compliance cannot be objectively assessed, but we
suspect that patient 2 may not have been fully
compliant with the therapy.
Fig 1 shows the data for the 3 patients. The overall
impression is that the blood protoporphyrin concen-
trations are unaffected by treatment and this is
J AM ACAD DERMATOLtest (P ¼ .29, P ¼ .40 for red cell and plasm
porphyrins, respectively) and there is no significan
difference between the values on and off the the
apy. The patients also showed no change in clinica
symptoms throughout the study time period.
Cholestyramine does not reduce blood proto
porphyrin IX concentrations in uncomplicated EP
and is therefore not an effective therapy for patien
with EPP. It has been proposed that cholestyramin
may be of value in protecting the liver in proto
porphyric liver disease, a hypothesis not assessed i
this study.
The authors would like to thank Dr Robert Dawe an
Dr Nigel Smeaton for statistical advice and would like t
acknowledge financial support from the UK Departmen
of Health via the National Institute for Health Researc
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A 53-question Web-based survey (www.
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The current state of dermatology training:
A national survey of graduating dermatology
residents
To the Editor: The education of residents is a
dynamic and challenging process that has greatly
evolved in the last several years. The comprehen-
sive dermatology residency experience from the
residents’ perspective has not been described since
1996.1 Since this time, elemental shifts have
morphed the once apprentice-style training into a
more formal education process. Given the diversity
of approaches to resident training, we conducted a
survey of graduating dermatology residents to as-
sess the current state of the dermatology residency
experience.fered to graduating resident physicians at all 10
Accreditation Council for Graduate Medica
Education (ACGME)eapproved dermatology res
dency programs in June 2011. To assess residen
comfort levels with medical, surgical, and pediatri
dermatology and histopathology, a 5-level Like
scale was used. Statistical analyses were performe
using chi-square tests for categorical variables an
Spearman’s rank correlation for ordinal variables. A
tests were two-tailed, and P values less than or equa
to .05 were considered significant.
A total of 127 surveys (39%) were received
Responding residents were primarily female (61%
with an average age of 32 6 3 years. The majorit
(53%) of residents reported an average program siz
of 7 to 12 total residents, with 70% having 6 to 15 ful
time attendings. Sixty-two percent of survey partic
pantsdescribed their clinics as ‘‘attending-run’’ (clinic
in which attendings have primary responsibility ove
care). Noassociationswere foundbetween the typeo
clinic and the level of anxiety of beginning one
career, stress level during residency, feelings of ‘burn
out’, and level of adequacy of training. Residents, o
average, attended 8 6 1 half-day clinics per week
with amedian of 1 pediatrics clinic perweek, and saw
7 to 12 patients per clinic. Higher levels of feelin
adequately trained among residents were associate
with working more clinics per week and seeing mor
patients per clinic (P ¼ .02 and P ¼ .05, respectively
Overall, 75% of respondents felt autonomous i
regards to patient care as third-year residents.
Regarding lectures, 81% of respondents had non
to 3 faculty-led lectures per week and 59% had non
to 3 resident-led lectures per week. Forty-six percen
had a mandatory research requirement, 38% had
formal mentorship program, and 84% had a cont
nuity clinic. Sixty-three percent studied 4 to 9 hour
outside of clinic per week and, on average, had 1 fu
day of academic time per week. Program characte
istics are summarized in Table I.
Regarding comfort and competency with medica
dermatology, 93% felt somewhat or very comfortabl
prescribing medications that require lab monitoring
89% with prescribing biologics, 80% with photothe
apy, and 43% with infusions. Regarding surgica
dermatology, 98% felt somewhat or very comfortabl
performing simple excisions, 45% performing flap
41% performing grafts, and 17% performing Moh
micrographic surgery. Results are summarized inFig 1
Assessing comprehensive nationwide residenc
curricula is difficult. Few studies have addressed th
issue, and among those conducted, the results ar
limited in scope.1-5 Interestingly, despite changes i
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The introduction of phototherapy has substantially changed the
therapeutic response of localized scleroderma (LS). Systemic
agents have been proposed for the treatment of LS, some with
potential side effects and varying degrees of success. There is
sufficient evidence in the literature to demonstrate that low dose
(20 J/cm2) and medium dose (50 J/cm2) UVA1 phototherapy is
beneficial in LS. The development of a metal halide lamp emit-
ting high levels of UVA1 radiation (340–400 nm) was first
described in 1981 (1), but the therapeutic potential for UVA1
phototherapy did not emerge until 1992 with the first successful
report of treating patients for acute exacerbations of atopic
dermatitis. It has now been shown to soften thickened plaques,
increase skin elasticity and reduce lesional skin thickness in
scleroderma (2–4). Recently (4), low-dose UVA1, medium-
dose UVA1 and narrowband UVB phototherapy were compared
demonstrating comparable efficacy of narrowband UVB and
low-dose UVA1 but medium-dose UVA1 being more effective.
In systemic sclerosis (SSc), studies of UVA1 are limited.
Improvement has been documented in acrosclerosis in those
patients with SSc (5). There is no documentation of treatment of
other features of SSc by phototherapy in the literature. We
describe a case of successful treatment of microstomia with
UVA1 phototherapy in a patient with SSc.
Case report
A 45-year-old woman with SCL701ve systemic sclerosis
presented with symptomatic sclerodactyly and microstomia,
which had been progressively worsening over the last 5 years.
Previous treatments included hydroxychlorquine and she
had declined systemic corticosteroids and other systemic
immunosuppressant therapy. There was no relevant past medical
history or family history and she worked as a solicitor.
On examination, there was evidence of significantly tight,
thick skin affecting the hands, face, arms and upper chest and
microstomia. She found it difficult to open her mouth and
articulate her words and there was a slight pinching of her nose.
SCL 70 antibodies were present in peripheral blood and other
blood tests including inflammatory markers, FBC, urea/
creatinine, LFTs and complement were normal. She was
commenced on 50 J/cm2 UVA1 phototherapy to the whole skin
surface 2–3 times weekly. After 10 treatments all the sclerotic
areas of skin including the perioral area were less indurated on
examination. After 21 treatments she could articulate words
normally and there was reduced furrowing around the mouth.
After 40 treatments and a total of 2225 J/cm2 she could open her
mouth more normally: the anterior–posterior diameter from the
lower margin of the front teeth to the upper margin of the lower
teeth had increased by 1 cm (25%) from 4 to 5 cm (Figs 1 and 2).
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Currently she says that brushing her teeth, eating and talking have
all become significantly easier following the treatments.
Discussion
Equipment to deliver UVA1 (340–400 nm) waveband has been
available from 1981 but it is only in the last 20 years that
increasing beneficial use of UVA1 has been documented (4).
UVA1 is accepted effective treatment for morphoea(2–4),
systemic scleroderma (3) and granulomatous chronic GVHD
(3). It is also used and may be effective in urticaria pigmentosa
(3, 4), scleredema adultorum Bushke (3, 4), granuloma annulare
(4), nodular prurigo (4), mycosis fungoides (3), atopic eczema
(4), polymorphic light eruption (4) and SLE (3).
Systemic sclerosis is difficult to treat. Despite advances in
disease-specific treatment of other rheumatologic diseases,
disease-targeted treatment in systemic sclerosis continues to be
elusive suggesting treatment involves a complex interaction of
specific targets. There are no published studies of treatment of
microstomia in systemic sclerosis. UVA1 phototherapy exerts its
therapeutic effects through modulation of three predominant
pathogenic mechanisms in sclerosis: immune dysregulation,
imbalance of collagen deposition and endothelial dysfunction
(5). In our case, UVA1 appears to have been effective in softening
sclerotic perioral skin and improving symptoms caused by the
microstomia. This case highlights how UVA1 phototherapy
should be considered early if patients with systemic sclerosis
and significant disability with skin involvement such as
microstomia are unable to tolerate systemic therapy, but also
importantly as an early adjunct to systemic therapy.
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Appendix C 
Heat map showing gene expression profiles of UVA1 and UVB at 6h (D, E) and 
24h (G, F) for selected genes with antioxidant activity  
 
This figure shows hierarchical clustering of genes statistically significant (p<0.05) for  
D UVA1 6h, E UVB 6h, F UVB 24h and G UVA1 24h.   Color saturation limits were 
set in log2 scale from -1 (bright green) to +1 (bright red). Genes associated with ROS 
metabolism and antioxidant activity are indicated by red and blue labels next to the gene 
name, respectively.  
 
This map shows intense differential expression predominantly at 6h, although there is 
still strong expression by UVB at 24h (F).  There is also a large degree of spread with 
some genes upregulated by UVB and others by UVA1. 
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